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C3-antigen complexes induce B cell proliferation and the synthesis of specific 
antibodies in the immune response. The mechanism is understood to involve the co- 
ligation of antigen receptor (IgM) and CD21 on the membrane of antigen-specific B 
cells. CD23 is the low-affinity IgE receptor and also binds to CD21. It has been shown 
by NMR spectroscopy that the binding sites for IgE and CD21 on CD23 are distinct and 
non-overlapping. CD23 is expressed as a homotrimer on the membrane of B cells and is 
cleaved by an endogenous metalloprotease to release soluble fragments that contain the 
binding sites for both IgE and CD21. It is suggested that these fragments, like the C3- 
antigen complexes, can co-ligate membrane IgE (mIgE) and CD21 on the surface of B 
cells to up-regulate IgE synthesis. This would enhance allergic responses in vivo. 
To test this hypothesis, a construct was generated to express a trimeric fragment of 
soluble human CD23 (LZ-CD23) and provide evidence for the protein's oligomeric 
state in solution using analytical ultracentrifugation. Surface plasmon resonance studies 
also showed that LZ-CD23 binds IgE with a high affinity. Confocal microscopy was 
used to demonstrate that LZ-CD23 caused the time-dependent re-distribution of 
fluorescently-labelled mIgE and CD21 on human tonsillar B cells, stimulated with anti- 
CD40 and IL-4 to induce heavy-chain switching to IgE. As early as 15 minutes 
following incubation with LZ-CD23, mIgE and CD21 were seen to co-cap in large 
aggregated clusters on the B cell surface. Additionally, the specificity of LZ-CD23 
towards these markers was demonstrated as LZ-CD23 had no effect on the surface 
distribution of CD38. 
LZ-CD23 was shown to be biologically active by enhancing the secretion of IgE from B 
cells. Moreover, evidence is presented that CD23 exerts its IgE-potentiating action by 
specifically targeting cells that are pre-committed to IgE. The mechanism thus appears 
to resemble that of the C3-antigen complex in the immune response, except that it is 
isotype rather than antigen-specific. These results shed light on the role of CD23 in IgE 
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Chapter 1 Introduction 
Chapter 1: Introduction 
1.1 Introduction to IgE and its role in allergy and parasitic disease 
IgE is one of five major classes of antibody found in mammals. Its roles in parasitic 
infection and allergic disease have been widely reported. IgE found locally in the gut 
can create unfavourable conditions for intestinal parasites, and IgE can mediate the 
cytotoxic activity of eosinophils against parasitic larvae (Capron et al., 1987; Capron 
and Capron, 1992; Lynch et al., 1999). From an evolutionary perspective, it is thought 
that the primary objective for IgE may be anti-parasitic, with allergic disease emerging 
as an undesirable response to otherwise innocuous environmental substances. In the 
western world, where the improvement of sanitary conditions has led to the virtual 
elimination of parasitic infections, the incidence of allergic disease continues to rise and 
is thought to afflict more than 30% of the population. 
Allergic disease is characterised by the overproduction of IgE in response to common 
environmental antigens such as pollen, dust mite and some foods. The umbrella of 
"allergic disease" encompasses several common conditions such as allergic rhinitis 
(hayfever) and asthma. However, the higher prevalence of these milder conditions over 
the last few decades also correlates with an increase in more serious allergic conditions 
such as anaphylactic shock, provoked by some foods and insect venoms. With allergic 
disease now described as the "number one environmental disease" (Barnes, 1991), the 
aim of much allergy research has been directed towards understanding the mechanisms 
behind IgE regulation with a view to identifying therapeutic targets to help diminish the 
morbidity and mortality associated with IgE-mediated diseases. 
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1.2 IgE and its receptors 
Whilst the serum concentrations of IgE (50-300ng/ml) are much lower when compared 
with other antibody isotypes (IgG 1 at 10mg/ml), it is the interaction of IgE with its 
receptors that powerfully amplifies its action. The "high affinity" receptor, FccRI. is 
expressed on monocytes, macrophages and basophils and binds IgE with a very high 
affinity (KA = 1010 M-1) through residues found in the C62 and CO domains (Gould et 
al., 2003). On mast cells and basophils, the receptor comprises four transmembrane 
subunits, 4y2, whereas the ß chain is absent in monocytes and dendritic cells (Kinet, 
1999). The a chain consists of two Ig-like domains, al and a2, which form the IgE 
binding site, whilst the y chain mediates transmembrane signalling on allergen binding, 
amplified by the ß chain on effector cells (figure 1.1). 
A feature that sets IgE-FcsRI binding apart from the interactions of other antibodies 
with their receptors is the ability of IgE to bind Fc8RI tightly in the absence of antigen. 
Once bound, IgE "sensitises" the cell until re-exposure with its cognate 
antigen/allergen. Cross-linking of IgE by allergen causes the release of inflammatory 
mediators, such as histamines and leukotrienes, leading to much of the pathology 
associated with an allergic reaction. This rapid cellular response is known as a type I, 
immediate hypersensitivity response. 
The second receptor for IgE is known as the low affinity IgE receptor, FcERII or CD23. 
The term "low affinity" is only relevant when comparing the interaction of IgE with 
FcsRI. This term can be misleading if read in the context of antibodies of other 
isoptypes because FccRII has an affinity for IgE that is comparable with the affinity of 
IgG with its high affinity receptor. 
-14- 





Figure 1.1: IgE and its receptors 
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1.3 Expression of CD23 
CD23 was first identified on B cells and monocytes as a receptor for IgE (Melewicz et 
al., 1982), but expression of CD23 has now been established on a variety of human 
haematopoietic cells including eosinophils, macrophages, platelets. follicular dendritic 
cells, some subsets of T lymphocytes and Langerhans cells (Delespesse et al., 1991). 
The expression of CD23 has also been reported on structural cells, such as smooth 
muscle (Belleau et al., 2005). In the context of B cells, CD23 has become recognised as 
a marker for antigen-activation through studies on Epstein-Barr-infected B cells 
(Kintner and Sugden, 1981; Thorley-Lawson et al., 1985). 
The wide range of expression and the diversity of cell types expressing CD23 suggests 
that it mediates a variety of different biological functions. In addition to cell surface 
expression, CD23 is also detected in bodily fluids in a soluble form (sCD23). Elevated 
levels of membrane or soluble CD23 may serve as a marker for a variety of diseases 
such as chronic lymphocytic leukaemia (Ling et al., 1991; Sarfati et al., 1990), allergy 
(Gagro et al., 1995), and rheumatoid arthritis (Delespesse et al., 1991). It has not been 
conclusively demonstrated, however, whether the observed CD23 is actively associated 
with the disease pathogenesis or whether its presence is merely a consequence of 
disease. 
1.4 Structure of CD23 
Human CD23 is encoded from a gene located on chromosome 19p13, clustered with the 
genes encoding DC-SIGN and DC-SIGNR (Soilleux et al., 2000). The nucleotide 
sequence was found to show homology to C-type lectins such as the asialoglycoprotein 
receptor, CD72 and the chicken hepatic lectin (Beavil et al., 1992; Ikuta et al., 1987; 
- 16- 
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Kikutani et al., 1986; Ludin et al., 1987). As a C-type lectin, CD23 is unique among 
other Fc receptors which all belong to the Ig superfamily. 
CD23 contains a single membrane-spanning domain and is expressed on the cell surface 
as a trimer (Beavil et al., 1995; Kilmon et al., 2004). The extracellular domain consists 
of three regions: an a-helical coiled-coil stalk, the C-type lectin head domain containing 
the binding sites for its ligands IgE and CD21 (described later) and a short tail at the C- 
terminus, containing an inverted RGD sequence (figure 1.2). Notably, the C-terminal 
tail is absent in murine CD23, which may be important in understanding some of the 
functional differences between the two molecules. 
The stalk region consists of a series of homologous repeats of 21 amino acids (3 in 
human and 4 in mouse), arranged as heptads with hydrophobic residues on one face of 
the molecule (Bettler et al., 1989a; Bettler et al., 1989b). Molecular modelling revealed 
that the periodicity of these heptads suggests that CD23 forms an a-helical coiled-coil 
(Beavil et al., 1992). Together with crosslinking data, observations by Beavil et al. 
suggested that CD23 would form a trimer instead of a dimer, as in proteins with leucine 
zipper motifs (Beavil et al., 1992; Dierks et al., 1993). Analysis of CD23 - IgE binding 
in mice by Dierks et al. (1993) revealed a biphasic interaction characterised by a high 
affinity (KA: 107 M-) and a low affinity (KA: 106 M-1) component. These observations 
led to a model in which CD23 forms trimers capable of high affinity binding to IgE 
through the avidity effect when lectin heads are brought into close proximity (Gould et 
al. , 1991) with the 
low affinity component mediated by monomeric CD23 molecules 
(Shi et al., 1997). 
-17- 
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Figure 1.2: Structure of human CD23 
Full length, membrane CD23 comprising the ligand binding lectin head, the stalk region and the 
extracellular tail region. A heptad repeat of hydrophobic amino acids along the stalk is shown in 
blue. The CD23a from differs from the CD23b form by the first 6-7 N-terminal amino acids. 
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Two isoforms of CD23 exist in humans, CD23a and CD23b which, as a consequence of 
alternative transcriptional initiation and RNA splicing, differ in their N-terminal 
intracellular sequence. CD23a is exclusively found on activated B cells, whereas CD23b 
is induced, in particular, by IL-4 (Ewart et al., 2002; Kohler and Rieber, 1993; Yokota 
et al., 1988). Although both isoforms have identical extracellular domains, their 
functions are quite distinct. CD23a contains an N-terminal YSEI motif, common for 
proteins targeted to coated pits (Geffen et al., 1993; Spiess, 1990), which could 
potentially cause endocytosis of IgE-coated particles (Montagnac et al., 2005). The b- 
form has been shown to be associated with phagocytosis of soluble IgE complexes 
(Montagnac et al., 2005). Murine CD23 was originally thought to exist only as the 
CD23a form, up-regulated in response to IL-4 together with co-factors such as LPS 
(Conrad et al., 1988). However, recently a murine CD23b form has been found and has 
been hypothesised to be involved in IgE-complex transport across the gastric epithelium 
(Bevilacqua et al., 2004; Yu et al., 2003). 
Recently the structures of the CD23 lectin head have been solved by both NMR 
spectroscopy (Hibbert et al., 2005) and X-ray crystallography (Wurzburg et al., 2006). 
The importance of these data, in terms of ligand and calcium binding, will be explained 
in subsequent sections. 
1.5 Formation of soluble CD23 fragments 
1.5.1 Cleavage of larger CD23 fragments by metalloproteases 
Although CD23 is initially expressed as a membrane associated molecule, it is readily 
cleaved from the cell surface into fragments of 37,33 and 29 kDa (Letellier et al., 1990) 
(figure 1.3). This cleavage is inhibited by interactions with IgE and IgE-immune 
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complexes (Guy & Gordon, 1987; Luo et al, 1991). It has been suggested that the 
binding of IgE helps stabilise the CD23 coiled-coil stalk, masking the protease 
recognition sites, thereby protecting it from cleavage (Gould et al., 1991). Additional 
observations demonstrated that binding of an anti-CD23 antibody directed to the stalk 
region, rather than the IgE-binding lectin head, provoked proteolysis by destabilising 
the stalk (Munoz et al., 1998). 
25 kDa CD23 
16 kDa CD23 4L" 
37 kDa CD23 
43 kDa CD23 
45 kDa CD23 
Figure 1.3: CD23 and its cleavage fragments 
CD23 is initially expressed as a 45 kDa protein on the cell surface. It undergoes cleavage from 
the cell by endogenous metalloproteases and a protease from the house dust mite, yielding 
smaller stalk deletion fragments, each retaining the lectin head. 
It is not clear what proteases are responsible for CD23 cleavage in vivo, although it has 
been suggested that CD23 undergoes an autocatalytic event (Letellier et al., 1990). In 
vitro experiments have shown that the release of the 37 kDa and 33 kDa fragments from 
membranes of B cell lines is mediated by a metalloprotease (Marolewski et al., 1998). 
This group characterised the CD23 protease as a membrane protein with a functional 
molecular mass of around 63 kDa. It was suggested that this protease may be a member 
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of the ADAM family of disintegrin metalloproteases due to observations that ADAM8, 
ADAM15 and ADAM28 could cleave CD23 from B cell lines (Fourie et al.. 200-33). 
Evidence suggests that ADAM8, with a molecular mass of around 60 kDa (Yamamoto 
et al., 1999), contributes to shedding of CD23 in vivo due to the observed physical 
association of both CD23 and ADAM8 on the surface of transfected cell lines (Fourie et 
al., 2003). The inhibition of metalloprotease activity on CD23 has been shown to 
correlate with the down-regulation of IgE as will be described below. 
1.5.2 Cleavage of smaller CD23 fragments 
Although the identities of the proteases responsible for the cleavage of the smaller 
fragments remain elusive, it has been demonstrated that the major house dust mite 
allergen Der p1 can cleave membrane CD23 (mCD23) in vitro. Der p1 is a 25 kDa 
protein with cysteine protease activity (Schulz et al., 1995). Its X-ray structure has been 
determined in both its pro-enzyme (Meno et al., 2005) and mature form (de Halleux et 
al., 2006), and it shows close structural similarity to papain and other papain-like 
cysteine proteases. Der p1 is known to cleave CD23 from the surface of B cells acting 
at two sites on both the C- and N-terminal sides of the CD23 lectin head (Schulz et al., 
1997). This dual cleavage event generates a 17 kDa fragment comprising the entire 
lectin head and part of the C-terminal tail, which, taken together, make up the minimum 
structural requirements for binding to IgE (Shi et al., 1997) and CD21 (Hibbert et al., 
2005). 
For Der p1 to cleave CD23 in vivo it must first gain access to immune cells shielded by 
the bronchial mucosa to which the allergen is first exposed following inhalation of dust 
mite faeces. Its function as a cysteine protease seems to play a fundamental role in 
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crossing this initial barrier and there is some evidence to suggest how this passage 
occurs. As a cysteine protease, its enzymatic activity needs to maintained by reduction 
of the thiol group cysteine in the active site, which is provided by high levels of 
glutathione found in the epithelial lining fluid of the lower respiratory tract (Cantin et 
al., 1987). It has been shown to cleave the anti-protease al -antitrypsin, which is 
normally involved in mucosal immunity (Kalsheker et al., 1996; Schulz et al., 1995), 
leaving it free to progress through the epithelium, possibly by disrupting cell-cell tight 
junctions, sealed by occludin (Wan et al., 1999). The allergen would then be able to 
gain access to sub-epithelial cells of the immune system, including B cells, where it 
could cleave CD23 from the cell surface. 
Further evidence for the allergenicity of Der p1 is linked to its cysteine protease 
activity and comes from the observation that CD25 (the alpha subunit of the IL-2- 
receptor on Thl cells) is also cleaved by the protease (Schulz et al., 1998). Thl cells 
rely on IL-2 for survival, and therefore a loss of the IL-2-R would probably skew the 
immune response toward a Th2 response, thus establishing a pro-allergic 
microenviroment in favour of IgE. The importance of its protease activity in allergy was 
further supported in an in vivo murine system where Der p1 immunisation was shown 
to cause an enhancement in both total and Der p 1-specific IgE which was irreversibly 
blocked by the cysteine protease inhibitor, E-64 (Gough et al., 1999). 
1.6 CD23 interactions 
1.6.1 CD23 - IgE interaction 
The striking feature of IgE is the additional Cc2 domain which replaces the hinge region 
in IgG (figure 1.4). The crystal structure of IgE reveals that it assumes a bent structure 
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in which the extra domains are folded back on to the C83 and CE4 domains (Wan et al.. 
2002). This structure suggests that on ligation with its high affinity receptor. IgE 
undergoes a conformational change involving CE2 and CE3 which may be responsible 
for its slow dissociation. 
IgE IgG 
Figure 1.4: Schematic showing structural differences between IgE and IgG 
Both IgE and IgG are made of two heavy and two light chains. In contrast to IgG, IgE contains 
an extra immunoglobulin domain (Cc2) where the IgG hinge region would be. 
No crystal structure has yet been solved for the CD23 - IgE complex, however the IgE 
- CD23 lectin head (derCD23) interaction has been analysed using NMR, which 
identified a number of contact residues mapping to the CE3 domain that are implicated 
in the interaction (Hibbert et al., 2005). Ultracentrifugation data show that monomeric, 
16 kDa CD23 binds to the IgE Cs3-4 dimer with a 2: 1 stoichiometry (Shi et al., 1997) 
indicating that there are two binding sites for CD23 on IgE. Thermodynamic analysis of 
binding at both sites led to two models being proposed for the interaction of trimeric 
CD23 with IgE. These models suggested that two CD23 lectin heads could either 
contact both CO domains of one IgE molecule, or equally, two lectin heads would 
contact one CO domain of one IgE molecule with the potential, in both models, to form 
large, cross-linked networks. 
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Despite the binding of IgE to the lectin domain, and the presence of exposed 
carbohydrate on C82 and Cc3, the CD23-IgE interaction is not dependent on 
carbohydrate (Vercelli et al., 1989a). Indeed, deglycosylated IgE Fc mutant has been 
shown to bind with a greater affinity to CD23 than wild type IgE Fc (Young et al., 
1995). 
As a C-type lectin, ligand interactions of CD23 are predicted to be calcium dependent. 
The requirement for calcium for the binding of IgE, however, is still controversial. 
Whereas calcium-dependent IgE binding was demonstrated by Richards and Katz 
(1990) the structure of derCD23, as solved by both NMR (Hibbert et al., 2005) and X- 
ray crystallography (Wurzburg et al., 2006) reveal quite different observations. CD23 
has two binding sites for calcium, one of which is conserved among C-type lectins 
(Weis et al., 1992). NMR analysis has shown that, on titration with calcium, the second, 
non-conserved, auxiliary calcium binding site is occupied (Hibbert et al., 2005). The 
authors concluded that the presence of calcium is not necessary to stabilise the lectin 
head for the ligand binding of derCD23 to CO. In contrast, the crystal structure of the 
lectin head reveals a conformational change in the presence of calcium (Wurzburg et 
al., 2006). These changes occur in areas that have been previously identified as being 
important for IgE Fc binding (Bettler et al., 1992) and may be important in 
understanding how calcium affects the affinity of CD23 for IgE. 
1.6.2 CD23 - CD21 interaction 
CD21 is also known as complement receptor 2 (CR2) and binds C3dg, a cleavage 
fragment of C3b, which covalently attaches to pathogens and enhances B cell responses 
to foreign antigens. In concert with CD19, its role is in co-stimulation during B cell 
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activation (Fearon and Carroll, 2000). Structurally, CD21 is a 145 kDa, integral 
membrane protein, the extracellular region of which is made up of 15/16 repeats of 60- 
75 amino acids known as short consensus repeats (SCR) numbered from the N-terminus 
(Weis et al., 1988) (figure 1.5). 
CD21 was originally identified as a co-receptor for CD23 by Bonnefoy and colleagues 
(Aubry et al., 1992; Pochon et al., 1992) . By using a panel of anti-CD21 antibodies, 
Aubry et al. (1994) reported that CD23 binds two regions on CD21, mapping to SCR 1- 
2 and SCR 5-8. They also showed that by treating CD21+ cells with the N-glycosylation 
inhibitor tunicamycin or mutating the three asparagines present on SCR 5-8, CD23 
binding was blocked suggesting that, in contrast to the protein-protein CD23 - IgE 
interaction, an N-linked sugar on SCR 5-8 is necessary for the CD21 - CD23 
interaction. However, treatment with tunicamycin did not block the interaction 
completely suggesting that binding is not achieved through carbohydrate recognition 
alone. The protein-protein interaction of CD23 binding to SCR 1-2 most probably 
completes the interaction. The observation that CD23 binds to SCR 5-8 makes this 
interaction novel because the other known ligands of CD21 - the Epstein-Barr virus 
coat protein gp350/220 (Fingeroth et al., 1984), C3dg (Lowell et al., 1989) and 
interferon-alpha (Delcayre et al., 1991) - only bind within SCR 1-2. 
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Figure 1.5: Schematic of CD21 
CD21 consists of 15-16 short consensus repeats numbered from the N-C termini. CD23 is 
known to bind to two areas on the molecule: SCR 1-2 via a protein-protein interaction and SCR 
5-8 by a protein-carbohydrate interaction. 
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A soluble form of CD21 (sCD21), corresponding to the entire 135 kDa extracellular 
domain, has been reported in human serum and supernatants of cell lines (Fremeaux- 
Bacchi et al., 1996; Ling et al., 1998). Although it is not clear by which mechanism 
CD21 is shed from cell surfaces, Ling et al. (1991) report that a probable source of 
serum sCD21 is the follicular dendritic cells which express high levels of the surface 
molecule. It has been demonstrated by western blotting and surface plasmon resonance 
(SPR), that sCD21 is present in human serum complexed with cleavage fragments of 
C3, and with monomeric and trimeric CD23 (Fremeaux-Bacchi et al., 1998). CD23 and 
CD21 complexes were seen to inhibit sCD23-induced synthesis of IgE on B cells, 
suggesting that the soluble CD21 fragments lose none of the immunoregulatory 
properties of the membrane-bound molecules. 
1.6.3 Interactions of CD23 with CD11b-CD18, CD11c-CD18 and the vitronectin 
receptor 
Human CD23 has been shown to bind specifically to two members of the ß2 integrin 
family CD 11 b-CD 18 (CR3) and CD 11 c-CD 18 (CR4) expressed on monocytes 
(Lecoanet-Henchoz et al., 1995). Binding is accompanied by the production of 
inflammatory cytokines including IL-1p, IL-6, and TNF3, indicating a physiological 
role for CD23 in the activation of monocytes. Lecoanet-Henchoz and colleagues also 
demonstrated that the monomeric soluble 25 kDa fragment of CD23 is also able to bind 
and activate human resting monocytes through the nitric oxide synthase (NOS) pathway 
(Aubry et al., 1997). It is not entirely clear where CD23 binds to CD I1 b/c, although 
Aubry et al. (1997) report that the interaction is calcium dependent due to sensitivity to 
the calcium chelator EGTA. 
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More recently, it was shown that the vitronectin receptor (CD51/CD61) and its 
associated CD47 molecule mediates synthesis of the pro-inflammatory cytokines, 
TNFa, IL-12 and IFNy, from human monocytes on interaction with sCD23 (Hermann et 
al., 1999). The vitronectin receptor, also known as the avß3 integrin, binds a variety of 
ligands and consequently has a number of biological roles, including tumour invasion, 
cell migration and angiogenesis (Felding-Habermann and Cheresh, 1993). The 
significance of the interaction with CD23 remains unproven, however it is likely to be 
important in chronic inflammatory disease, such as rheumatoid arthritis, in which 
sCD23 and TNFa are implicated. 
1.7 Effector functions of CD23 
1.7.1 Facilitated antigen presentation 
Facilitated antigen presentation (FAP) involves the receptor-mediated recognition of 
native antigen which is required for subsequent presentation of processed antigen 
(peptides) by MHC molecules. CD23 has been shown to act as a receptor for IgE- 
antigen complexes in the presentation of allergen to T cells. The passive immunisation 
of IgE along with its cognate antigen has been previously shown to enhance IgG 1 
responses in mice up to 100-fold in contrast to immunisation with antigen alone. This 
enhanced response was shown to be strictly dependent on CD23 (Hjelm et al., 2006). 
In atopic disease, CD23 has also been shown to present a dust mite allergen, Der p II, 
complexed with Ig from human serum, to Der p 11-specific CD4+ clones (van 
der 
Heijden et al., 1993). This was also mediated by IgE and not IgG, as it was completely 
blocked with polyclonal IgE, but not polyclonal IgG, found in the serum of atopic 
individuals. In addition, CD23-mediated FAP in humans is also thought to involve 
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CD21 (Grosjean et al., 1994). CD23 is non-covalently associated with MHC II on the 
surface of B cells (Bonnefoy et al., 1988b). Additionally, IgE-allergen complexes with 
CD23 and HLA-DR can be endocytosed and the antigenic peptides and HLA-DR 
recycled to the cell surface together (Karagiannis et al., 2001). 
1.7.2 B cell growth factor 
Soluble CD23 fragments (25 kDa) together with IL-1 have been shown to rescue 
germinal centre B cells from apoptosis in vitro (Liu et al., 1991). Survival may be 
promoted by the up-regulation of Bcl-2. In humans this is thought to occur in concert 
with CD21 as a subset of anti-CD21 antibodies, sharing the CD23 binding site, has been 
seen to rescue B cells from apoptosis (Bonnefoy et al., 1993). In addition to B cell 
survival, sCD23 also promotes the differentiation of pro-thymocytes to T cells (Bertho 
et al., 1991) and myeloid precursors to basophils (Arock et al., 1991). 
1.8 CD23 and IgE regulation 
1.8.1 Introduction 
In humans, both the expression of surface CD23 on B cells and monocytes, and serum 
levels of sCD23 are significantly increased in allergic individuals after exposure to 
allergen (Gagro and Rabatic, 1994; Gagro et al., 1995). Moreover, a reduction of 
allergen-induced CD23 expression on B cells has been observed after successful 
immunotherapy. These changes correlate with diminished serum levels of IgE in these 
patients and strongly suggest a role for CD23 in IgE regulation. Indeed, several studies 
have shown that monoclonal antibodies that bind CD23 can modulate IgE production. 
Depending on the location of the antibody binding site on CD23. IL-4-driven IgE 
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production is seen to be either enhanced (Wakai et al., 1993) or suppressed (Bonnefov 
et al., 1990; Nakamura et al., 2000; Sarfati and Delespesse, 1988). 
The main focus of recent investigations has been to establish the relative importance of 
mCD23 versus the cytokine-like activities of sCD23 on IgE synthesis. As a wealth of 
data suggests, CD23 has dichotomous functions depending on whether it is membrane- 
bound or in solution, leading to the notion that CD23 is a molecule with a "split 
personality" (Gould et al., 1991). Indeed, the structural form that CD23 takes seems to 
be integral to its role in IgE regulation. 
1.8.2 Down-regulation of IgE Synthesis through membrane CD23 
Sherr et al. (1989) were the first to demonstrate that IgE immune complexes inhibited 
IgE synthesis, probably mediated by crosslinking of human mCD23. These findings 
were confirmed in subsequent mouse in vitro studies (Cho et al., 1997). In vivo 
experiments using knockout or transgenic mice further confirmed these observations. 
On challenge with T cell-dependent antigens, IgE levels were increased by several 
orders of magnitude compared with controls in CD23-deficient mice, while other 
antibody classes, except IgG I, which is co-regulated with IgE, remained unchanged (Yu 
et al., 1994). This suggests that allergic responses in mice would be more severe in the 
absence of CD23. Furthermore, inhibition of mCD23 cleavage is seen to correlate with 
a down-regulation of IgE production in human B cells in vitro (Christie et al., 1997; 
Wheeler et al., 1998) and in human PBL-reconstituted SCID mice in vivo (Mayer et al., 
2000) suggesting that mCD23 is inhibitory to IgE. In contrast, the over-expression of 
CD23 in mice results in decreased IgE and IgGi responses to parasitic challenge and 
cellular activation by anti-IgD with no significant changes to other antibody classes 
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(Texido et al., 1994). Additionally, Cho et al. (1997) report decreased IgE protein 
secretion, but unchanged levels of s-germline gene transcripts. in a similar CD23-over- 
expressing transgenic mouse system. Furthermore, Saxon et al. (1991) observed a 
correlation between decreased secretion of human IgE and lower levels of E-mRNA 
coding for secreted, but not membrane IgE following engagement of CD23 with either 
IgE-immune complexes or anti-CD23 antibodies. 
1.8.3 Up-regulation of IgE Synthesis by soluble CD23 fragments 
In contrast, sCD23 fragments have been shown to stimulate IgE production in vitro. 
This was first proposed by Sarfati et al. (1984b) who observed a dose-dependent IgE 
increase in B cells, taken from allergic patients, cultured with supernatants from the 
RPMI 8866 B cell line containing high levels of CD23. In that study, the IgE- 
potentiating molecule was simply known as an "IgE-binding factor", but its identity was 
later suggested to be sCD23, as sCD23 was seen to have the same effect (Bonnefoy et 
al., 1988a). This suggestion was explored further by Pene et al. (1988b), who showed 
that the IgE-stimulating effects of cell line-derived sCD23 on B cells from non-allergic 
patients were enhanced in the presence of suboptimal levels of IL-4. As sCD23 had no 
effect on IgE in the absence of IL-4, this further supported the requirement for IL-4 in 
human IgE up-regulation, not only directly, through its capacity to induce B cell IgE 
class switching (Lebman and Coffman, 1988), but also indirectly by promoting CD23 
expression and cleavage into fragments that drive IgE up-regulation from IgE- 
committed B cells (Sarfati et al., 1990). To build the bigger picture, a synergy between 
IL-4 and the T cell-derived CD40 ligand signal in IL-4-induced IgE production was 
demonstrated by Jabara et al. (1990), thus suggesting that IL-4-driven IgE production in 
vivo is T cell dependent (Vercelli et al., 1989b). This synergy is now understood in that 
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IL-4 induces Cc-germline gene expression through the transcription factor STAT6 
(Linehan et al., 1998), while CD40-L up-regulates NF-KB required for both E germline 
gene and DNA recombination (Iciek et al., 1997). The mechanism of CD23-induced 
IgE up-regulation, however, remains unclear (see below). 
1.8.4 Antagonistic roles of sCD23 fragments with different molecular weights 
While many early studies reported the IgE-potentiating effects of sCD23 in cell-free 
supernatants, IgE suppression by B cell supernatant-derived CD23 fragments (Sarfati et 
al., 1984a) and T cell-derived CD23 fragments (Deguchi et al., 1983) was also observed 
and later attributed to antagonistic effects from cleavage fragments of different 
molecular weights (Sarfati et al., 1992). It became apparent that smaller molecular 
weight sCD23 cleavage products have a suppressive effect on IgE synthesis (Sarfati et 
al., 1992), whereas fragments larger than 25 kDa enhance IgE synthesis (Chretien et al., 
1990; Sarfati et al., 1984b; Saxon et al., 1990). Although the exact mechanisms by 
which sCD23 fragments exert their regulatory function on IgE synthesis remain unclear, 
the interaction with CD21 appears to play a key role. When CD21 was identified as a 
second ligand for CD23 (Pochon et al., 1992), its potential in IgE regulation was 
explored. Aubry et al. (1992) demonstrated that the engagement of CD21 by antibodies, 
or the addition of recombinant sCD23, could increase IL-4-dependent IgE synthesis 
from PBMCs. On the other hand, treatment with certain anti-CD23 antibodies causes 
the opposite effect, by preventing CD23 cleavage into IgE-stimulating fragments 
(Aubry et al., 1992; Bonnefoy et al., 1990). 
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1.9 IgE feedback mechanism: co-crosslinking of membrane IgE (mIgE) and 
CD21 by CD23 
1.9.1 Introduction: B cell activation by co-crosslinking of membrane IgM 
(mIgM) and CD21 
Lymphocytes must be able to proliferate in response to very low concentrations of 
antigens. The broad specificity and sensitivity to a vast array of antigen recognition sites 
cannot be met by an individual's naive B cell receptor (BCR) repertoire, which consists 
of low affinity receptors that form through gene rearrangement taking place in the 
absence of antigen. In naive B cells, this low affinity BCR (membrane IgM, mIgM) is 
aided by the presence of the co-receptors CD21 and CD 19 which lower the threshold for 
B cell proliferation by up to two orders of magnitude (Carter and Fearon, 1992). The 
activation of B cells by co-ligation of mIgM and CD21/CD19 was tested directly by 
Dempsey et al. (1996) who prepared fusion protein multimers of the complement 
cleavage component C3d and hen egg lysozyme (HEL). By crosslinking the HEL- 
specific BCR and CD21 with the C3d-HEL fusion protein, they found that the threshold 
of B cell activation was reduced by several orders of magnitude and was accompanied 
by the proliferation of cells and secretion of HEL-specific IgM. These observations 
provided the basis for a model in which it is proposed that sCD23 can cause the up- 
regulation of IgE from IgE+CD21+ B cells (figure 1.6). By analogy with complement- 
decorated antigen co-crosslinking mIgM and CD21 and thereby activating naive B cells, 
CD23 could co-ligate mIgE and CD21 on IL-4-stimulated IgE+ cells causing cell 
proliferation and up-regulation of IgE. 
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sCD23 
mlgE CD21 
Figure 1.6: sCD23 co-ligation of mIgE and CD21 
By analogy with the antigen-specific naive B cell activation by antigen complexed with 
complement, B cells expressing mIgE and CD21 may be activated through co-ligation of these 
molecules by sCD23 leading to up-regulation of IgE synthesis. 
1.9.2 IgE Feedback mechanism 
A feedback mechanism for the regulation of IgE by CD23 and CD21 has been proposed 
by Gould and colleagues (Gould et al., 1997). This is illustrated in figure 1.7. It is 
proposed that following allergen exposure, IL-4 released from mast cells sensitised by 
IgE, induces CD23 up-regulation and release from B and T cells. This local source of 
sCD23 can bind to membrane CD21 on B cells and, through possible co-ligation with 
membrane IgE, induce IgE up-regulation in the IL-4-rich milieu. As IgE levels rise 
above the affinity constant for its low affinity receptor, the positive feedback is 
terminated as IgE and IgE-allergen complexes bind both to sCD23 fragments, 
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sequestering them from CD21, and to mCD23, transmitting an inhibitory signal on IgE 
production from the B cell. This negative feedback mechanism ensures that allergen- 








Figure 1.7: Feedback mechanism for the regulation of IgE by CD23. 
The ligation of CD23 on the surface of B cells by IgE complexed with allergen is hypothesised 
to cause the downregulation of IgE from committed B cells. When IgE concentrations drop 
below the affinity constant for IgE binding to mCD23, mCD23 is cleaved from the cell surface. 
Soluble CD23 acts as a mitogen and growth factor for B cells and could act by co-ligating both 
mIgE and CD21 on the surface of activated B cells. These B cells are rescued from apoptosis 
and respond by proliferating and secreting IgE. As levels of IgE rise above the affinity constant 
for IgE binding to mCD23, IgE synthesis is down-regulated by signalling through mCD23 that 
is no longer cleaved from the cell surface. 
1.9.3 CD23-CD21-IgE interactions 
Until recently, there was a lack of structural evidence to substantiate the above 
hypothesis. The binding of CD23 to CD21 relies, in part, on the "lectin like" protein- 
carbohydrate recognition (Aubry et al., 1994), whereas CD23-IgE binding is 
independent of glycosylation (Vercelli et al., 1989a; Young et al., 1995) but probably 
dependent on calcium (Richards and Katz, 1990; Wurzburg et al., 2006). Simultaneous 
interaction between all three molecules, however, was still speculative. Recent NMR 
data has established that the binding sites for CD21 and IgE on CD23 are distinct and 
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non-overlapping (Hibbert et al., 2005). This was confirmed by forming a CD23-IgE- 
CD21 trimolecular complex using a Der p 1-cleaved CD23 fragment (derCD23) and 
CD21 (SCR 1-2). Oligomeric sCD23 fragments could therefore crosslink multiple 
CD21 and mIgE molecules with the potential to create large cross-linked networks on 
the B cell surface. 
1.10 Aims of this thesis 
It has proven difficult to reproduce the high affinity binding of IgE to CD23 using 
recombinant fragments of sCD23. Only a chimeric form of CD23, in which an 
isoleucine zipper was attached to the extracellular domain of CD23, was found to bind 
to IgE with a comparable affinity (Kelly et al., 1998). This molecule, known as LZ- 
CD23, formed a more stable trimer, and it was even shown to inhibit IgE binding to the 
high affinity IgE receptor, FcsRI. 
LZ-CD23 was therefore reconstructed for the work described in this thesis to further 
characterise the CD23-IgE and CD23-CD21 interactions and to investigate further 
whether they might act in concert to regulate IgE synthesis from B cells. LZ-CD23 was 
purified following a bacterial expression, using vectors kindly donated from the 
laboratory of D. Conrad at the Virginia Commonwealth University, USA. Its molecular 
weight has been assessed by analytical ultra-centrifugation and gel filtration 
chromatography, and its binding properties were explored using surface plasmon 
resonance. 
The capacity of LZ-CD23 to co-ligate CD21 and IgE on the surface of primary human 
B cells was also investigated by confocal microscopy, and its ability to up-regulate IgE 
synthesis from primary human B cells was assessed by cell culture and ELISA. 
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Chemicals, reagents, buffers, solutions and media 
All chemicals were purchased from Sigma and solutions diluted in deionised water 
unless otherwise stated 
Acrylamide: 30% (w/v) acrylamide/0.8% (w/v) bis-acrylamide stock (Severn biotech) 
APS: Ammonium persulphate prepared as a 10% stock and store at 4°C 
Bicarbonate buffer (pH 9): 0.1 M NaHCO3 
Carbonate-bicarbonate buffer (pH 9.8): 11% 0.2M anhydrous sodium carbonate, 
14% 0.2M sodium hydrogen carbonate 
Coomassie Blue Stain: 0.05% Coomassie brilliant blue dissolved in methanol, 
deionised water and acetic acid mixed at a 5: 5: 1 ratio 
Coomassie destain: 5% methanol, 7.5% acetic acid 
DTT: Prepared as a1M stock and stored at -20°C 
Extraction solution 1: 10 mM Tris-HCl pH 7.9,25% sucrose, 0.1 M KCI, 10 mM 
DTT, 2 mM PMSF 
Extraction solution 2: 300 mM Tris-HCl pH7.0,100 mM EDTA, 0.1 g lysozyme 
Extraction solution 3: 20 mM EDTA, 1M LiC1,0.5% Igepal 
Extraction solution 4: 10 mM Tris-HCl pH7.9,2.5 mM EDTA, 1M LiCI, 0.5% Igepal, 
10 mM DTT, 1 mM PMSF 
Extraction solution 5: 10 mM Tris-HC1 pH 7.9,2.5 mM EDTA, 2% Igepal, 10 mM 
DTT, 2 mM PMSF 
Extraction solution 6: 10 mM Tris-HC1 pH7.9,2.5 mM EDTA, 0.5% Igepal, 10 mM 
DTT, 2 mM PMSF 
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FACS Buffer: 4% normal goat serum in PBS 
FACS Fix Buffer: 1% Formaldehyde in FACS buffer 
Gel Filtration run buffer: 0.5M Tris-HC1 pH 7.2,250 mM NaCl, sterile filtered 
HBS-Ca: Hepes buffer with calcium used for surface plasmon resonance. 10 mM 
Hepes, 150 mM NaCl, 2 mM CaCl2,0.05% NaN3,0.005% surfactant p20 
Hypotonic buffer for CD21 ELISA: 10 mM sodium phosphate (pH 7.4), 25 mM NaCl 
Luria-Bertani media: IOg bactotrypone, 5g yeast extract, 10g, NaCl pH 7.5 dissolved 
in 1L of deionised water then autoclaved to sterilize 
M9 Salts (5X, 1L): 27.3g Na2HPO4,12g KH2PO4,2g NaCI, 4g NH4C1 
M9 media (500m1): 100ml 5X M9 salts, 361 ml deionised water, OA M CaC12,1 M 
MgSO4 then autoclaved and supplemented with 12.5m1 20% casamino acids, 25m1 
glucose and 0.5m1 10 mg/ml thiamine 
MACS buffer: 2 mM EDTA, 0.5% BSA in PBS, sterile filtered 
Microscopy cell fixative: 2% formaldehyde, 0.05% NaN3 in sterile PBS 
PBS: 0.14M NaC1,2.7 mM KC1,1.5 mM KH2PO4,8.1 mM Na2HPO4, pH7.4 
PBS-T: PBS with 0.05% TWEEN-20 
PMSF: Prepared as a 100 mM stock in isopropanol and stored at -20°C 
SDS-PAGE gel sample buffer (4X): 0.25M Tris-HC1 pH6.8,0.01% Bromophenol 
Blue, 40% glycerol, 8% SDS (with 10% ß-mercaptoethanol added for reducing buffer) 
SDS-PAGE gel running buffer (10X, 1L): 30.2 g Tris pH 6.8,114g Glycine, IOg SDS 
SDS-PAGE buffer for stacking gel: 0.5M Tris H-C1,0.4% SDS, pH 6.8 
SDS-PAGE buffer for separation gel: 1.5M Tris-HC1,0.4% SDS, pH 8.8 
TEMED: NNN'N'-tetramethylethylenediamine 
TBS: 50 mM Tris-HC1 pH 7.4,100 mM NaCl 
Western blot anode buffer: 0.3M Tris-HCl pH 10.4,20% methanol 
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Western blot cathode buffer: 25 mM Tris-HCl pH 9.4,40 mM c-aminocaproic acid, 
20% methanol 
2.1.2 Antibodies and recombinant proteins 
Table 2.1: Anti-CD23 antibodies 
Antibody Source Epitope Application 
BU38 I. MacLennan, Birmingham, 
UK Lectin head Western blot, ELISA 
EBVCS-4 W. Sugden, WI, USA Lectin Head ELISA 
CD23-FITC 
(MHM6 DakoCytomation, Ely, UK Lectin head FACS 
clone) 
Table 2.2: Anti-CD21 antibodies 
Antibody Source Epitope Application 
BU32 Biogenesis, Poole, UK SCR 9-11 Microscopy, FACS 
BU33 I. MacLennan, Birmingham, SCR 5-8 ELISA, microscopy, 
UK FACS, western blot 
IF8 Biogenesis, Poole, UK SCR R 12 Microscopy, FACS 
HB5 ATCC SCR 3-4 ELISA, microscopy, FACS 
Anti-CD21 APC BD Unknown FACS (BLy4 clone) 
Table 2.3: Anti-IgE antibodies 
Antibody Source Specificity Application 
Goat anti-IgE Vector, Polyclonal FACS, microscopy FITC/biotin Peterborough, UK 
Rabbit anti-human DakoCytomation 
IgE capture , Ely, UK 
Polyclonal ELISA 
antibody 
Goat Anti-human DakoCytomation, Polyclonal Western blot 
IgE HRP Ely, UK 
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Table 2.4 Other antibodies 
Antibody Source Specificity/Isotype Application 
Mouse-HRP DakoCytomation, Rabbit anti-mouse ELISA Ely, UK 
Streptavidin-HRP Aersham, Bucks, N/A ELISA UK 
Anti-CD40 G28.5, ATCC Mouse anti-human Cell culture 
Mouse-FITC/RPE DakoCytomation, IgGI FAGS control Ely, UK 
Rabbit-FITC/RPE DakoCytomation, omation, Igel FAGS control y, UK 




Mouse anti-human Microscopy 
Table 2.5 Fluorochromes/secondary antibodies 
Antibody Source Isotype Application 
Goat anti mouse Molecular probes, IgG1 Microscopy/FAGS 
Alexa 488 Eugene, OR, USA 
Streptavidin-RPE 
DakoCytomation, N/A FAGS 
Ely, UK 
Streptavidin-Cy3 
Amersham, Bucks, N/A Microscopy 
UK 
Anti biotin-Cy3 
JaI kson, Soham, N/A Microscopy 
U 
Table 2.6 Recombinant proteins and purified proteins 
Protein Source Application 
derCD23 
E. coli expressed and purified by Biacore, ELISA 
G. Grundy and S. Fabiane 
sCD21 SCR 1-16 
Baculovirus expression. Gift Biacore, ELISA 
from VM. Holers, CO, USA 
sCD21 SCR 1-2 
Baculovirus expression. Gift Biacore, ELISA 
from J. McDonnell, Oxford, UK 
Anti-NIP IgE ATCC ELISA 
IgE standard WHO ELISA 
IL-4 R&D systems Cell culture 
Transferrin Sigma Cell culture 
Insulin Sigma Cell culture 
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2.2 Protein expression in E. coli 
2.2.1 LZ-CD23 Protein Expression 
lOng recombinant LZ-CD23 expression vector (kind gift from Dr. D. Conrad, 
University of Virginia) was used to transform BL21 competent cells (Invitrogen). 
Transformation involved heat shocking the cells for 90 seconds at 42°C and selecting 
transformed cells by growing on LB plates containing 30 µg/ml kanomycin. A single 
colony was selected and grown in lml LB media with 30 µg/ml kanomycin for 8 hours. 
This lml culture was added to an overnight culture of 200ml M9 media containing 30 
µg/ml kanomycin, 20% casamino acids, 20% glucose, 10 mg/ml thiamine, 0.1 M CaC12 
and IM MgSO4. The following day 20ml overnight was added to 500ml M9 medium. 
containing 30 pg/ml kanomycin and the above supplements, in a 2L conical flask. The 
culture was incubated at 37°C with orbital agitation at 200 RPM until the A600 reached 
0.6-1.0. Expression of LZ-CD23 was then induced with 0.4 mM IPTG. Following a 
further 4 hour incubation period, cells were harvested by centrifugation at 5000 RPM 
for 30 minutes in a GSA rotor. Pellets were frozen at -80°C. 
2.2.2 Extraction of LZ-CD23 from Inclusion bodies: Method 1 
Inclusion bodies were extracted using a method modified from that described by 
Bohmann and Tjian (1989). The cell pellet was resuspended in 72m1 of extraction 
solution 1 to which 18m1 of extraction solution 2 was added and incubated on 
ice for 10 
minutes. 90ml of solution 3 was added then vortexted and sonicated on 
ice to break up 
larger cellular clumps, then centrifuged for 10 minutes at 10,000 RPM 
in a GSA rotor at 
4°C. The cell pellet was then resuspended in 200m1 solution 4, sonicated and pelleted as 
before. This step was repeated using the same volumes of solutions 5 and 6. The 
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resultant pellet of inclusion bodies was solubilised in 5ml 6M Guanidine-HCI. Insoluble 
material was removed by centrifugation for 5 minutes at 10,000 RPM at 4°C. Dissolved 
protein was stored in aliquots of 20 mg at -80°C. 
2.2.3 Extraction of LZ-CD23 from inclusion bodies: Method 2 
A commercial extraction solution was chosen to increase protein yield and abrogate the 
need for repeated sonication. The protocol for BugBuster Protein Extraction Reagent 
was followed according to the manufacturer's handbook (Novagen). 
2.2.4 Refolding 
The refolding method was adapted from Taylor et al., (1992). In brief, 20mg of protein 
in 6M Guanidine was reduced on addition of 10 mM DTT in 100 mM Tris-Acetate, pH 
8.6 and incubated at room temperature for 1 hour. Protein was then diluted 10-fold in 6 
M Guanidine, 0.5 M Tris-Acetate, pH 8.6 and 100 mM oxidised Glutathione. The 
protein was incubated for 24 hours at 4°C. The protein was then further diluted 100-fold 
into refold buffer containing 100 mM Tris-Acetate pH8.6, IM Guanidine-HCI, 3 mM 
cysteine and 2 mM CaC12. The dilution was performed slowly in order to minimise the 
formation of aggregates. The protein was then allowed to refold at 4°C for 36 
hours in 
the dark. 
2.2.5 Concentration of protein 
To avoid degradation by proteases, refolded LZ-CD23 in solution contained 
10 µM 
TLCK and EDTA-free Protease Inhibitor Cocktail tablets (Roche) and 
2 mM CaCl2. 
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Proteins were concentrated by ultrafiltration using 10 kDa MW cut off PLGC 
membranes (Millipore) in Amicon stirred cells. The ultrafiltration process was carried 
out at 4°C under pressure from compressed nitrogen. 
2.2.6 Gel filtration chromatography 
A Biosep 200 column (Phenomenex) was chosen following previous success purifying 
other recombinant CD23 fragments by R. Reljic and G. Grundy. The column was 
equilibrated with 0.25 M Tris-HC1,0.125 M NaCl, pH 7.2, at a flow rate of 
0.75m1/minute. 500 µl aliquots of refolded LZ-CD23 were injected onto the column and 
separated according to size. Aggregated material elutes first in the dead volume, being 
unable to diffuse into the pores of the gel matrix and refolded material of variable size 
elutes later as a function of size and shape. 
2.3 Protein characterisation 
2.3.1 Estimation of protein concentration 
In order to accurately assess the amount of protein present in a sample, UV 
spectrophotometry was employed. A spectrum measuring wavelengths between 240 and 
340 nm was recorded on a Cary Varian UV-visible spectrophotometer using an 
appropriate buffer as a baseline blank. An estimate of the protein concentration using a 
1 cm pathlength quartz cuvette (Hellmann) was calculated from the 
Beer Lambert 
equation: 
A= csl (2.3.1) 
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where A is the absorbance at 280nm, c is the concentration (mg/ml), c the molar 
extinction coefficient (M-icm-') and 1 is the pathlength (cm). The absorbance of a1 
mg/ml solution can be determined by the ratio of c (calculated from the sequence by 
Pepsort) to molecular weight. Table 2.7 contains values for recombinant proteins used 
in this thesis: 
Table2.7: Absorbance values used to calculate concentrations for recombinant 
proteins 
Protein Molecular weight (Da) 
Extinction coefficient 
(M-1 cm-1 ) 
A280 of 1 mg/ml 
LZ-CD23 36,831 58,090 1.58 
derCD23 16,145 45,430 2.81 
IgG 150,000 204,000 1.36 
IgE-Fc 124,410 95,700 1.3 
sCD21 112,973 149,740 1.33 
sCD21 (1-2) 17,391 26,510 1.52 
2.3.2 SDS-PAGE 
SDS-PAGE was employed throughout the protein purification process as a means of 
assessing the presence of a protein, its purity and its approximate molecular weight. 
Electrophoresis methods were based on the method employed by Laemlli (1970) and 
used gels prepared according to the recipes displayed in table 2.8. Following boiling in 
loading buffer (with or without reducing conditions), up to 30µ1 samples were loaded 
onto the gel. The molecular weight marker mixture used was SeeBlue Plus 2 
(Invitrogen). A voltage of up to 150 mV was applied and protein allowed to separate 
until the dye front reached the bottom of the gel. 
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Table 2.8: Solution ratios for SDS-PAGE mini gels 
Stacking 8% 10% 12% 14% 15% 
gel separation separation separation separation separation 
H2O (ml) 3.18 4.83 4.03 3.18 2.84 2.36 
Gel buffer 
(ml) 1.25 2.50 2.50 2.50 2.50 2.50 
30% 




50 50 50 50 50 50 
TEMED 
(µl) 
25 7.5 7.5 7.5 7.5 7.5 
2.3.3 Coomassie gel staining 
Coomassie blue stain was used to visualise proteins separated on SDS-PAGE gels for 
between 5-10 µg of sample per well. Gels were soaked in the staining solution and 
incubated overnight at room temperature on an orbital shaking platform. To remove the 
background stain, coomassie de-stain solution was applied for up to 48 hours until the 
protein bands were visible. 
2.3.4 Western blotting 
Western blotting was used as a means to visualise specific proteins samples run on a gel 
at concentrations as low as 5 ng/well. To this end, several protein samples, titrated to 
between 100-10 ng per gel well were added to each gel to achieve bands that were sharp 
and distinct, neither overloaded nor too low to visualise all molecular weight species in 
a sample. Following electrophoresis, proteins were transferred to nitrocellulose 
(Schleicher and Schuell) by a semi-dry method. For this method, 2 pieces of thick 
Whatman blotting paper soaked in either anode or cathode buffer were used to sandwich 
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the nitrocellulose-gel layer between electrode plates. The nitrocellulose is positioned to 
face the anode layer. At 20v, transfer of the highest molecular weight marker was 
usually complete by 30-40 minutes. 
The nitrocellulose membrane was then blocked with 2% milk powder in PBS-Tween 
(PBS-T) for 1 hour at room temperature or overnight at 4°C. CD23 was probed with 1 
µg/ml BU38 (or BU38-biotin) in 1% milk/PBS-T for either 1 hour at room temperature 
or over-night at 4°C with gentle agitation. Unbound antibody was washed away with 
two, 10-minute washes with PBS-T. A polyclonal rabbit anti-mouse-HRP antibody or 
steptavidin-HRP (DakoCytomation) was applied at 1/2000 in 1% milk-PBS-T for 1 
hour at room temperature. The membrane was then washed 4 times with PBS-T before 
addition of SuperSignal chemoluminescence substrate (Pierce). Protein bands were 
visualised by exposing the membrane to autoradiography film (Kodak). The film was 
developed using an X-automat machine. 
2.4 Sedimentation equilibrium analytical ultracentrifugation 
2.4.1 Principles of sedimentation equilibrium 
Sedimentation equilibrium is an analytical ultracentrifugation (AUC) technique that 
measures the response of a protein in solution spun at speeds that over time cause the 
establishment of a concentration equilibrium between sedimentation of protein away 
from the rotational axis and the back diffusion of molecules through a solvent. For 
sedimentation equilibrium, the sedimentation and back diffusion forces cancel out and 
net transport of molecules is equal to zero. The concentration distribution across the cell 
becomes independent of molecular shape and it is possible to determine the 
homogeneity of a sample as species of different molecular weights and stoichiometry 
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diffuse along the concentration gradient as a function of the molecular mass or masses 
of the components. 















Figure 2.1. Forces experienced by a sample in a sedimentation experiment 
The sample chamber rotates around the Axis A at an angular velocity Co. The sedimentation, or 
centrifugal force, experienced by the sample is represented as Fc with opposing buoyant (Fb) 
and drag (Fd) forces acting in the opposite direction. 
The above figure suggests that, when a sample in solution is exposed to a centrifugal 
force there are three forces acting on it at any one time. The sedimentation or centrifugal 
forces relate to the mass (m) of the protein and the angular velocity of the rotor (air). 
The counter forces combining the upward buoyant force and the viscous drag of the 
solvent are related to the space occupied by the protein in solution, known as the partial 
specific volume, (v' and the density of the solvent, (p). The net force (F) can be 
summarised thus: 
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F=w rM(1-vp) (2.4.1) 
where M is the relative molecular mass and r is the distance from the centre of rotation. 
The velocity (v) acquired by the sample is dependent on the frictional coefficient of the 
sedimenting particle (fi and the angular velocity and is defined as the sedimentation 
coefficient, s (or velocity to centrifugal force ratio) where N is Avogadro's number: 
v M(l - vp) s= _ 
w2r Nf 
(2.4.2) 
The equilibrium between the centrifugal force and the back diffusion (D) can be 




Where R is the gas constant, T the absolute temperature in Kelvin and f the frictional 
coefficient. The sedimentation coefficient (s) and diffusion coefficient (D) can be 
combined to give the following ratio: 
S M(1- vp) 
D RT 
(2.4.4) 
This combination is a common way of determination the molecular weight, M of 
macromolecules. 
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At equilibrium, the balance between component sedimentation and upward diffusion 
can be expressed thus: 
rD 
dC 
= sw2r2C dr 
(2.4.5) 
Where D is the diffusion constant, s the sedimentation coefficient, e the angular 
velocity and dC the concentration of sample at any radial position, r. 
2.4.2 Experimental procedure 
All experiments and data analysis were kindly performed by R. Beavil using a Beckman 
XL-A. Samples are monitored in real time by UV visual absorbance measured as a 
function of the radial position along the sample cell. Figure 2.2 illustrates the setup of a 
sedimentation equilibrium experiment where the concentration gradient of a sample cell 












Figure 2.2: Schematic of a two sector AUC cell for sedimentation equilbrium 
The concentration of the sample at any radial position is measured by the absorbance 
and the partial specific volume (v) is determined from the amino acid sequence and 
corrected to 4°C. Solvent densities (p) for TBS have previously been measured (Shi et 
al., 1997). Rotor speeds were adapted depending on the expected CD23 oligomer size 





Speed RPM = 
2.336x1012 (2.4.6) 
M(1- vp) 
In addition, I N2 of this speed and the average of the two speeds was calculated to give 
three different speeds to accurately measure the buoyant molecular mass: M(1- vp) as 
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described previously (Shi et al., 1997). Data was acquired as an average of 25 
absorbance measurements at a wavelength of 280 nm and a radial spacing of 0.001 cm. 
2.4.3 Data analysis 
Data was analysed using SigmaPlotTM software to apply curve fits and to generate 
residual plots used to assess the quality of the fit. The simplest model would describe a 
pure, non-associating protein preparation and is modelled on the following single, ideal 
fit using absorbance values measured during the experimental run: 
Ar = Ao[HM(1 1PXr2-ro2)] +E (2.4.7) 
Where Ar = absorbance at radius r, A0 = absorbance at reference radius r0, M= 
molecular weight, v= partial specific volume, p= density of the solvent, H describes a 
rotor speed constant, w2/2RT (w = angular velocity or 27t/60 x RPM, R= gas constant 
and T= absolute temperature in Kelvin) and E=a baseline correction term calculated 
by centrifuging the sample at high speed to deplete the meniscus of sedimentable 
absorbance. 
Equation 2.4.7 can be modified to describe a model where a protein self-associates into 
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A single species (monomer): 





Second species (dimer): 
Ar = A2 
[2HM(1-vpXr2-r02)] 
(2.4.10) 




Where A2 = A, 2 x kl (kl for monomer - dimer association) and A3 = A13 x k2 (k2 for 
monomer - trimer association). The combined equation for the monomer-dimer-trimer 
fit is merely a sum of the exponentials and can be written: 








A third model was applied to the LZ-CD23 data set to describe a mixture of non- 
interacting protein species. For example, for a protein sample containing 2 components, 
Al and A2: 
A2 alone = AOAI 
[HM. 
41(1-v. 4l oXr2ro2 
)] (2.4.13) 
and: 
Al alone = A0A2[HM. 
a2 (I-V: 12PXr2ro )] (2.4.14) 
Thus: 
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- VA 2PXr2 ro 
2 )1 
oat E (2.4.15) 
ods 
The above equations were used to model the sedimentation equilibrium data in chapter 
4, section 4.4. 
2.5 Surface plasmon resonance (SPR) 
2.5.1 Principles of SPR 
SPR was used to study the kinetics of the interaction between CD23 and IgE. SPR- 
based instruments use an optical method to measure the refractive index changes near a 
sensor surface. In the case of an SPR sensor chip, this surface is the base of a flow cell 
to which a ligand is immobilised to either carboxymethylated dextran chains (CM5) or 
(in the case of a biotinylated ligand) a streptavidin surface itself coupled to a thin metal 
surface. The term surface plasmon resonance refers to the change in intensity of 
monochromatic polarised light which is reflected at a specific angle when surface 
plasmons (electromagnetic waves that propagate parallel to a metal interface) are 
excited at a metal surface. The metals that support surface plasmons are typically gold 
or silver and the angle where the "dip" in intensity is observed is known as the SPR 
angle. SPR reflectivity measurements can be used to detect protein interactions by the 
changes in local refractive index when the target molecule is adsorbed to the gold 
surface. When an analyte binds to its ligand, the angle of incidence increases and the 
change from unbound to bound can be measured in real time and plotted as response 









Resonance signal (RU) 
Materials and Method 
Refleded intensity 
REflected intensity 
Figure 2.3: Illustration of SPR principles 
Binding of an analyte (green ellipses) to an immobilised ligand (red ellipses) can be measured 
by the change in refractive index of the SPR angle at the receptor surface (yellow bar). The shift 
between angle X and angle Y, observed when analyte is bound (B) or unbound (A) to ligand, 
can be plotted as a change in resonance signal, also known as a resonance unit (RU), as a 
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A major advantage of SPR analysis is that the binding response is particularly sensitive 
where 1 RU is the equivalent of around 1 pg mm-2. The need for large amounts of 
proteins is therefore abrogated and association and dissociation rates can be measured 
between very weakly interacting binding partners (<106 M- I). 
2.5.2 Preparation of the sensor chip flow cells 
The interaction between LZ-CD23 and IgE was measured using IgE Fc bound to a 
Biacore sensor chip. A sensor chip comprises 4 flow cells, to which the ligand is 
immobilised by primary amines (CM5 sensor chip) or streptavidin-biotin (SA sensor 
chip). On each sensor chip, one flow cell is kept free from ligand and used as a negative 
control background signal, which is subtracted from the experimental sensorgrams. To 
avoid the problems associated with achieving favourable orientations for IgE 
immobilisation, a biotinylated version of the IgE Fc was used and tethered with high 
affinity to a streptavidin-coated chip. The flow cell for the LZ-CD23-IgE Fc interaction 
was prepared by immobilising a medium density of 500-700 RUs of protein diluted in 
0.1 M sodium acetate buffer, pH 4.0. Unbound sites and the empty, negative flow cell 
were then blocked by injecting 1 µg/ml biotin. 
The binding kinetics of a monomeric CD23 fragment (derCD23) and IgE Fc were also 
examined. As well as measuring the interaction for derCD23 flowed over IgE Fc, the 
reverse orientation was also investigated. To achieve this, derCD23 in PBS was directly 
coupled to an EDC: NHS-activated CM5 carboxymethyl dextran chip surface at a 
similar, medium density of around 500 RUs. Since amine-coupling chemistry is 
involved in CM5 sensor chip preparation, neither LZ-CD23 preparation could be 
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coupled to a sensor chip in the same way as IgE Fc due to the presence of the amine 
Tris in both buffers. 
2.5.3 Flow cell regeneration 
A typical running buffer used for SPR analysis is HBS containing EDTA to chelate 
contaminating metal ions. Due to the calcium-dependent nature of CD23 binding, the 
presence of EDTA abrogated any binding between LZ-CD23 and IgE Fc. On removal of 
EDTA, and on addition of 2 mM CaCl2, a binding signal was evident, but due to the 
differences in refractive indices between the running buffer (HBS) and buffers into 
which LZ-CD23 was stored (gel filtration buffer or TBS-Ca) there was a substantial 
bulk change that could not easily be corrected using the BiaEvalution software. To 
minimise this problem, the same running buffer used to store the analyte (either gel 
filtration buffer or TBS) was used. 
To regenerate a binding surface after each run, for subsequent kinetic analysis, the 
interaction between ligand and analyte must be disrupted. This is typically achieved by 
injecting buffers of low pH or high salt concentration over the binding surface. The LZ- 
CD23 - IgE Fc binding surface was not readily disrupted by repeated injections of 
glycine pH 2.5, as shown by the sensorgrams which did not reach a stable baseline. 
Since LZ-CD23 did not bind in the presence of EDTA, running buffer supplemented 
with 10 mM EDTA was therefore used to regenerate the binding surface, and following 
optimisation of this method, it was found that three injections of 10 µl were sufficient to 
achieve identical replicate traces. 
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2.5.4 Experimental procedure 
All experiments were carried out at 25°C using a BiacoreTM 3000 (Biacore Int. SA, 
Switzerland. ) LZ-CD23 in gel filtration-Ca buffer or TBS-Ca, or derCD23 in HBS-Ca 
were injected over the immobilised IgE Fc chip in duplicate at a variety of 
concentrations at a flow rate of 20 µl/min with an association phase of 360 seconds and 
dissociation phase of 480 seconds. FcE2-4 was injected over the derCD23 chip in 
duplicate at a variety of concentrations at a flow rate of 2Oµ1/min with an association 
phase of 360 seconds and dissociation phase of 480 seconds. Regeneration of the 
interaction surfaces for both proteins was achieved by 3 injections of EDTA at a 
concentration of 10 mM in TBS or gel filtration buffer. Data was analysed using 
BlAevaluation Software 4.01 (Biacore, Switzerland). 
2.5.5 Kinetic analysis 
The simplest interaction describes a 1: 1, ligand: analyte, association which can be 
described by the Langmuir model described below: 
A+BH AB (2.5.1) 
Where the association rate can be written: 
d[ABI 
= kQ [AB] (2.5.2) dt 
And the dissociation rate: 
- 
d[AB] 
= kd [AB] (2.5.3) dt 
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At equilibrium the association and dissociation rates are equal: 
ka[A]ABI =kd[AB] (2.5.4) 




= kD kp [AB] 
(2.5.5) 
Or the equilibrium constant: 
kQ [AB] 
= kA (2.5.6) kd [A][B] 
Terms used in SPR analysis are substituted into the rate equation so that: 
d [AB] 
-k a 
[A] [B] _ kd [AB] (2.5.7) dt 
becomes: 
dR 
= kaC(Rmax -R)-kdR (2.5.8) dt 
Where C is the concentration of ligand [A]. Rm equals the concentration of 
immobilised receptor [B] and R is the SPR signal associated with the formation of 
complex [AB]. 
For the interaction between LZ-CD23 and IgE, a second model was used to appreciate a 
more complex binding event. The following model was applied to the interaction 
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between a full length monomeric CD23 fragment (exCD23) and IgE Fc by Hibbert et al. 
(2005). The model assumes that the interaction is biphasic and involves the competition 
of monomeric or oligomeric CD23 for the same binding site on the Cs3 domain of 
Fcc2-4. This can be described thus: 
Al +BH AM (2.5.9) 
plus: 
A2+Bt-> A2B (2.5.10) 
where Al = monomeric CD23, A2 = oligomeric CD23 and B= the ligand CO of Fcs2- 
4. Two rate equations can then be derived: 
dR l- kal C, 41 (Rm. - Rl - R2 - kdl RI (2.5.11) dt 
dR2 
-k a2CA2 
(Rm - R1 - R2) - kd2 R2 (2.5.12) dt 
where the total response is the sum of R1 and R2. From these parameters a fit will 
incorporate values for two association and two dissociation constants. 
The BIAevalutionTM software is able to solve the above equations and apply the fit to 
the data curves. A plot of residuals between the fit and data is an indication of the 
quality of the fit where points randomly distributed round zero indicates a good fit. A x, 
2 
value is also calculated from the residuals and is also an indication of the closeness of 
the fit where a value between 0 and 2 was considered suitable. 
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2.6 Cell culture 
2.6.1 Culture of Raji and AF10 B cell lines 
Raj i and AF 10 cell lines were used in microscopy experiments to test antibodies against 
CD21 and IgE respectively. The Raji cell line is aB lymphocytoma established from a 
Burkitt's Lymphoma (EBV) patient (Pulvertaft, 1964). AF 10 cell lines were derived 
from the IgE myeloma cell line, U266 (Hassner and Saxon, 1984; Sherr et al., 1989). 
Both cell lines were cultured in RPMI 1640 media supplemented with l0µg/ml 
penicillin, 100µg/ml streptomycin, 2 mM glutamine and 10% FCS (all Gibco). Cells 
were maintained at a concentration of 5x 105 ml-' and passaged 24 hours prior to use. 
2.6.2 Isolation of human tonsillar B cells 
Tonsils were obtained with ethical approval following informed consent from patients 
undergoing routine tonsillectomies from Guy's and St. Thomas' Hospital NHS Trust, 
London. Tissues were disrupted by cutting with sterile forceps and scalpel to release 
cells into 5m1 RPMI 1640. Suspended cells were removed and stored and the tissue 
further disrupted several times until no more cells were released. Fibrous tissue was 
allowed to sediment under gravity for 5 minutes and the supernatant removed and 
centrifuged at 1500 RPM for 7 minutes. The pellet was resuspended in 4m1 RPMI 1640 
and layered onto 9m1 Ficoll and centrifuged at 2000 RPM for 20 minutes (brake off). 
The interface was removed by pipetting, washed in RPMI and centrifuged at 1500 RPM 
for 10 minutes. T lymphocytes were then depleted by rosetting mediated by sheep red 
blood cells (SRBC) treated with 2-amino-ethylisothiouronium bromide (AET). 
SRBC- 
AET were prepared by washing 25m1 SRBCs (TCS Biosciences) with PBS 
for 10 mins, 
1200 RPM. This was repeated 4 more times before addition of 10ml 2% AET, pH8 
for 
15 mins 37°C. The SRBCs were then washed a further 4 times in PBS and resuspended 
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in 25 RPMI 1640 culture media. CD3+ rosetting was achieved by adding 3ml SRBC- 
AET to the cell pellet followed by centrifugation at 800 RPM for 2 minutes. Cells were 
then incubated at 4°C for 30 minutes. Following gentle resuspension, cells were layered 
onto Ficoll and centrifuged at 2000 RPM for 20 minutes (brake off). Cells from the 
interface were removed by pipetting and washed with complete media (CM) (RPMI 
1640 supplemented with 10µg/ml penicillin, 100µg/ml streptomycin, 2 mM glutamine 
and 10% FCS (HyClone)) and centrifuged at 1000 RPM for 10 minutes. The phenotype 
of these cells was assessed by flow cytometry at this stage and the cells treated again 
with AET-SRBC if levels of T cells were above 3%. Residual red blood cells were lysed 
by osmotic shock to the cell pellet then immediately topping up with additive- 
supplemented RPMI followed by centrifugation at 1200 RPM for 5 minutes. Cells were 
resuspended in RPMI culture media supplemented with the above additives and FCS, 
counted by 0.4% Trypan blue exclusion and concentrations adjusted to 5x 105 ml-1. 
2.6.3 Isolation of B cells from human peripheral blood mononuclear cells 
(PBMCs) by MACS 
The blood of allergic and non-allergic patients was obtained by V. Carr in the laboratory 
of S. Durham, Royal Brompton and Harefield NHS Trust, London. Patients were 
characterised as allergic or non-allergic based on the results of a skin-prick tests (SPT) 
and radioallergosorbent tests (RAST). ACD-treated blood (90 ml) was diluted 1: 1 in 
PBS. 20 ml of blood/PBS was layered onto 15 ml Ficoll and centrifuged for 2000 RPM 
for 20 minutes (brake off). Cells from the interface were pipetted off and washed in PBS 
by centrifugation at 2000 RPM for 10 minutes. The cell pellet was resuspended in 
MACS buffer, counted and CD19+ B cells were separated by a MACS LS column 
according to the manufacturer's handbook (MACS CD19 Multisort kit. Miltenyi- 
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Biotec). Following separation, cells were resuspended in additive-supplemented RPMI 
culture media, counted by Trypan blue exclusion and adjusted to 5x 105 MI-1. 
2.6.4 Culture of B cells isolated from human tonsils or PBMCs 
35 µg/ml Transferrin and 5 µg/ml Insulin were added to all cells in culture media. Cells 
were cultured in media alone or media with 200 U/ml IL-4 (R &D Systems) and 1 
µg/ml anti-CD40. Cells were cultured at 5x 105 ml-1 in sterile 24 or 96 well Nuclon 
plates (Nunc). Tonsillar B cells were cultured for up to 10 days and PBMCs up to 21 
days at 37°C with 5% CO2. Duplicates or quadruplicates were made for each condition 
depending on the cell yield. Cells were harvested on the days dictated by the experiment 
by centrifugation at 1200 RPM and supernatants were stored at -20°C until use. 
2.7 Flow cytometry 
B cells were harvested and separated from the cell culture supernatant by centrifugation 
at 1200 RPM for 5 minutes. Cell pellets were resuspended in FACS buffer, added to 
FACS tubes and antibodies applied. Cells were incubated for 20 minutes. Unbound 
antibodies were removed from the cells by washing twice with FACS buffer through 
centrifugation at 1200 RPM for 5 minutes. Cells were fixed in FACS 
fix buffer and 
surface expression of the marker in question assessed using a 
FACSCalibur flow 
cytometer. The data was analysed using CellQuestTM software. 
2.8 IgE stimulation assays 
Purified tonsil B cells were seeded in quadruplicate in sterile 96 well plates to a 
final 
concentration of 5x 105 cells ml-1 in culture medium 
in the presence or absence of 200 
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U/ml IL-4 and 1 µg/ml anti-CD40. LZ-CD23 was added to wells to a final concentration 
of 1000,100 or 10 ng/ml either on day 0, or on the days indicated by the experiment. 
Cells were harvested by centrifugation at 1200 RPM for 5 minutes and the supernatants 
retained. IgE content was analysed by the ELISA described below. 
2.9 Enzyme-Linked Immunosorbant Assays (ELISA) 
2.9.1 Preparation of biotinylated antibodies 
Antibodies were diluted to a concentration of 1 mg/ml in bicarbonate buffer (pH9). 
Biotin was prepared by mixing 10 mg 6-(Biotinamidocaproylamido)caproic acid N- 
hydroxysuccimide ester (Biotin-X-X-NHS) in I ml DMSO. Antibodies were mixed with 
biotin at a molar ration of 1: 8 and rotated for 1 hour at room temperature in the dark. 
Free biotin was removed by buffer exchange in TBS using a desalting column followed 
to the manufacturer's instructions (Pierce). 
2.9.2 Quantitative IgE ELISA 
96 well MaxiSorb (Nunc) were coated with 100µ1 anti-IgE capture antibody (as listed in 
table 2.3) diluted at 1 in 7000 in carbonate-bicarbonate buffer and incubated overnight 
at 4°C. The coating buffer was discarded and unbound sites blocked with 2% Marvel in 
PBS-T for 1 hour at room temperature. The plate was washed twice with PBS-T. A 
standard curve was generated by doubling serial dilutions of anti-Np IgE or WHO IgE 
standard in 1% Marvel/PBS-T (starting at 800 ng/ml) to produce 10 triplicates. 
Supernatant samples were added in quadruplicate along with internal controls of known 
IgE concentration and the plate incubated at 4°C overnight. The plate was washed 4 
times with PBS-T and IgE detected with anti-IgE-HRP (Dako) applied at a dilution of 
1 
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in 2000 in 1% Marvel/PBS-T, 100 µl/well. The plate was incubated at room temperature 
for 4 hours. After washing the plate 4 times in PBS-T, the reaction was developed using 
5 mg/ml OPD in phosphate-citrate buffer, 50µl/well. The reaction was allowed to 
develop in the dark for 10-20 minutes. The colour reaction was stopped with 3M HCI. 
50µl/well. The A492 of the plate was recorded by a Titertek plate reader and the standard 
curve determined by AscentTM software. The concentrations of the samples were 
estimated from the linear part of the curve and if necessary, samples diluted until the 
readings lay within this sensitivity range. The sensitivity was typically 10-100 ng/ml. 
2.9.3 LZ-CD23 - IgE ELISA 
Microtiter plates were coated with 100 nM LZ-CD23 diluted in TBS-Ca overnight at 
4°C, 100µl/well. Unbound antibody was discarded and the plate blocked with 5% BSA 
in 100µl/well TBS-Ca-T for 1 hour at room temperature. IgE (WHO standard) and IgE- 
Fc were double-diluted, in 1% BSA-TBS-Ca-T, in triplicate from 10 nM to give 10 
dilutions and incubated at room temperature for 3 hours. Following 4 washes in TBS- 
Ca-T, the reaction was developed with OPD as described above. 
2.9.4 LZ-CD23 - CD21 ELISA 
Plates were coated with 100 nM LZ-CD23 in TBS-Ca as for the CD23-IgE ELISA 
described above. To allow for the salt-sensitive interaction between CD21 and its 
ligands as documented previously by Sarrias et al., (2001) a hypotonic sample, blocking 
and wash buffer was used (10 mM sodium phosphate, 25 mM NaCI, pH 7.4). The plate 
was blocked with 100µl/well 1% BSA for 1 hour at room temperature. CD21 
from 
baculovirus (SCR 1-16) was diluted in sample buffer from 100 nM and allowed to bind 
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for 3 hours at room temperature. The interaction was detected using HB5 at a 
concentration of 2µg/ml incubated for 2 hours at room temperature, followed by rabbit- 
anti mouse-HRP (1 in 2000) added for 1 hour at room temperature, then developed with 
OPD. 
2.9.5 LZ-CD23 - CD21 inhibition ELISA 
Maxisorb microtiter plates were coated with 100 nM LZ-CD23 in TBS-Ca overnight at 
4°C. The plate was blocked with 1% BSA in hypotonic buffer 1 hour at room 
temperature. 100 nM sCD21 was incubated in the presence of either LZ-CD23 or BSA 
double-diluted from 100 nM for 1 hour at room temperature in a 96-well, non-adherent 
plate (Nunc). These samples were then applied to the LZ-CD23 plate in triplicate for 2 
hours at room temperature. The interaction was detected using 2µg/m1 HB5 for 2 hours 
at room temperature, followed by 1 in 2000 rabbit anti-mouse-HRP for 1 hour at room 
temperature. The enzyme reaction was revealed with OPD. 
2.10 Confocal microscopy 
2.10.1 Principles 
Confocal microscopy was used to visualise the localisation of CD21 and IgE on the 
surface of primary human B cells and cell lines. It is used as an imaging technique in 
preference to conventional fluorescence microscopy due to the ability to obtain images 
with superior contrast and resolution through the elimination of out-of-focus light which 
can reduce the quality of an image. In conventional, wide-field 
fluorescence 
microscopy, the entire specimen is flooded with light, typically 
from a xenon or 
mercury lamp. This light is reflected by a dichromatic mirror which absorbs and reflects 
at different wavelengths. All fluorochromes labelling a specimen are excited 
by this 
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light at the same time and emit fluorescence at a different wavelength to the excitation 
beam. This light is then focussed through an objective lens, passing through the 
dichromatic mirror, and the information detected by a photomultiplier. The information 
received by the photomultiplier will include in-focus light from the area and focal plane 
of interest on the sample, where the intensity of the light source is greatest, as well as 
out-of-focus light reflected from areas of the specimen that are illuminated by the light 
source but receive less intense light such as deeper or shallower focal planes than the 
one at the focus of the lens. The resulting image of the specimen can be distorted by 
poor resolution, poor contrast and haze contributed by this out-of-focus light. This 
distortion is often encountered when samples are greater than 2 µM thick, due to 
reflection of light from several focal planes, as well as with samples labelled with 
multiple fluorochromes. The confocal microscope avoids this problem by focussing 
light from a laser through a pinhole placed in front of the light source. This focussed 
light then passes through a lens at a single focal plane of the specimen, the focal plane at 
the focus of the lens. The excited fluorochromes on the specimen emit fluorescence 
which passes through an objective lens at a pinhole of the same focus as the first. These 
two lenses with the same focus are known as confocal lenses. Out-of-focus light from 
focal planes other than the specimen is not focussed through these pinholes, is not 
detected by the photomultiplier and is thus eliminated. These principles are illustrated in 
figure 2.4. 
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Figure 2.4: Concepts of confocal microscopy 
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As the light used to illuminate the sample is focussed only on one spot, in order to build 
up an image this light must be scanned across the specimen. This used to be achieved by 
vibrating the sample but in the case of biological samples where vibration of the 
specimen can cause distortion, it is the light source that is scanned across a sample using 
a series of mirrors, hence the term Laser Scanning Confocal Microscope (LSCM), the 
most frequently encountered confocal microscope. The information detected by the 
photomultiplier is stored, as the light beam is scanned across a sample, and the resulting 
image is composed pixel by pixel. The microscope is said to have a small depth of field 
resulting from the single scan of a sample at one focal plane. This single scan is also 
known as an optical section. A novel feature of the confocal microscope is that a series 
of optical sections can be scanned sequentially which can be stacked on top of each 
other to create a pseudo-3D image. The resulting image is known as a Z-stack, so- 
named from the axis at which the laser scans through the sample. 
2.10.2 Fluorochromes and microscope filters 
Two confocal microscopes were used for the visualisation of fluorescently labelled 
cells. These two microscopes were a Zeiss LSM 510 and a Leica DMR. Fluorochromes 
were chosen to be compatible with the filter settings of both these microscopes. Alexa 
488 was chosen because of its superior fluorescence and slower photobleaching in 
comparison to FITC (Panchuk-Voloshina et al., 1999). Both FITC and Alexa 488 have 
similar absorbance and emission spectra as shown in figure 2.5 making Alexa 488 a 
suitable alternative to FITC. 
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The counter dye to Alexa 488 was the cyanine dye, Cy3. Like Alexa dyes, cyanine dyes 
have been engineered to be more photostable when excited by high-intensity laser 
beams. Its emission spectrum is shown in figure 2.6 and when compared with Alexa 
488, it is clear that the two emission peaks are distinct and the emission fluorescence 
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Figure 2.6: Absorption and emission spectrum for Cy3 with the emission spectrum 
compared with Alexa 488 
emission 
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Both the Zeiss and Leica confocal microscopes are equipped with filters capable of 
exciting both Alexa 488 and Cy3. The summary of these filter settings complete with 
the fluorochromes they excite is shown in table 2.9. 
Table 2.9: Filters and lasers to excite fluorochromes used in confocal microscopy 
experiments 
Filter Laser Reads Excites Fluorochrome Fluorochrome 
fluorescence fluorochrome absorbance emission 
maximum maximum 
488 nm Argon 530 nm ± 30 Alexa 488 495 nm 519 nm 
543 nm Helium 600 nm ± 30 Cy3 556 nm 573 nm 
neon 
2.10.3 Cell staining 
A variety of antibodies was available for the staining of surface CD21, IgE or CD3 8 
(listed in table 2.2,2.3 and 2.4). All staining took place in a flow cytometry tube. For 
staining of cell lines and primary cells, 5x 105 cells were washed twice in PBS by 
centrifugation for 4 minutes at 1200 RPM. The cells were either fixed before or after 
staining to compare the antibody binding capacity (as described in detail in chapter 5). 
For cells fixed before staining, the following step was carried out before the primary 
antibody was applied. 500µl microscopy fixative (2% formaldehyde, 0.05% azide 
in 
PBS) was applied to the cell pellet, cells resuspended and incubated 
for 20 minutes at 
room temperature. The cells were washed again twice in PBS. The 
following steps are 
common for both cells fixed before or after staining. The primary antibody 
layer (anti- 
CD21; anti-IgE; anti-CD21 + anti-IgE; anti-CD38 depending on the experiment) was 
applied to the cell pellet, cells resuspended, allowed to 
incubate at room temperature for 
20 minutes then washed twice with PBS. The diluted secondary antibody-fluorochrome 
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or streptavidin-fluorochrome was added to the cell pellet, cells were resuspended and 
allowed to bind for 20 minutes in the dark. Cells were washed once in PBS then once 
again in microscopy fixative. The fix buffer was poured away so that only around 50µ1 
remained in the bottom of the FACs tube. The cells were resuspended and spread across 
the entire surface of a polysine-coated microscope slide. A drop of hard-setting 
VectorshieldTM fluorescence preserver was applied to the centre of the slide and a 
50mm x 13mm coverslip carefully lowered onto the slide to spread the fluorescence 
preserver evenly. Slides were left overnight in the dark to allow the fluorescence 
preserver to set and seal the cells onto the slide. 
2.10.4 LZ-CD23 redistribution of CD21 on Raji and CD21, IgE or CD38 on 
human tonsil B cells 
LZ-CD23 was diluted to a concentration of 500 nM in cell culture medium (CM). 5x 
105 cells were washed in PBS, pelleted in flow cytometry tubes and put on ice. LZ- 
CD23 was added to tubes and incubated for 0,15,30 and 60 minutes. Control cells were 
also incubated in the absence of LZ-CD23. Cells for harvesting at 15,30 and 60 minutes 
were incubated at 37°C whilst cells for the 0 minute time point were kept on ice for 5 
minutes. On harvesting, all cells were immediately fixed in 2% formaldehyde, 0.05% 
azide in PBS then stained for surface CD21 and IgE as described in 2.10.3. 
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2.10.5 Acquisition of images 
All images were acquired using the Leica or Zeiss confocal microscopes with the filter 
settings as described above. Images were taken with a x63, plan apochromat, oil 
immersion lens. Digital images were magnified a further 2-fold using the inbuilt optical 
zoom function provided with the acquisition software. 
2.11 Statistical tests 
The significance of difference between two populations was calculated using a 2-tailed, 
un-paired T-test. P values less than or equal to 0.05 were considered significant, and 
those greater than 0.05 considered non-significant. Calculations were performed using 
Microsoft Excel software. 
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Chapter 3: Production of a trimeric fragment of soluble CD23 
3.1 Introduction 
This chapter describes the production and purification of a soluble, recombinant 
fragment of CD23 which should have the ability to form trimers in solution. Several 
attempts have been made to synthesise recombinant trimers of CD23, for the study of 
ligand kinetics and to investigate effects on IgE homeostasis, but most have exhibited 
poor resistance to proteases. Due to this problem, most of the biological and biophysical 
studies carried out on CD23 have utilised the 16kDa monomeric fragment which is 
stable by virtue of containing no degradable stalk portion. 
CD23 is able to form stable trimers on the surface of the cell and in solution through the 
non-covalent interactions of the alpha helical stalk (Beavil et al., 1995). The structure of 
the stalk region allows the formation of trimers due to hydrophobic amino acids 
arranged in heptad repeats along the length of the stalk region, that drive alpha helical 
coiled-coil association (Beavil et al., 1992). When cleaved from the cell surface, it 
initially retains the majority of its stalk region, which, in theory, should allow it to self- 
associate as a trimer in the absence of the constraints afforded by anchorage to the cell 
membrane. 
For the studies presented in this thesis, a recombinant form of human CD23 was 
developed, in collaboration with the laboratory of D. Conrad, to drive the association of 
the helical stalk and thus allow fragments to assume a trimeric conformation in solution. 
To achieve this, a leucine zipper motif was fused to the N-terminus of the extracellular 
sequence of CD23. The human version of the protein was designed to contain amino 
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self-association and IgE binding capacity in comparison with other incremental stalk 
deletion mutants (Chen et al., 2002). 
Production of this engineered CD23 fragment was designed to enhance the formation of 
trimers in solution and provide a better understanding of the interaction of CD23 with 
its B cell ligands, CD21 and IgE, and its biological activity. 
3.2 Cloning of the LZ-CD23 vector 
The cloning vector for human LZ-CD23 was obtained from D. Conrad following work 
carried out to characterise a mouse chimeric extracellular CD23 fragment with a 
modified leucine zipper (LZ) portion fused to the N-terminus. As reported by Chen et 
al, (2002), human LZ-CD23 was constructed using the mouse LZ-CD23 comprising 
amino acids 86-331, described by Kelly et al, (1998) as a template. The human 
counterpart PCR product coding for amino acids 45-321 and the modified LZ sequence 
was cloned into the same pET24a vector containing the original mouse sequence by 
replacing the corresponding mouse sequence with the human fragment. The resulting 
human LZ-CD23 45-321 expression vector is shown in figure 3.1. In the original report 
(Chen et al., 2002), work was also published using a second human LZ-CD23 where the 
stalk had been mutated to its minimal length needed to retain IgE binding, containing 
amino acids 148-321. However, all the work reported in this thesis was carried out using 
the full length, 45-321 amino acid construct. 
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Figure 3.1: Expression vector for LZ-CD23 amino acids 45-321 
The human LZ-CD23 construct was cloned into the original murine LZ-CD23 pET24a vector 
by replacing the corresponding mouse sequence. 
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3.3 Expression of LZ-CD23 in E. coli 
BL21(DE3)pLyS-S E. coli competent cells were transformed with the human LZ-CD23 
pET24a vector as described in the chapter 2, section 2.2. Expression from the T7 
promoter was induced by the addition of 0.4 mM IPTG at A600 of 0.6-1. Following 
protein induction, samples were taken each hour up to 4 hours to monitor the protein 
accumulation (figure 3.2 A). Protein was expressed at high levels in the insoluble cell 
fraction, stored in inclusion bodies. At the end of the induction period, cell pellets were 
separated from the supernatant by centrifugation. 
3.4 Extraction of inclusion bodies 
Protein misfolding is common when bacteria over-express proteins (Baneyx and 
Mujacic, 2004). In these cases, protein is sequestered from the cell in the form of 
insoluble inclusion bodies. Whilst these inclusion bodies are easily separated from the 
other cellular proteins by centrifugation, specialised measures are needed in order to 
correctly refold the protein from aggregate. Two methods were employed to extract 
inclusion bodies from cell pellets (chapter 2, section 2.2.2 & 2.2.3). The first method 
(from Bohmann and Tjian, 1989) usually resulted in protein yields of around 50 mg 
from 1L of cell culture. In contrast, yields from the BugBusterTM' extraction procedure 
produced almost double the amount of protein per litre of cell culture, with yields of 
around 100 mg/L. SDS-page analysis of solubilised inclusion bodies shows the protein 
content to be moderately pure and clear of cellular contaminants due to multiple 
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Figure 3.2: LZ-CD23 expressed by E. Coli 
A: LZ-CD23 expression was monitored following IPTG induction. Samples were taken at 0,1, 
2,3 and 4 hours and run on a 15% denaturing SDS-PAGE gel and stained with Coomassie blue. 
B: Following solubilisation of the inclusion bodies, protein was run on a 12% SDS-PAGE gel 
and either probed with anti-CD23 (BU38 clone) followed by anti-mouse-HRP or stained with 
Coomassie blue. 
3.5 Refolding LZ-CD23 from solubilised inclusion bodies 
Inclusion bodies were separated from the soluble cell fraction and solubilised in 6M 
Guanidine HCl prior to refolding. The protocol for LZ-CD23 refolding was adapted 
from Taylor et al, (1992) and used small, concentrated batches of 10-13 mg of protein 
per refold. In brief, incorrectly linked disulphide bonds, formed as a product of 
inclusion body sequestration, were first reduced. Protein was then diluted into refold 
buffers as detailed in chapter 2, section 2.2.4, to gradually remove the denaturant and 
allow the correct formation of disulphide bridges in the lectin heads, whilst avoiding the 
formation of aggregates resulting from intermolecular disulphide bonds. The correct 
reshuffling of disulphide bridges was promoted by the formation of a glutathione 
intermediate before dilution into a cysteine-containing buffer. At each dilution step, the 
risk of aggregation was reduced by the careful, slow dilution of protein 
into each buffer. 
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In contrast to the original Taylor protocol, which completely removed the Guanidine- 
HCl from the refold buffer, IM Guanidine-HCl was retained in the final refold buffer 
and was not removed entirely until buffer exchange during gel filtration. This was 
deemed necessary because in the stages following refolding, much protein was lost 
through aggregation and precipitation which could not be alleviated by slow dilution. 
This concentration of Guanidine was therefore low enough to allow the protein to refold 
but high enough to prevent aggregation. 
3.6 Ultrafiltration of LZ-CD23 
The refolded LZ-CD23 was then concentrated down to approximately 1Oml by 
ultrafiltration ready for size exclusion purification. The ultrafiltration unit was a stirred 
cell forcing the protein solution through a membrane by pressurized nitrogen. The 
membrane was chosen to retain molecules of IOkDa or greater. Several membranes 
were tested with the requirement that protein solution should be rapidly filtered with 
minimal retention on the membrane surface. The membrane that satisfied this 
prerequisite was a PLGC membrane. From its amino acid sequence, the predicted 
molecular weight of LZ-CD23 was estimated as 37,637 Da. However, due to the 
elongated stalk of CD23 and its non-globular structure, LZ-CD23 behaves differently 
depending on its orientation, so a smaller pore size was necessary to avoid undue loss of 
protein. Prior to use, the assembled stirred cell unit was allowed to equilibrate at 
4°C. 
3.7 Purification of LZ-CD23 by gel filtration 
The method of gel filtration was chosen to purify refolded 
LZ-CD23 following previous 
successes from this laboratory on other bacterially expressed 
CD23 fragments. Gel 
filtration columns had previously been tested in this 
laboratory by Gabrielle Grundy 
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(2001) and the most appropriate one for CD23 fragment separation was chosen to be the 
Superdex 200. For a column to be effective, it must be able to separate correctly folded 
material from aggregate, break-down products and other small molecules left over in the 
refold buffer. The Superdex 200 satisfied these needs by having a matrix that would 
resolve between 1OkDa and 600kDa to allow for discrimination between monomeric 
and oligomeric species, as well as smaller degradation products and aggregate. The 
initial running buffer used was of relatively high ionic strength (125 mM NaCI) and 
highly buffered (250 mM Tris), thought to be necessary to prevent CD23 from 
interacting with the charged surface of the matrix. The CD23 stalk region is highly 
susceptible to cleavage by exogenous proteases, so steps were taken to reduce 
proteolysis. Prior to use, the column was treated with protease inhibitors by running 
buffer supplemented with 10µM TLCK and Protease Inhibitor Cocktail tablets (Roche) 
through the column. Protease inhibitors in these buffers were also injected directly onto 
the column to ensure that the injection mechanism was thoroughly flushed through and 
cleaned. Buffer used to equilibrate the column was cooled to below 4°C and all running 
buffers were kept on ice during the course of the gel filtration runs to further minimise 
degradation. The tubes used to collect fractions from the separated protein species were 
also washed in protease inhibitor-supplemented buffer, arranged on a pre-cooled, water- 
jacketed rack and covered with foil to prevent entry of proteases found in dust during 
overnight runs. These steps were found to vastly improve the quality of the traces seen 
during size exclusion chromatography and influenced the integrity of the protein as 
assessed by western blots and SDS-PAGE gels following each subsequent purification 
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Figure 3.3: Size exclusion of LZ-CD23 fragments by gel filtration 
A: Elution profile (A280) of refolded LZ-CD23 on a Superdex 200 column. Samples were run at 
0.75m1/min in 250mM Tris-Ac pH7.2 and 125mM NaCl. Fractions were collected at 1 minute 
intervals to encompass both major peaks. 
B: Anti-CD23 western blot of each fraction collected. The first peak was shown to contain all 
the CD23 sample, whereas the second peak accounts for other smaller molecules absorbing at 
A280 found in the refold buffer. 
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3.8 Characterisation of fractions by western blot analysis 
Fractions collected were subjected to non-reducing SDS-PAGE and anti-CD23 western 
blot analysis to determine which fractions contained LZ-CD23 and also whether this 
protein existed as larger molecular weight material or breakdown products. Each 
preparation of LZ-CD23 was characterised by two peaks on a gel filtration trace. CD23 
was found to be present in only the first peak (figure 3.3 B). In this peak, the majority of 
protein was found to be of the correct molecular mass for monomeric LZ-CD23 
(37kDa) with no breakdown species smaller than 30kDa. There were also some larger 
molecular weight species present in fractions 5-7 though by this method it was not 
possible to distinguish whether these bands corresponded to aggregated material or 
correctly folded oligomer. 
3.9 Ultrafiltration of pooled fractions and assessing the final protein integrity 
To further assess the identity of the CD23 found in this first peak, fractions 5-9 were 
pooled and concentrated by ultrafiltration to 0.5-1 mg/ml. Ultrafiltration was carried out 
in al Oml Amicon stirring cell with al OkDa cut off membrane as before. Before protein 
was added, the cell was washed with a filtered solution of the same protease inhibitors 
used to treat the gel filtration column. The cell was allowed to equilibrate at 4°C 
overnight before ultrafiltration was performed. Final concentrated preparations were 
then assessed for protein integrity by SDS-PAGE and anti-CD23 western 
blot analysis 
(figure 3.4 A). LZ-CD23 was shown to run at 37kDa with minimal breakdown products 
or other contaminants. In addition, the final prepared LZ-CD23 was re-injected onto 
the 
Superdex 200 gel filtration column under the same conditions used 
for size exclusion 
(figure 3.4 B). This step was performed to demonstrate that the smaller molecules 
in the 
refold buffer, absorbing at A280 therefore visible 
in the second peak in figure 3.3a, were 
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no longer present and thus not contributing to the overall concentration of the final 
preparation which would lead to misrepresentative quantification of the protein used in 
the assays described in future chapters. 
















Figure 3.4: Western blot and gel filtration analysis of pooled fractions 
a) Fractions containing LZ-CD23 were pooled and concentrated to 0.5-1 mg/ml by 
ultrafiltration. Protein was precipitated with acetone and run on a non-reducing SDS-PAGE gel 
and either stained with Coomassie blue or probed with anti-CD23 (BU38). b) The final 
concentrated LZ-CD23 sample was re-injected onto the Superdex 200 gel filtration column 
under the same conditions used for size exclusion. The second peak present in figure 3.3a is no 
longer present. 
3.10 Stability of protein in physiological buffers 
In order to characterise the protein further, it was desirable to study the protein in 
buffers resembling more physiological conditions in terms of pH and ionic strength. As 
described above, the buffer used for size exclusion contained a sufficiently high 
concentration of Tris and NaCl necessary to prevent CD23 fragments 
from being 
retained in the column matrix. In future chapters, the biological 
functionality of the 
protein will be described, when it was necessary to add LZ-CD23 
into a number of 
cellular systems. A major concern was that the high concentration of 
Tris in the buffer 
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would be toxic to the cells. LZ-CD23 was therefore dialysed into a number of buffers 
that resembled physiological conditions (ionic concentrations of 100-200 mM NaCl. 50 
mM buffer concentration and pH7.4). Following dialysis into three buffers (TBS-Ca, 
HBS-Ca and PBS, all supplemented with 10 µM TLCK and Protease Inhibitor cocktail 
tablets) it was observed that the protein readily degrades as observed by western blot 
analysis (figure 3.5). Although the majority of protein was still of the correct molecular 
mass, it was consistently noticed that large amounts of precipitate accumulated in the 
dialysis tubing and this accounted for around 50% of the protein originally dialysed in 
each case. This loss impeded future analysis of the protein, as the amount of protein 
remaining following precipitation was too meagre to use in any subsequent assays. It 
would appear that the dialysis procedure, such as the length of the buffer exchange, 
requiring at least 24 hours with two buffer changes, and the manipulation of the protein 
transferred into and out of the dialysis tube, possibly exposed the protein to proteases 
and consequent degradation. The precipitation might be due to the aggregation of 
misfolded protein once the highly buffered environment of the size exclusion buffer is 
removed. 
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Figure 3.5: LZ-CD23 stability in physiological buffers 
LZ-CD23 was dialysed into buffers resembling physiological conditions (0.05M buffer, pH7.2- 
7.5,0.1-0.2M NaCl) ahead of usage in ex-vivo cellular assays. LZ-CD23 was dialysed into 10 
volumes of buffer for at least 24 hours with two buffer changes. Protein concentration (A, «) 
was estimated before and after dialysis to estimate protein loss through aggregation and 
precipitation. LZ-CD23 integrity was then assessed by SDS-PAGE followed by probing with 
anti-CD23 antibody (BU38 clone). 
3.11 Size exclusion chromatography using physiological running buffer 
Due to excessive loss of protein through precipitation, it was decided to discontinue any 
dialysis steps. In place of a separate dialysis into physiological buffer, refolded LZ- 
CD23 was subjected to gel filtration using TBS-Ca as the running buffer to exchange 
the buffer during the size exclusion. Despite the five-fold difference in Tris 
concentration between the original size-exclusion running buffer (250 mM Tris) and 
TBS-Ca (50 mM), the elution profiles are almost identical (figure 3.6a, cf. figure 3.3a). 
As previously demonstrated in figure 3.3b by western blot, all the CD23 was found in 
the first major peak (figure 3.6b) and the majority found to run at approximately 37kDa. 
As observed in figure 3.3b, some lanes contained higher molecular weight species 
which could not be characterised by western blot. LZ-CD23 fractions were pooled and 



















Figure 3.6: Gel filtration using TBS-Ca as running buffer 
a) Elution profile (A280) of refolded LZ-CD23 on a Superdex 200 column. Samples were run at 
0.75m1/min in 50mM Tris-Ac pH7.4,125mM NaCl and 2mM CaCl2. Fractions were once again 
collected to encompass both major peaks. b) Anti-CD23 western blot of each fraction collected. 
All CD23 was found in the first major peak as shown before in figure 3.3b. The elution profile 
and fraction characterisation was the same using either TBS-Ca or 0.25M Tris as running buffer. 
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3.12 Summary and discussion 
The work in this chapter describes the expression and purification of a recombinant 
fragment of soluble CD23 for use in ligand interaction studies and biological assays. 
This recombinant fragment differs from other CD23 fragments by virtue of an N- 
terminal leucine zipper motif (LZ) added to the end of the stalk region to promote self- 
association of the protein in solution. The vector was kindly donated by D. Conrad who, 
in collaboration with this laboratory, had engineered a human form of LZ-CD23 
containing amino acids 45-321, coding for the entire lectin head and stalk region. LZ- 
CD23 described here is the human counterpart of a murine LZ-CD23 fragment (amino 
acids 48-33 1) which Conrad and colleagues had previously demonstrated to interact 
with such a high affinity to IgE that FccRI-IgE binding could be inhibited (Kelly et al., 
1998). 
LZ-CD23 was expressed in an E. coli expression system, using a protocol previously 
used to express another CD23 fragment, rCD23 (Reljic, 1996). Two methods were 
employed to extract the protein from inclusion bodies. The first method from Bohmann 
and Tjian (1989) resulted in yields of 50 mg/L, using a labour intensive protocol. 
However, up to 100 mg/L protein could be extracted using a commercially available 
extraction solution resulting in protein that appeared moderately pure on an SDS-PAGE 
gel, probably owing to the multiple washing and centrifugation steps. 
Following the original refolding protocol for the mouse CD23 chimera, it was observed 
that large amounts of aggregate would form and precipitate out of solution during 
ultrafiltration, resulting in highly degraded protein. Due to the complete and rapid 
removal of Guanidine-HCl from the refold buffer in the original protocol, 
it appeared 
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likely that protein rapidly formed intermolecular disulphide bonds leading to 
aggregation before correct refolding was complete. It was therefore decided to retain 
guanidine in the refold buffer at a low enough concentration to prohibit premature 
disulphide bond formation, yet still allow the refold to proceed gradually. Using this 
modification, protein was not seen to aggregate during ultrafiltration when a stirring cell 
unit and l OkDa cut-off membrane, that had been pre-treated with protease inhibitors and 
allowed to equilibrate at 4°C, was used. 
Previously in this laboratory, various methods have been employed to separate correctly 
folded CD23 fragments from break-down products or aggregated protein. Hydrophobic 
interaction chromatography (HIC) was used by G. Grundy to purify the lectin head 
portion of CD23 (derCD23). This method was unsuitable for LZ-CD23 purification due 
to poor elution characteristics; it appeared that LZ-CD23 was retained on the column 
and hydrophobic interactions between the column and the protein were not easily 
disrupted by the standard decreasing ammonium sulphate concentration gradient elution 
buffers. Anti-CD23 affinity columns were used to purify a full length extracellular SPD- 
CD23 fusion protein (Grundy, 2001). This method for LZ-CD23 was abandoned due to 
the appearance of a large amount of degraded material on subsequent western blots, as 
well as concerns regarding the disruption of trimeric fractions by the antibody 
destabilising any potential self-association. An IgE affinity column was also 
investigated, but abandoned due to small amounts of protein being eluted from the 
column. 
Gel filtration was therefore employed to purify LZ-CD23 following some success with 
other full length extracellular CD23 fragments (Grundy, 2001; Relj ic, 1996) . 
The 
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running buffer originally chosen was formulated to contain a high concentration (250 
mM) of Tris buffer with 125 mM NaCI to avoid the retention of protein on the gel 
matrix. Due to excessive loss and degradation of protein during dialysis of LZ-CD23 
into physiological buffers for use in subsequent biological systems and biophysical 
characterisations, it was decided to run the size-exclusion purification step using 
physiological TBS-Ca as the running buffer. This modification resulted in an elution 
profile identical to that observed using the original high-Tris running buffer and similar 
yields, suggesting that protein in this buffer was not being retained on the column and 
eluted at different times. Most importantly, it carried the advantage of reducing handling 
and possible exposure to proteases whilst changing the buffer to one suitable for further 
characterisation studies. 
At each step prior to the storage of the protein, the integrity of LZ-CD23 was assessed 
by western blot and non-reducing SDS-PAGE. It would have been highly desirable to 
assess whether the refold had indeed been successful in producing correctly folded 
trimeric protein, but the correct molecular weight or oligomerisation state could not be 
assessed by either SDS-PAGE or indeed gel filtration. The reasons for this and a study 
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Chapter 4: LZ-CD23 ligand binding properties and molecular 
weight determination 
4.1 Introduction 
Soluble CD23 fragments are hypothesised to promote IgE synthesis through the co- 
ligation of CD21 and mIgE (see figures 1.6 and 1.7). This requires that CD23 should 
bind with a high affinity to these ligands, which may be facilitated by stalk-mediated 
oligomerisation. LZ-CD23 was designed to be oligomeric in solution by virtue of the 
leucine zipper added at the N-terminus. This chapter addresses the kinetics of ligand 
binding by surface plasmon resonance (SPR) and the oligomeric state by analytical gel 
filtration and sedimentation equilibrium analytical ultracentrifugation. 
4.2 Molecular mass determination by analytical gel filtration 
By calibrating a column used to purify protein samples by size exclusion with markers 
of known molecular masses, it is possible to estimate the molecular mass of an 
unknown protein by comparison with the elution profiles of the markers. Two 
preparations of LZ-CD23 will be described in this thesis, having been purified to a 
standard suitable for use in biological and biophysical experiments. They differ only by 
the buffer used for gel filtration in chapter 3, the first being gel filtration buffer (250 
mM Tris-Acetate, pH 7.4; 125 mM NaCI) and the second, TBS-Ca (50 mM Tris- 
Acetate pH 7.4; 125 mM NaCl; 2 mM CaC12) as described in chapter 3, figures 3.3 and 
3.6 respectively. For standardisation, these two preparations of LZ-CD23 will 
be 
referred to in this thesis as LZ-CD23 A (gel filtration buffer) and 
LZ-CD23 B (TBS- 
Ca). 
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Using either gel filtration or TBS-Ca as running buffers, a Superdex 200 gel filtration 
column was calibrated and standard curves prepared to assess the molecular mass of 
LZ-CD23 (figure 4.1; table 4.1). 
Table 4.1: Molecular mass standard biophysical data and elution times 
Protein Molecular Sedimentation Stokes Elution time 
Standard mass (Da) coefficient (s) X Radius (mins) 
(nm) X Gel TBS- 
Ca filtration 
buffer 
Cytochrome C 12,400 1.71 1.64 23.72 23.27 
Carbonic 
Anhydrase 29,000 3.01 2.7 21.17 21.48 
BSA 66,000 4.22 3.55 17.37 18.17 
Alcohol 
dehydrogenase 150,000 5.11 4.6 16.36 16.64 
Beta amylase 200,000 8.3 5.4 15.14 15.41 
* Values from Smith (1970) 
Using the equation calculated from the calibration standard curve, the molecular mass 
for LZ-CD23 A, eluting at 15.17 minutes in gel filtration buffer, was estimated as MW 
210,000 and LZ-CD23 B, eluting at 15 minutes in TBS-Ca3 as MW 198,000. These 
values do not correspond to the predicted molecular mass of 37,637 Da for a monomeric 
species, or 113,000 for a trimer as estimated from the amino acid sequence (see 
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Figure 4.1: Calibration of Superdex 200 column in gel filtration buffer or TBS-Ca 
The gel filtration column was calibrated with protein markers of known molecular weights 
(BSA: Mr 66,000; Cytochrome C: Mr 12,400; carbonic anhydrase: Mr 29,000; alcohol 
dehydrogenase: Mr 150,000 and beta amylase: Mr 200,000) run in A: gel filtration buffer at 
0.75ml/min and B: TBS-Ca at 0.75ml/min. 
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4.3 Theoretical determination of LZ-CD23 molecular mass 
Due to the size and shape of CD23, which is not a spherical, globular protein but much 
more elongated due to the stalk, the movement of LZ-CD23 through a solvent will be 
influenced by the shape constraints of the stalk. This explains why the molecular mass 
extrapolated from the standard calibration curves result in values far exceeding the 
predicted molecular mass. The diffusion of a protein through a given medium, be it a 
gel matrix or other solution, is influenced by several parameters. A force (F) applied to 
a molecule will compel movement in one direction, be it by electrical current, the 
pumping of solution through a column or a centrifugal force imposed by spinning a 
sample. The molecule will then move with a velocity, v, and experience a resistance to 
its motion from the medium. This frictional force can be described as -fv here f is the 
frictional coefficient and the negative sign indicates that the frictional force opposes the 
forward force. A constant velocity will be reached when the net force acting on the 
molecule is equal to zero. This can be summarised in the following equation: 
ft+F=0orF=fv (4.3.1) 
The velocity can be measured knowing the force and from this the frictional coefficient 
can be determined. The importance of the frictional coefficient in the hydrodynamics of 
a particle is that it summarises the two parameters which influence the movement of a 
particle through solution: the size and shape of the molecule. 
Resistance is experienced because solvent molecules have to travel round the 
macromolecule in question, in addition to drag caused by the viscosity of the solvent. 
Resistance is therefore highly dependent on the size and shape of a molecule: spheres 
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will experience less resistance than rods or prolate spheroids. Frictional coefficients 
have not been calculated for every particle shape, but the following has been expressed 
for a sphere of radius, R: 
fo=61r7R (4.3.2) 
The above equation is also known as Stokes' Law, where i is the viscosity of the 
medium and R is the radius of sphere (the Stokes' Radius) experiencing the minimum 
frictional coefficient (fo) for a given volume in a solvent. The Stokes radius for each of 
the molecular mass standards used to calibrate the gel filtration column are listed in 
table 4.1. For a sphere of frictional coefficient fo, the frictional ratio (f/fo) would always 
be equal to 1.0, and any other particle shapes compared with a sphere of equal partial 
specific volume would always have a frictional ratio greater than 1.0. For example, BSA 
a globular protein, has a frictional ratio of around 1.31 (Harrington et al., 1956) whereas 
the rod-like tropomysin has a frictional ratio of 2.07 (Fowler and Bennett, 1984). 
Although a frictional ratio for LZ-CD23 was not obtained, by comparison with proteins 
sharing similar structural characteristics to CD23 and stalk fragments of CD23 (table 
4.2), it can be estimated that this value would be higher than 1 and potentially in the 
region of 2. Therefore, due to the hydrodynamic complexities of proteins of difference 
sizes and shapes as described above, it was not possible to determine the molecular 
mass of LZ-CD23 by gel filtration, or indeed by non-reducing SDS-PAGE. It would be 
very informative to obtain an accurate molecular mass by means of sedimentation 
velocity analytical ultracentrifugation. This was attempted, but the presence of 
different 
species within the LZ-CD23 sample made this impossible. 
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Table 4.2: Examples of frictional ratios for rod-like proteins 
Molecular Frictional 
Protein Reference 
mass (Da) ratio (f2j ) 
Tropomyosin 60,000 2.07 Fowler and Bennett, 1984 
Myosin 213,000 1.57 Stafford et al.. 2005 
Mannose binding Wallis and Drickamer 225 000 22 . 
protein (trimer) 1999 
R. Beavil (personal 
CD23 stalk (monomer) 14,500 1.81 
communication) 
R. Beavil (personal 
CD23 stalk (trimer) 43,500 1.98 
communication) 
4.4 Analysis of LZ-CD23 at sedimentation equilibrium 
Sedimentation equilibrium analytical ultracentrifugation was used as a means of 
assessing whether samples of LZ-CD23 B had folded as a trimer in solution. All 
experiments and analysis were performed by R. Beavil using a Beckman Optima XL-A 
and data analysed using Sigma Plot software as described in the methods. 
All centrifugation experiments were set up and performed at 4°C, but during initial runs, 
LZ-CD23 B was seen to be degraded by the end of an experiment, when protein was 
assessed by SDS-PAGE, as shown in figure 4.2. Although pre-cooled, the cells 
containing the samples were not washed with protease inhibitors in the initial runs. Due 
to the length of a sedimentation equilibrium run (around 5 days), even a small amount 
of protease present would have sufficient time to degrade the protein. As a result of this 










Figure 4.2: SDS-PAGE of LZ-CD23 B before and after initial sedimentation equilibrium 
run 
LZ-CD23 B protein samples were analysed by SDS-PAGE before (A) and after (B) 
centrifugation to assess the effect of centrifugation on the protein integrity. Protein was seen to 
be degraded by the end of the run. 
To improve on this, the AUC cell sample chambers were washed with 10 µM TLCK 
and Complete Protease tablets (Roche) as described previously in chapter 3 to treat 
ultrafiltration equipment. Sample chambers were assembled and protein added also at 
4°C. These modifications were sufficient to avoid protein degradation during the course 
of the experiment (figure 4.3). 
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Figure 4.3: SDS-PAGE of LZ-CD23 B before and after sedimentation equilibrium at 4°C 
LZ-CD23 protein samples were analysed by SDS-PAGE before (A) and after (B-D) 
centrifugation to assess the effect of centrifugation on the protein integrity. The protein was 
analysed at three optical densities: 0.8 (B); 0.6 (C) and 0.4 (D). 
LZ-CD23 B was diluted in TBS-Ca to give three optical densities of A280 0.8,0.6 and 
0.4 and centrifuged at 7000,9000 and 11,000 RPM. These speeds were chosen based on 
predication of the CD23 multimer size (see chapter 2, equation 2.4.6). The three models 
described in chapter 2, section 2.4 were applied to the absorbance values and fitted 
simultaneously to all three protein concentration data sets. The data obtained were 
found to best fit a model describing a two component, non-interacting protein sample 
(figure 4.4 A). From various combinations of values, the two components were 
estimated as monomeric and hexameric LZ-CD23 based on predictions for fragment 
sizes. The models describing a single, homogenous monomer or trimer species was 
rejected because the data did not fit the model. This was indicated by the non-randomly 
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Figure 4.4: Analysis of LZ-CD23 B at sedimentation equilibrium 
Three dilutions of LZ-CD23 B diluted in TBS-Ca (A, 80 0.8,0.6 and 11.4) were loaded into a pre- 
cooled AUC cell washed with protease inhibitors with a blank, reference cell containing TBS- 
Ca only. Protein was centrifuged at 7000,9000 and 11,000 RPM and A2go values collected as a 
function of radial distance. Data shown here are for the 9000 RPM data set and are 
representative of all three speeds. Curves, fits and residuals are shown for the most appropriate 
model to describe the sample (A) with only the poorly fit residuals shown 
for the rejected 
models (B-C). Analysis was carried out as described in section 2.4. 
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4.5 CD23-Ligand binding analysis by ELISA 
LZ-CD23 Li nd Int ions 
A practical way of determining whether a protein has refolded correctly is by testing its 
ligand binding capability. For future biological studies with LZ-CD23 to prove fruitful, 
it was necessary to assess the ligand binding capability of LZ-CD23 to IgE and CD? 1. 
To test this rapidly, two ELISA systems were used, modified from existing protocols. 
incorporating recombinant ligands at our disposal. 
4.5.1 CD23-IgE interaction 
Assays to study the interactions for a variety of recombinant CD23 fragments with IgE 
have been previously optimised and are described by G. Grundy (2001). Basing the LZ- 
CD23-IgE ELISA protocol on one such protocol, LZ-CD23 was coated directly to a 
solid phase using LZ-CD23 B, in TBS-Ca (chapter 2. section 2.9.3). Previous 
experience in this laboratory has shown that direct immobilisation of IgE to a solid 
phase gives poor ligand binding. When LZ-CD23 is immobilised to a solid phase. whole 
IgE or IgE-Fc were shown to bind in a dose-dependent manner (figure 4.5). 
Despite applying IgE fragments at equimolar concentrations. there is a difference in 
binding of IgE-Fc or whole IgE to LZ-CD23. This may be due to differences in specific 
activity between the recombinant IgE-Fc and the human pooled serum IgE samples or 
perhaps an attribute of the steric accessibility of the binding site to the immobilised 
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Figure 4.5: LZ-CD23 - IgE binding interaction by ELISA 
IOOnM LZ-CD23 B was immobilised to a Microtiter plate in TBS-Ca. IgE binding was assessed 
using triplicate samples of whole IgE (WHO standard) and IgE-Fcc2-4. Binding was detected 
with anti-IgE-HRP and revealed with OPD. A492 readings were corrected for background 
binding (BSA control and empty wells). 
4.5.2 CD23-CD21 interaction 
Two methods were chosen to study the binding of LZ-CD23 to soluble CD21 (sCD21) 
and are described in chapter 2, sections 2.9.4 and 2.9.5. The first involved detecting the 
direct interaction of sCD21 with immobilised LZ-CD23 based on an assay described by 
Fremeaux-Bacchi et al (1996). CD21-ligand binding has been previously shown to be 
sensitive to high salt concentrations (Guthridge et al., 2001; Sarrias et al., 2001; 
Szakonyi et al., 2001), and therefore the sample buffer used to titrate sCD21 onto LZ- 
CD23 was modified to contain reduced salt concentrations. LZ-CD23 B was 
immobilised as before in TBS-Ca and sCD21 titrated in the hypotonic sample buffer. A 
dose-dependent interaction was revealed using the anti-CD21 antibody HB5 (chapter 2, 



































Figure 4.6: LZ-CD23 - CD21 binding interaction by ELISA 
CD21 binding was assessed directly (A) by titrating sCD21 (baculovirus) over immobilised LZ- 
CD23 B and indirectly (B) by incubating increasing concentrations (0 to 100nM) of either LZ- 
CD23 B (or a BSA control) with lOOnM sCD21 and calculating the binding inhibition (see 
text). For both methods, CD21 was detected by HB5 followed by anti-mouse HRP and revealed 
with OPD. Results show triplicate averages +/- SD. 
nd Interactions 
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The second method involved an indirect detection of the interaction. As before. LZ- 
CD23 B was immobilised to the solid phase. Instead of titrating sCD21. the highest 
concentration of CD21 (100 nM) that bound directly in figure 4.6 A was kept constant 
and incubated with either LZ-CD23 or BSA titrated down from 100 nM. The binding of 
sCD21 was revealed as with the direct assay and a percentage inhibition of sCD21 
binding by either LZ-CD23 or BSA was calculated from the following calculation: 
A° -A ix 100 
Ao 
(4.5.1) 
where AO is the A492 with no LZ-CD23 or BSA added and A; is A492 with the addition of 
inhibitor (LZ-CD23 or BSA). Results are shown in figure 4.6 B. 
Using the concentrations chosen for the assay, it was not possible to reach 100% 
inhibition. Due to a lack of protein at the time of the assay, larger concentrations of 
inhibitor or ligand could not be used. It was also not practical to reduce the 
concentrations and then adjust the levels of either protein accordingly because this 
ELISA system was not sufficiently sensitive. The lack of sensitivity may be due in part 
to the differing glycosylation of the baculovirus-expressed sCD2 1. The interaction 
between CD23 and CD21 is thought to involve both a protein-protein interaction, via 
SCR 1-2 and a protein-carbohydrate interaction, via SCR 5-8 (Aubry et al.. 
1994). If the 
type of glycosylation on sCD21 was insufficient to allow the protein-carbohydrate 
interaction, the affinity would be reduced and the sensitivity of this 
interaction 
compromised. 
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4.6 Surface plasmon resonance (SPR) analysis of the CD23-IgE interaction 
SPR was used to measure the kinetics of the interaction between LZ-CD23 and I(-'E. 
Although affinity constants can be deduced from ELISA assays, SPR analysis offers a 
more sensitive and precise way of quantifying protein: protein binding kinetics. 
including both association and dissociation rate constants, in real time, with the 
additional advantage of requiring relatively small amounts of protein. 
4.6.1 Kinetic analysis of LZ-CD23 and derCD23 with IgE Fc 
The CD23 - IgE Fc interaction has been previously characterised extensively by 
Hibbert et al., (2005), comparing the binding kinetics for a full length monomeric 
fragment (exCD23) with monomeric derCD23. The following section describes the 
comparison between the interaction of LZ-CD23 and derCD23 with IgE Fc, and the data 
obtained by Hibbert et al. 
The IgE Fc flow cell was prepared as described in chapter 2, section 2.5.3. LZ-CD23 
and derCD23 were double-diluted down from 200 nM to 12.5 nM and injected in 
duplicate to monitor successful regeneration of the chip surface. The trace from the 
blank flow cell was subtracted from each ligand: analyte trace to correct for non-specific 
binding. Figure 4.7 shows the comparative interactions between LZ-CD23 and derCD23 
with immobilised IgE Fc. The LZ-CD23 trace shown here is for LZ-CD23 
A. However. 
both traces obtained for either protein stored in gel filtration buffer 
(LZ-CD23 A) or 
TBS-Ca (LZ-CD23 B) were found to be identical. 
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Figure 4.7: SPR sensorgrams of the LZ-CD23 and derCD23 interaction with IgE Fe 
Serial dilutions ('00 n NI, :., U nN'l, 5 n, I) of LZ-CD23 A and derCD23 were 
injected over biotinylated IgE Fcs2-4 immobilised to a streptavidin sensor chip at a ligand 
density of 500 RUs. After an association phase of 360 seconds, the dissociation was measured 
for 480 seconds. Fits are shown for each binding trace (coloured shapes superimposed over data 
lines) and residuals for the fits are shown below each sensorgram. Results for LZ-CD23 B were 
identical (data not shown). 
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Whilst both proteins bind to IgE Fc, the sensorgrams are markedly different. The 
derCD23 - IgE Fc interaction was characterised by fast on and off rates, whereas LZ- 
CD23 was observed both to bind to IgE Fc and dissociate with much slower kinetics. 
The data was analysed using BlAcore BIAevalutionTM software, using the models used 
by Hibbert et al., chosen as appropriate estimations of the interactions. The simplest 
ligand: analyte interaction can be described by the 1: 1 Langmuir model, as explained in 
chapter 2, section 2.5.5. However, the interaction between full length CD23 and IgE Fc 
is known to be more complex. The model chosen by Hibbert et al. is based on the 
interactions of a heterogeneous analyte (CD23 in its monomeric or oligomeric form) 
competing for the same binding site on CO. This model is described in section 2.5 and 
was applied globally to the data set obtained for the LZ-CD23 interaction with IgE Fc. 
The values are summarised in table 4.3. This interaction is clearly biphasic with a high 
and low affinity component (KD 2x 10-6 and 1x 10-8 M respectively). These values are 
consistent with the biphasic interaction reported by Hibbert et al.: (KD 1.1 (±0.2) x 10-6 
M and 3.9 (±0.6) x 10-8 M). 
In contrast, the Langmuir model was applied to the derCD23 interaction with IgE Fc 
because, in the absence of the stalk region, the single lectin head should behave as a 
monomer, thus satisfying a 1: 1 interaction (table 4.3). A KD value of 1.8 x 10-6 M was 
observed. This suggests that the stalk region of LZ-CD23 is responsible for the 
higher 
affinity component of the CD23-IgE interaction, and that oligomerised 
lectin heads are 
able to bind with a higher "avidity" than a monomeric 
lectin head alone. This 
interpretation is also consistent with the slower dissociation rate 
for LZ-CD23. 
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Table 4.3: Summary of kinetic data obtained by SPR for the CD23-IgE Fc 
interaction 
Ligand (immobilised) Analyte Kinetic model KD (M)* x2 
IgE Fc LZ-CD23 Competing interaction (1) 2.0x 10- 
(2) 1.0x10-8 
0.082 
IgE Fc derCD23 1: 1 1.8x106 - 1.01 
derCD23 IgE Fc 1: 1 1.1x106 - 1.21 
"` ico values were obtained from global fits and therefore do not have errors 
4.6.2 Kinetic analysis of IgE Fc binding to immobilised derCD23 
A potential drawback of SPR analysis is the effect that immobilising a ligand to a solid 
phase might have on the binding of an analyte. An immobilised receptor is merely an 
approximation of what will realistically occur at a cell surface, and binding kinetics 
could differ depending on the orientations of ligand favoured by different 
immobilisation procedures. To check the interaction between CD23 and IgE Fc, the 
orientation of the experiment was changed, with derCD23 coupled via primary amines 
to a CM5 chip (chapter 2, section 2.5.2) and IgE Fc as analyte. The sensorgrams, fits 
and residuals are displayed in figure 4.8. 
When analysed with the same 1: 1 model, the binding constants for either derCD23 as 
ligand (1.1 x 10-6 M) or analyte (1.8 x 10-6 M) were not found to differ significantly. It 
can thus be assumed that the binding constants are not adversely affected by 
immobilisation of ligands in these orientations. This is consistent with observations by 
Hibbert et al. (2005), who observed no difference between derCD23 - IgE Fc 
interacting in either orientation (KD 1.3 (± 0.3) X10-6 M) 
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Figure 4.8: SPR sensorgram of IgE Fe interaction with immobilised derCD23 
derCD23 was immobilised to a CM5 sensor chip at a ligand density of 400RUs. Serial dilutions 
(1000 n M, n iIy250 nM, ä of IgE Fc was injected over for 360 seconds 
and allowed to dissociate for 480 seconds. Fits are shown for each trace (coloured shapes 
superimposed over data lines) and residuals for the fits are shown below each sensorgram. 
4.7 Summary and discussion 
The data presented in this chapter describe a biophysical characterisation of LZ-CD23 
with its ligands, IgE and CD2 1. In order to address the hypothesis that the up-regulation 
of IgE requires the co-ligation of surface IgE and CD21 by CD23, it was necessary to 
demonstrate the IgE and CD21 binding capacity of LZ-CD23. Specifically, it was 
important to demonstrate that this LZ-CD23 fragment was capable of high affinity 
binding mediated by the presence of the stalk region and potentially enhanced by the 
leucine zipper motif. 
To determine whether the leucine zipper had mediated oligomerisation of LZ-CD23 in 
solution, a value for the absolute molecular mass was sought. The limitations of 
molecular mass determination using the liquid phase separation techniques available to 
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us have been discussed in section 4.3 and consequently, a value could not be determined 
by these means. An alternative approach was investigated using sedimentation velocity 
analytical ultracentrifugation, but due to the heterogeneity of the protein sample as a 
consequence of incomplete folding, this method of molecular mass determination was 
also unsuccessful. 
Sedimentation equilibrium was then used to analyse the composition of the sample. By 
this method the LZ-CD23 was shown not to be pure, instead comprising of at least two 
non-interacting components estimated to be monomers and hexamers. At the three 
speeds used for these experiments, only the data that were visible on a sedimentation 
equilibrium trace could be fitted to the models. Thus any larger, heavier material, which 
would sediment to the bottom of the cell, or very small, unsedimentable material, would 
not establish a concentration gradient across the cell and would thus not be analysed. It 
could not be determined whether both components were active, although in the absence 
of a monomer oligomer equilibrium, at least one of the components may be inactive. 
The formation of higher-order CD23 complexes has been demonstrated previously 
using chemical cross-linking (Dierks et al., 1993) and in addition, recent structural data 
support the self association of monomeric lectin heads at higher concentrations 
mediated by apposing electrostatic interactions on opposite faces of the lectin head 
(Hibbert et al., 2005). Although the concentrations used in the AUC experiments 
described here were not as high as the millimolar concentrations used by Hibbert et al., 
the presence of the stalk and leucine zipper sequence in LZ-CD23 may allow the 
association of monomers and lower the threshold for intermolecular association of the 
lectin heads. 
-107- 
Chapter 4 LZ-CD23 Ligand Interactions 
IgE binding was demonstrated by ELISA using soluble IgE and IgE Fc bound to 
immobilised LZ-CD23, and by SPR using LZ-CD23 bound to immobilised IgE Fc. 
Kinetic data from SPR analysis were obtained by applying the most appropriate model 
to describe the LZ-CD23 or derCD23 interaction with IgE Fc. Kinetic data have 
previously been obtained for the interaction between a full length, monomeric, 
extracellular CD23 fragment (exCD23) and IgE Fc (Hibbert et al., 2005). These data 
were compared with the data obtained for the LZ-CD23 - IgE Fc interaction. The 
analysis model takes into account the presence of both monomers and oligomers 
(heterogeneous analytes) competing for binding to the same site (Cc3). A clear biphasic 
interaction is noticed for both the exCD23 - IgE Fc interaction obtained by Hibbert et 
al., (KD 1.1 (±0.2) x 10-6 M and 3.9 (±0.6) x 10-8 M) and the LZ-CD23 - IgE Fc 
interaction (KD 2x 10-6 and 1x 10-8 M). The biphasic kinetics for monomeric exCD23 
was explained by "ligand-induced oligomerisation", where the self association of 
exCD23 was mediated by the presence of the stalk. 
The striking difference between the data obtained by Hibbert et al., and those presented 
here, can be observed in the dissociation sensorgrams. A sudden drop in signal before a 
slow decline is observed by Hibbert et al., whereas the dissociation curve for LZ-CD23 
is characterised by a slow decline from the termination of analyte injection with no 
initial drop of signal. This difference suggests a greater proportion of the "fast-off' 
component for exCD23 used by Hibbert et al., than for LZ-CD23. Whilst ligand- 
induced oligomerisation can explain the slow dissociation for both proteins, LZ-CD23 
may have a smaller "fast off' component, owing to the presence of oligomers, as 
demonstrated by the AUC data, as well as enhanced high affinity binding due to the 
leucine zipper motif. 
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For the derCD23 - IgE Fc interaction, a Langmuir model was applied on the basis that a 
monomeric lectin head would bind with a 1: 1 interaction. A low affinity interaction (KD 
= 1.1 x 10-6 M) was observed, consistent with Hibbert et al., (KD = 1.3 (± 0.3) x 10-6 M). 
Interestingly, derCD23 does not dissociate fully from IgE Fc immediately following the 
end of the injection. This can be seen by the less randomly dispersed residuals in the 
dissociation phase as well the slightly elevated x2 in both figures 4.7 and 4.8. Instead, at 
the higher analyte concentrations, a small fraction of material appears to dissociate more 
slowly before reaching a base level. This observation could be a product of the 
experimental conditions. In these experiments, Cc2-4 and derCD23 were immobilised at 
a density of around 500RUs. As discussed by Hibbert et al., a high ligand 
immobilisation density (>500RUs) introduces some multiphasic behaviour, and even 
monomeric derCD23 appears to have a higher affinity component. This can happen 
when the analyte rebinds to ligand molecules immobilised in close proximity before 
dissociating fully. 
LZ-CD23 was shown to bind weakly to CD21 by ELISA. The weak interaction as 
shown by incomplete inhibition (figure 4.6 B) could be due to the wash steps having 
disrupting the interaction. The weak binding may also be due to different glycosylation 
of the full length CD21 (SCR1-16) expressed in baculovirus. This would affect 
protein: carbohydrate binding by SCR 5-8 and pivot the whole interaction on the 
protein: protein ligation by SCR 1-2. A full length molecule may require the stabilisation 
of the interaction with SCR 5-8 whereas CD21 1-2 would not. Although CD21 1-2 was 
at our disposal, no antibody specific for this epitope, nor indeed a polyclonal anti-CD2 1, 
was available. Another explanation for this weak interaction may be due to the amount 
of correctly folded material in the preparation. If only a proportion of the LZ-CD23 
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were able to bind to CD21, the concentrations applied to the ELISA may have been an 
underestimation of the amount required to bind. 
It was not possible to obtain kinetic data by SPR for the CD23-CD21 interaction due to 
problems with immobilising CD21 to a sensor chip. These difficulties are probably due 
to the orientation in which CD21 couples to a sensor surface, which may mask the 
binding sites for CD23. Two fragments of CD21 (CD21 1-16 and CD21 1-2) were used, 
but both fragments appeared to couple with unfavourable orientations as no CD23 
binding was observed. The same low salt, hypotonic buffer used for the CD23-CD21 
ELISA was used as a running buffer to address the issues of salt dependence and 
potential ionic shielding of binding sites but again, these efforts were not fruitful. These 
problems appear to be shared by other groups who study CD21-ligand kinetics and have 
been overcome by using a form of CD21 biotinylated at the C-terminus (Asokan et al., 
2006; Sarrias et al., 2001). This CD21 is expressed as a fusion protein with the biotin 
carboxyl carrier protein (BCCP), an active subunit of acetyl-CoA carboxylase from E. 
coli. A lysine residue on this subunit acts as a biotin acceptor and directs biotinylation to 
the C-terminus, thus allowing immobilisation to a streptavidin chip and avoiding the 
problems of unfavourable immobilisation by amine-coupling. 
Although the data obtained by sedimentation equilibrium suggest a mixture of unfolded 
material, the kinetic data obtained by SPR supports the idea that the LZ-CD23 analysed 
here is still capable of high affinity binding to IgE driven by the stalk and enhanced by 
the leucine zipper. In the absence of a large amount of low affinity component as 
demonstrated by the slow dissociation sensorgram trace, the leucine zipper appears to 
be playing an important role in enhancing the self association of at least a proportion of 
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the molecules, in comparison with other full length, extracellular CD23 fragments 
which have been analysed (Hibbert et al., 2005). 
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Chapter 5: CD21 and IgE fluorescent staining using confocal 
microscopy and the effect of LZ-CD23 on cell lines 
5.1 Introduction 
In the previous chapter, the ability of LZ-CD23 to bind to both IgE (as IgE Fc) and 
CD21 was demonstrated. In comparison with monomeric derCD23, LZ-CD23 was 
shown to bind to IgE with a high affinity. This high affinity binding was postulated to 
be due to the stalk-mediated oligomerisation of LZ-CD23, enhanced by the leucine 
zipper motif. Oligomerisation of LZ-CD23 would thus allow crosslinking of either 
membrane-bound IgE or CD21 through the co-operative binding of the multiple lectin 
heads. In addition, if they were both present on the same cell surface, both CD21 and 
IgE could be co-crosslinked by oligomerised LZ-CD23. 
A major concept in cell biology is the idea that the fluid mosaic membrane and 
cytoskeleton are integrated as a supramolecular complex. Crosslinking of surface 
molecules on lymphocytes establishes signalling platforms when a cell responds to 
extracellular stimuli. The clustering of these molecules on the cell surface may then be 
accompanied by an accumulation of signalling proteins under the lipid bilayer, which 
sets up a signalling cascade with a variety of outcomes. Crosslinking of molecules on 
the cell surface has been demonstrated using specific antibodies that cause "patching" or 
clumping of molecules in the plane of the membrane. These patches may then collect at 
one pole of the membrane, a process called "capping" (reviewed by Bretscher and Raff, 
1975). These phenomena were originally observed by Taylor et al. (1971) and highlight 
not only the fluidity of the membrane but also demonstrate how the formation of 
localised patches (a passive process) shifts to a metabolically active process as patches 
accumulate or "cap" at one point on the membrane. 
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The work in the following two chapters describes a series of experiments using confocal 
microscopy to visualise the effect of LZ-CD23 on the localisation of CD21 and 
membrane IgE (mIgE) on the surface of cells. This chapter documents the optimisation 
of a fluorescence staining protocol to visualise CD21 and IgE using human cell lines. 
The protocol was designed to be applied to experiments using human B cells which will 
be reported in chapter 6. The aim of the optimised protocol is to assess the capability of 
LZ-CD23 to cause the redistribution of CD21 and mIgE on the surface of cells, 
observing the potential formation of patches and caps of these markers, and the 
significance of these events. 
5.2 Optimisation of cell staining conditions 
In order to visualise cell surface movements of two markers as a function of time under 
the influence of an exogenous protein, a protocol had to be devised that allowed the 
incubation of cells with the protein followed by a staining procedure that would avoid 
loss of cells and minimise handling and exposure to sources that may influence marker 
movement, whilst retaining the morphology of the cells as they exist in vivo. Before a 
staining protocol was devised, conditions were explored that would allow the successful 
staining of cellular molecules in vitro. 
5.2.1 Adhering cells to slides 
In vivo, CD23 would probably act on B cells in a liquid phase in the blood or 
intercellular spaces in tissues. Therefore to replicate a representative environment, it 
was decided to incubate cells with LZ-CD23 and carry out the staining steps in a flow 
cytometry tube. This would allow both LZ-CD23 and later, antibodies, to freely 
circulate between cells without the obstruction of a solid layer. The risk of removing 
cells attached to a slide or coverslip by washing or excessive handling would also be 
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minimised. Following incubation with LZ-CD23 and staining, cells were mounted on 
slides in a solid-setting fluorescence guard (Vector) to retain morphology. 
5.2.2 Fixing cells 
Later experiments will detail how the effects of LZ-CD23 on surface CD21 and mIgE 
were assessed as a function of time. Following a period of incubation in the presence or 
absence of LZ-CD23, cells were removed and stained. To avoid post-incubation marker 
movement on live cells, it was necessary to find some way of "freezing" the cells in 
time, thus retaining surface molecules in place. This was achieved by fixing the cells 
immediately on harvesting. 
The perfect fixative should result in immobilisation of the antigens of interest while 
conserving the cellular architecture. Fixatives commonly used are organic solvents, such 
as ethanol or acetone, or formaldehyde. Organic solvents are used frequently to fix 
tissue samples sectioned from cryoblocks or paraffin. These solvents fix sections 
attached to slides by dehydrating cells and precipitating the proteins onto the cellular 
architecture supported by the microscope slide. However, when acetone was applied to 
B cells in suspension with no solid support, cells were seen to burst as water leaves the 
cell, down the osmotic gradient, accompanied by precipitation of protein and nucleic 
acid out of the lysed cells, visible as white debris on the side of the flow cytometry tube. 
In contrast, formaldehyde fixes tissue by crosslinking protein via intermolecular linking 
of free amino groups, and retains the cellular structure better than organic solvents. 
A 
disadvantage is that the antigenicity of cell components can be lost through denaturation 
of the antigens. This loss of antigen binding capacity to a protein as a result of 
formaldehyde fixation is a form of epitope masking and is discussed further below with 
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regard to CD21 and mIgE staining. As all steps of the experiments were to take place in 
solution, formaldehyde fixation was chosen. The microscopy fixative was formulated to 
contain 2% formaldehyde and 0.05% azide in PBS. 
5.2.3 Choice of antibodies for CD21 binding 
A panel of antibodies against CD21 and IgE were available and each tested as 
candidates for staining human B cells (chapter 2, tables 2.2 & 2.3). The four monoclonal 
antibodies against CD21 bind to distinct epitopes on CD21 as shown in figure 5.1. The 
binding sites for the four monoclonal antibodies in figure 5.1 have been previously 
determined, leading to the partial determination of the CD23-CD21 interaction site 
(Aubry et al., 1994). Ideally, for the antibody to not interfere with, or block the binding 
of LZ-CD23 to CD21, it should not bind at the same place as CD23. As shown in figure 
5.1, BU33 binds the same epitope as CD23, but initially, for comparison, all four anti- 
CD21 antibodies were tested for binding capacity to Raji cells, a CD21-expressing 
human B cell line (Pulvertaft, 1964). 
Monoclonal antibodies were applied to cells and incubated for 20 minutes at room 
temperature as described in chapter 2, section 2.10.3. To compare the binding capacity 
of the antibodies to fixed and unfixed antigens, some of these Raji cells were fixed prior 
to the addition of the primary antibody. CD21 binding was revealed with a goat anti- 
mouse conjugated to Alexa 488 (Molecular probes) chosen for its superior signal and 
resistance to photobleaching (Panchuk-Voloshina et al., 1999). Three dilutions of this 
secondary fluorochrome conjugate were then applied (1/10,1/100,1/1000). As a 
negative control to observe non-specific binding, cells were incubated with the 
highest 
concentration (1/10) of Alexa 488 alone. This negative control consistently gave no 
signal. 
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CD23 binding site (SCR 1-2) 
HB5 binding site (SCR 3-4) 
CD23 binding site (SCR 5-8) 
BU33 binding site (SCR5-8) 
BU32 binding site (SCR 9-10) 
IF8 binding site (SCR 11-16) 
Figure 5.1: Structure of CD21 and binding sites for four monoclonal anti-CD21 antibodies 
CD21 consists of 15-16 short consensus repeats (SCRs) numbered from N to the C terminus. 
The binding sites for 4 monoclonal anti-bodes are shown relative to the two binding sites for 
CD23. 
Staining was assessed by both flow cytometry and confocal microscopy and the results 
for all four antibodies shown in figures 5.2 and 5.3. The results from the flow cytometry 
analysis clearly show each dilution to have stained above the negative, background 
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level. Although there is some discrepancy between cells stained before or after fixing, 
the level of intensity is not duly altered. Indeed for the HB5 and BU32 histograms. the 
fixing may even have enhanced staining. 
The flow cytometry laser is more powerful than a confocal microscope which accounts 
for a difference in sensitivity between the two methods. When observing the confocal 
micrographs, it was moticed that in all cases, the signal obtained from the 1/1000 
dilution of Alexa 488 was not discernible from the negative control levels. These 
images have thus been omitted from the figures. 
At all dilutions and for both fixing conditions, IF8 stained with a very low intensity, 
although cells stained before fixing appear to stain better than those stained afterwards. 
The generally low intensity may be due to the location of the IF8 epitope, at the most 
membrane proximal part of the CD21 molecule (figure 5.1). This epitope may have 
reduced accessibility for the antibody, with fixing exacerbating this problem. This 
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Figure 5.2: Binding of BU33 and HB5 anti-CD21 antibodies to Raji cells assessed by flow 
cytometry and confocal microscopy 
Raji cells (5x 105) were stained with 1µg BU33 or HB5 either before or after fixing with 2% 
formaldehyde and 0.05% azide in PBS. Alexa 488 was diluted to 1/1000 -; 1/100 ; 1/50 or 
1/10 - and applied for 20 minutes in the dark at room temperature. 
Cells were analysed using 
flow cytometry (solid blue peaks represent negative, Alexa 488 1/10 stained cells) and confocal 
microscopy. 
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Figure 5.3: Binding of BU32 and IF8 anti-CD21 antibodies to Raji cells assessed by flow 
cytometry and confocal microscopy 
Raji cells (5x105) were stained with 1µg BU32 or 1178 either before or after fixing with 2% 
formaldehyde and 0.05% azide in PBS. Alexa 488 was diluted to 1/1000 -; 1/100 ; 1/50 or 
1/10 - and applied for 20 minutes in the dark at room temperature. 
Cells were analysed using 
flow cytometry (solid blue peaks represent negative, Alexa 488 1/10 stained cells) and confocal 
microscopy. 
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The distribution of surface molecules is something that cannot be discerned by floxv 
cytometry analysis, whereas the confocal micrographs clearly show a difference in 
molecule localisation between cells fixed before or after the addition of antibody. 
Whereas the cells fixed before staining display a halo-like staining profile, suggesting 
evenly distributed CD21 over the cell surface, cells fixed following staining are defined 
by more punctuate areas of staining around the cell circumference, indicative of the 
"patches" observed by Taylor et al., (1971). As each of the antibodies used were 
complete molecules, it is likely that cell surface CD21 on the live cells were crosslinked 
by the bi-valent F(ab' )2 of the antibody, which accounts for the patches of fluorescence. 
As the fixing step was delayed until the end of the protocol and the markers were still 
mobile throughout the binding of the primary antibody, this is a plausible explanation. 
In contrast, the fixed cells would have their CD21 immobilised before crosslinking 
could take place, and CD21 would therefore appear more evenly distributed round the 
cell surface. Interestingly, the capping observed by Taylor et al., (1971), where patches 
of fluorescence coalesce in large clumps at one area of a cell, was not observed. This is 
probably because a bivalent monoclonal antibody recognising only one epitope would 
only have the capacity to crosslink two molecules. 
As a result of the comparative antibody binding study, HB5 was chosen to stain CD21 
owing to its superior CD21 detection and most importantly its low interference with 
CD23 binding as has been previously reported (Aubry et al., 1994). 
5.2.4 IgE staining on AF10 cells 
The mIgE-expressing, B cell lymphoma AF 10 cell line was used to test the 
binding of a 
polyclonal anti-IgE antibody. The choice of this anti-IgE antibody was made 
following 
previous success in this laboratory (Karagiannis et al., 
2003). To eventually visualise 
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two surface markers simultaneously, the method of detecting the IgE antibody had to be 
different to the CD21 antibody. This was achieved using a biotinylated anti-IgE 
followed by a streptavidin-conjugated Cy3. Cy3 is not detected using the filter and laser 
settings built into the FACSCaliburTM flow cytometer used for flow cytometry analysis, 
so results shown in figure 5.4 display only confocal images of mIgE staining. The 
negative control for this experiment used the highest concentration of streptavidin-Cy3 
applied to cells in the absence of anti-IgE. Biotin (also known as vitamin H or B7) is 
found in human cells as a cofactor for a number of carboxylase reactions as well as 
DNA replication. In tissue section staining, it is often recommended to use a biotin 
blocking reagent to avoid cross reactivity of streptavidin-fluorochromes with 
intracellular biotin. The negative control observed for this protocol was consistently 
blank and thus blocking for intracellular biotin was unnecessary (images not shown). 
As with CD21 staining on Raji cells, the lowest concentration of 1 µg/ml streptavidin- 
Cy3 did not give images discernable from the negative control and these images are thus 
omitted here. Also in common with the CD21 staining, the timing of cellular fixation 
influences the staining characteristics of IgE. Cells fixed before incubation with primary 
antibodies once again were characterised by even, halo-like staining around the cell 
circumference (figure 5.4 A). In contrast to the Raji cells, staining for mIgE before cells 
were fixed led to what appears to be intracellular staining. Cells were scanned through 
the Z-axis to check that this apparent intracellular staining was not merely the top or 
bottom of the cell touching the coverslip or slide, spreading the markers over the plane 
of view. 
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With the live cells fixed after staining, it is possible that the crosslinking polyclonal 
antibodies caused internalisation of IgE. The anti-IgE may have bound to surface IgE. 
was then detected by the streptavidin-Cy3 and the whole complex internalised before 
the cell was fixed. 
A: Cells fixed before staining 
B: Cells fixed after staining 
Figure 5.4: Binding of anti-IgE to AF10 cells assessed by confocal microscopy 
AF 10 cells (5x105) were stained with 2µg biotinylated anti-IgE (Vector) 
before or after fixing 
with 2% formaldehyde and 0.05% azide in PBS. Streptavidin conjugated 
Cy3 was diluted to 
100pg/ml and 10µg/ml and I µg/ml and applied to cells for 20 minutes 
in the dark at room 
temperature. Cell staining was assessed by confocal microscopy. 
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5.3 LZ-CD23 redistribution of CD21 on Raji cells 
Before LZ-CD23 was added to human B cells, the effect it may have on one surface 
marker was explored. CD21 was chosen to test this, firstly by having a plentiful supply 
of cells to practise the experimental procedure, but also to back up observations in 
chapter 4 of the CD21 binding capability of LZ-CD23. CD21 was also chosen to 
provide an estimate of the amount of LZ-CD23 needed for the experiments in the 
following chapter, to bind CD21 on human cells in suspension and to study 
redistribution of surface markers. 
The effects of CD21 on cells incubated in the presence and the absence of LZ-CD23 
over 60 minutes was examined following the optimised protocol described in chapter 2, 
section 2.10.4. The affinity of LZ-CD23 for CD21 is unknown, therefore the 
concentration to be added to Raji cells was chosen based on the affinity of LZ-CD23 for 
IgE Fc. This value was calculated as 10-8 M, or 10 nM, so a concentration of LZ-CD23 
in excess of this were used (50x excess) to allow for a lower binding affinity to CD21. 
Following incubation for up to 60 minutes, cells were immediately fixed and HB5 was 
used to stain CD21 using protocol described in chapter 2, section 2.10.3. Cells were 
visualised using confocal microscopy. 
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The images showing examples of Raji cells incubated with LZ-CD23 B for 0.15. 30 
and 60 minutes are shown in figures 5.5-5.8 respectively, and images for cells incubated 
in the absence of LZ-CD23 B, for the same times. The cells were observed for the three 
types of staining observed by Taylor et al., (1971): 
1) Ring or halo staining where the staining is uniform around the cell periphery, 
2) Patches where brightly stained patches are randomly distributed around the cell 
surface, and 
3) "Caps" where the fluorescence is localized at one end of the cell. 
Cells incubated in the presence of LZ-CD23 were seen to have a different surface CD21 
staining profile than cells incubated in the absence of LZ-CD23. At 0 minutes (figure 
5.5 A), CD21 is seen as a halo around the cell circumference, as was observed for HB5 
staining in figure 5.2 B. At 15 minutes (figure 5.6 A), CD21 has begun to group in 
patches, characterised by a more punctuate staining. This is also observed at the 30 
minute time point, where the patching is more pronounced (figure 5.7, A). At 60 
minutes, patching is still observed in some (figure 5.8, panels Ai, ii & iv), but not all 
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Figure 5.5: LZ-CD23 B effect on Raji cell surface CD21,0 minutes 
5x 105 Raj i cells were incubated in the presence (A) or absence (B) of LZ-CD23 B for 5 minutes 
on ice. Cells were immediately fixed then stained with 1µg HB5 followed by a1 in 10 dilution 
of goat anti-mouse Alexa 488. Cells were visualised by confocal microscopy. Each panel is a 
different field of view. 
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Figure 5.6: LZ-CD23 B effect on Raji cell surface CD21,15 minutes 
5x10' Raji cells were incubated in the presence (A) or absence (B) of LZ-CD23 B for 15 
minutes at 37°C. Cells were immediately fixed then stained with 1 µg HB5 followed by a1 in 10 
dilution of goat anti-mouse Alexa 488. Cells were visualised by confocal microscopy. Each 
panel is a different field of view. 
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Figure 5.7: LZ-CD23 B effect on Raji cell surface CD21,30 minutes 
5x105 Raji cells were incubated in the presence (A) or absence (B) of LZ-CD23 B for 30 
minutes at 37°C. Cells were immediately fixed then stained with 1µg HB5 followed by a1 in 10 
dilution of goat anti-mouse Alexa 488. Cells were visualised by confocal microscopy. Each 
panel is a different field of view. 
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Figure 5.8: LZ-CD23 B effect on Raji cell surface CD21,60 minutes 
5x105 Raji cells were incubated in the presence (A) or absence (B) of LZ-CD23 B for 60 
minutes at 37°C. Cells were immediately fixed then stained with I µg HB5 followed by a1 in 10 
dilution of goat anti-mouse Alexa 488. Cells were visualised by confocal microscopy. Each 
panel is a different field of view. 
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In comparison, cells incubated in the absence of LZ-CD23 retained a halo-like staining 
around the cell throughout the 60 minute time-period. This suggests that LZ-CD2 I is 
influencing the movement of CD21 over a period of 60 minutes. As would be expected. 
when cells are incubated on ice, cellular metabolic processes are halted, and association 
of LZ-CD23 with CD21 is slowed; no movement of CD21 under the influence of LZ- 
CD23 is observed. At the later time points, and when cellular processes are restored 
when incubated at 37°C, LZ-CD23 appears to be crosslinking surface CD21 and 
causing the clumping of CD21 patches over the cell surface. This observation is similar 
to the effect of the bivalent anti-CD21 antibodies on membrane CD21 as observed in 
figures 5.2 and 5.3. There, it was hypothesised that the antibodies were crosslinking 
CD21 and causing the patching of mobile receptors on the surface of live cells. With the 
multivalency of a trimeric LZ-CD23 molecule, crosslinking could be occurring in a 
similar way. This will be explored further in the following chapter, which describes the 
effect of LZ-CD23 on primary human B cells expressing both CD21 and mIgE. 
5.4 Summary and discussion 
A protocol optimised for the visualisation of B cell surface CD21 and mIgE using 
confocal microscopy has been described in this chapter. 
A selection of anti-CD21 monoclonal antibodies was used to stain the Raji human B cell 
line in order to choose a suitable candidate for the staining of primary 
human B cells 
(see next chapter). Due to its superior staining when used under the 
high intensity laser 
of a confocal microscope (Panchuk-Voloshina et al., 1999), 
Alexa 488 was used to 
visualise CD21 binding. A range of dilutions of Alexa 
488 was investigated to achieve 
the best signal. Some antibodies fared better than others under the 
fixing conditions. IF8 
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stained the weakest, possibly due to steric hindrance of the antibody reaching its epitope 
at the most membrane-proximal region of CD21 (figure 5.1). The HB5 clone was 
chosen not only for its bright staining, but also, and most importantly, due to its low 
degree of interference with CD23 binding, as has previously been reported (Aubry et 
al., 1994). 
The effect of LZ-CD23 on CD21 expressed on Raji cells was also assessed in order to 
practise the protocol on a plentiful supply of cells and to gain experience in observing 
various types of staining. The work of Taylor et al. (1971) reported the "patching" and 
"capping" of cell surface immunoglobulin in response to anti-Ig antibodies. When LZ- 
CD23 is added to Raji cells, CD21 is seen to cluster in patches as early as 15 minutes, 
with the appearance of some caps on later time points. In comparison, cells incubated 
without LZ-CD23 are not observed to alter the localisation of CD21 on the cell surface 
and are characterised by a uniform ring of CD21 staining. The effect of patching and 
capping was not seen on all cells however, which suggests that the effect of LZ-CD23 
on these cells is modest. Given that Raji cells were seen to express very high levels of 
CD21 as observed by flow cytometry, the concentration of LZ-CD23 was perhaps only 
sufficient to cause partial crosslinking and thus more noticeable patching or capping 
was not observed. 
The protocol described here was designed for the double staining of 
CD21 and mI`gE on 
the same cell, however there is no cell line available co-expressing 
both of these 
molecules. The effect of LZ-CD23 on primary 
human B cells will be described in the 
following chapter, and patching and capping of 
CD21 and mIgE on the surface of the 
same cell will be explored in more detail. 
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Chapter 6: LZ-CD23 redistribution of IgE and CD21 on 
primary human B cells 
6.1 Introduction 
In the previous chapter, a protocol was optimised for the staining of CD21 and 
membrane IgE (mIgE) on human B cell lines. The protocol was devised to allow for the 
co-staining of CD21 and mIgE on a single cell by avoiding cross-reactivity or non- 
specific binding. The co-ligation of CD21 and mIgE by LZ-CD23 on primary human B 
cells is explored in this chapter. 
Recent structural studies demonstrated that IgE and CD21 bind at distinct, non- 
overlapping sites on the lectin head of CD23 (Hibbert et al., 2005). Therefore, an 
oligomer of CD23 will not only be able to bind both CD21 and mIgE simultaneously. 
but also have the potential to aggregate these molecules on the cell surface, creating the 
potential for the formation of large co-crosslinked networks of CD21 and mIgE. It is 
this co-crosslinking of CD21 and mIgE that is hypothesised to be responsible for the up- 
regulation of soluble IgE (sIgE) from a subset of B cells committed to mIgE expression 
but not yet terminally differentiated to the IgE-secreting, CD21- plasma cell phenotype 
(Gould et al., 1997). 
Confocal microscopy was used to visualise the surface dynamics of CD21 and mIgE on 
human tonsil B cells under the influence of LZ-CD23 to elucidate whether LZ-CD23 
has the ability to co-crosslink these surface molecules. In addition, the specificity of the 
CD23-ligand surface interaction was also examined by visualising the effect of 
LZ- 
CD23 on a cell surface marker known not to bind CD23, 
CD38. 
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6.2 Expression of CD21 and mIgE on human B lymphocytes 
B cells do not constitutively co-express both CD21 and mIgE. The surface B cell 
receptor (BCR) expressed on a mature, resting B cell is IgM together with the co- 
stimulatory molecules CD21, CD19 and CD81 (Fearon, 1993). Isotype class-switching 
to IgE is induced by TH2 in the T cell zones of lymph nodes. TH2 cells secrete IL-4 and 
IL-13 and provide CD40 ligand (CD40-L) to ligate B cell-expressed CD40, the synergy 
of which causes the class switching of BCR to mIgE (Jabara et al.. 1990). To induce in 
vitro class switching of B cells to IgE, recombinant IL-4 is used with the addition of 
anti-CD40 antibody, a surrogate CD40-L. 
The B cells used in the microscopy and subsequent biological assays were isolated from 
human tonsils (chapter 2, section 2.6.2). In order to determine whether co-expression of 
both CD21 and mIgE is possible, and on what proportion of cells, B cells from five 
tonsil donors were cultured for up to 10 days in complete culture media (CM) alone 
(chapter 2, section 2.6.2) or in the presence of anti-CD40 and IL-4. Surface expression 
of CD21 and mIgE was assessed by flow cytometry (chapter 2, section 2.7. antibodies 
listed in tables 2.2 and 2.3) and levels of sIgE assessed by IgE-specific ELISA (chapter 
2, section 2.9.2). Figure 6.1 shows one example, representative of five 
donors, of how 
marker expression profiles on tonsil B cell donors can be modulated by culturing with 
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Figure 6.1: Expression levels of surface CD21, mIgE and sIgE on tonsil B cells 
Tonsil B cells were cultured in the presence (red squares) or absence (black diamonds) of 1 
pg/ml anti-CD40 and 200 IU/ml IL4 and monitored for the expression of CD21 (A), mIgE (B), 
CD21+IgE+ cells (C) by flow cytometry and sIgE (D) by ELISA. Results displayed here are 
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It was observed that culture of cells with anti-CD40 and IL-4 over 10 days caused an 
initial rapid and accelerated loss of CD21 from the cell surface (figure 6.1 panel A). In 
contrast, CD21 levels in cells not induced to class switch to mIgE retain CD2 1 
expression on the cell surface. As was expected, the culture of cells with anti-CD40 and 
IL-4 causes the up-regulation of mIgE on the cell surface from around day 5 or 6 of 
culture, which correlates also with the detection of sIgE in the supernatant. typically 
from day 6 (figure 6.1, panels B and D). 
Cells found to be positive for both CD21 and mIgE were observed at the time point after 
mIgE had been up-regulated and when levels of CD21 had not been lost by culture with 
anti-CD40 and IL-4. In the donor example displayed in figure 6.1, these cells were 
observed from day 6, although in 3 donors, the highest levels of CD21+IgE+ cells were 
seen on day 8 (table 6.1). 
As a result of these phenotypic profiles of cells over a 10 day culture period, it was 
found that CD21+IgE+ cells are observed from day 6 or 7, with the highest levels, 
comprising between 16-29% of the cells, typically on day 8 (table 6.1). By repeating the 
same experiment for 5 donors, it was also observed that while mIgE is induced on the 
surface of 5 donors' cells, the percentage of cells expressing mIgE between 
donors «as 
highly variable. This variability between donors is explored further 
in the following 
section. 
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Table 6.1: Percentage CD21+IgE+ tonsil B cells over a 10-das- culture with anti- 
CD40 and IL-4 for 5 donors. (Highlighted areas indicate highest levels) 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Day 1 8.1 5.1 2.5 6.4 4.5 
Day 2 8.8 5.3 2.8 5.7 5.8 
Day 3 7.5 4.5 2.5 7.6 6.4 
Day 4 8.3 5.2 3.3 7.9 6.5 
Day 5 12.4 8.9 4.0 8.9 10.2 
Day 6 14.5 10.7 11.6 10.8 
Day 7 21.5 15.8 11.6 21.3 
Day 8 19.8 15.3 
Day 9 20.4 27.4 15.6 23.2 12.4 
Day 10 20.8 27.1 15.1 23.7 12.7 
6.3 Expression of CD21 and IgE between allergic and non-allergic donors 
Due to ethical restrictions, the tonsils obtained from tonsillectomy donors are not 
characterised as allergic or normal. It was therefore possible that the observed 
differences in IgE production by anti-CD40 and IL-4 were a reflection of allergic status. 
Since studies with LZ-CD23 attempt to understand how CD23 fragments may exert 
their IgE-potentiating effect on B cells expressing mIgE, it was important to ascertain 
that the observations using anti-CD40 and IL-4-class switched B cells were not merely a 
product of a donor's allergic profile. As a means of testing this, B cells were isolated 
from the PBMCs of 5 characterised allergic and 4 non-allergic donors (chapter 
2. 
section 2.6.3), cultured with anti-CD40 and IL-4 (as for the tonsil B cells 
in section 6.2) 
and the expression of CD21 and mIgE assessed by flow cytometry and sIgE 
by ELISA. 
B cells found in the blood are mainly of the naive phenotype with a proportion 
of 
circulating memory B cells, unlike the tonsil which contains a 
heterogeneous mix of 
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cells from the naive, activated, memory and plasma cell lineage at different sta, es of 
differentiation (reviewed by Freitas et al., 2000; Calame et al.. 2003). The response of 
naive B cells to T cell-derived stimuli is less immediate than memory B cells which are 
characterised by a more robust reactivity on stimulation. Although the mechanism for 
this difference is unclear, memory cells have been shown to enter cell division much 
earlier than naive cells on stimulation with CD40-L and cytokines (Tangye et al.. 21003). 
To account for the delayed appearance of mIgE on naive cells, the assay was extended 
to 21 days and, due to a much lower B cell count from PBMCs than tonsils, 4 time 
points were chosen (0,7,14 and 21 days) to allow naive cells from the blood time to 
undergo class switching and express and secrete any IgE when cultured with anti-CD40 
and IL-4. 
To assess whether the levels of CD21, mIgE, CD21+IgE+ cells and sIgE differed 
significantly between allergics and normals, the mean percentage of each marker in the 
allergic and normal groups for each time point was used to calculate the P-value by a 
Student T-test. The gauge for significance was taken as P<_ 0.05. 
Cells cultured longer than 10 days in media alone have a high mortality rate so floww 
cytometry could not be performed due to insufficient numbers for acquisition. The 
results shown in figures 6.2-. 6.5 respectively are therefore for anti-CD40/IL-4- 
stimulated cells only. 






























Figure 6.2: Expression levels of CD21 on PBMC B cells from normal and allergic donors 
PBMC B cells from 5 allergic (black crosses) and 4 normal (red squares) patients were isolated 
by CD19 MACSTM positive selection. Cells were cultured in the presence of 1µg/ml anti-CD40 
and 200 IU/ml IL4 and monitored for the expression of CD21 by flow cytometry on day 0 (A), 
day 7 (B), day 14 (C) and day 21 (D). The P-value was calculated for each time point from the 
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Figure 6.3: Expression levels of mIgE on PBMC B cells from normal and allergic 
donors 
PBMC B cells from 5 allergic (black crosses) and 4 normal (red squares) patients were 
isolated 
by CD19 MACSTNI positive selection. Cells were cultured in the presence of 
1 pg/ml anti-CD40 
and 200 IU/ml IL4 and monitored for the expression of mIgE 
by flow cytometry on day 0 (A), 
day 7 (B), day 14 (C) and day 21 (D). The P-value was calculated 
for each time point from the 
mean percentage of mIgE cells for the allergic and normal groups where 
P <_ 0.05 was 
considered significant. 
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Figure 6.4: Expression levels of sIgE on PBMC B cells from normal and allergic donors 
PBMC B cells from 5 allergic (black crosses) and 4 normal (red squares) patients were isolated 
by CD19 MACSTM positive selection. Cells were cultured in the presence of 1 ýtg/ml anti-CD40 
and 200 IU/ml IL4 and monitored for the expression of sIgE by flow cytometry on day 7 (A), 
day 14 (B), and day 21 (C). The P-value was calculated for each time point from the mean 











































































U Normals Allergies Normals Allergics 
Figure 6.5: CD21+IgE+ PBMC B cells from normal and allergic donors 
PBMC B cells from 5 allergic (black crosses) and 4 normal (red squares) patients were 
isolated 
by CD 19 MACSTN1 positive selection. Cells were cultured in the presence of 
I pg/ml anti-CD40 
and 200 IU/ml 1L4 and monitored for the expression of CD21 
'IgE+ by flow cytometry on day 0 
(A), day 7 (B), day 14 (C) and day 21 (D). The P-value was calculated 
for each time point from 
the mean percentage of CD21+1gE+ cells for the allergic and normal groups 
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For each marker at each time point, there was no significant difference between cells 
isolated from allergic and non-allergic donors. These observations are not unexpected 
given that induction of IgE class-switching by incubation with anti-CD40 and IL-4 is an 
allergen-independent event, therefore precluding any variability in expression levels 
resulting from allergic sensitivities of the donor. 
6.4 LZ-CD23 redistribution of human tonsil B cell CD21 and IgE 
Previous data in section 6.2 of this chapter demonstrated that CD21'IgE- cells were 
detected from day 6 and are typically at their highest on day 8 of culture with anti-CD40 
and IL-4. Tonsil B cells to be incubated with LZ-CD23 were therefore analysed from 
day 6 by flow cytometry for co-expression of CD21 and IgE. A flow cytometry plot of 
cells stained for CD21 and mIgE on day 8 is shown in figure 6.6 and clearly 
demonstrates the up-regulation of IgE and emergence of CD2l+IgE+ cells comprising 
25% of the cellular compartment on incubation with anti-CD40 and IL-4. 
Previous data presented in chapter 5, section 5.3 showed that CD21 was redistributed on 
the surface of the Raji cell line in the presence of LZ-CD23. I therefore sought to 
determine whether LZ-CD23 was able to co-ligate CD21 and mIgE on the surface of 
CD21+IgE+ human tonsil B cells using the protocols described in chapter 2. sections 
2.10.3 and 2.10.4. Cells were viewed by confocal microscopy. 
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Figure 6.6: CD21 and IgE levels of tonsil B cells on day 8 of culture 
Tonsil B cells used for microscopy were incubated with 5µg/ml anti-CD40 and 2001U/ml 11-4 to 
induce IgE class switching. On day 7-8, a sample of 5x105 cells were assessed for surface CD21 
and IgE levels by flow cytometry to check for co-expression. Cells cultured with anti-CD40 and 
IL4 have upregulated IgE on 30% of cells with 25% of live gated cells positive for both CD21 
and IgE. 
Consistent with the results in figure 6.6 where 25% cells incubated with anti-CD40 and 
IL-4 co-expressed CD21 and IgE, not all cells visualised by microscopy were 
CD21+IgE+; a proportion of CD21+ or IgE+ cells were also present. Only double- 
positive cells were observed for this experiment to study co-ligation of CD21 and mIgE. 
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Figure 6.7: Redistribution of CD21 and IgE on primary human B cells by LZ-CD23 B 
Tonsil B cells positive for CD21 and IgE on day 8 of culture with I pg/ml anti-CD40 and 200 
IU/ml IL4 were incubated in the presence (A) or absence (B) of 500 nM LZ-CD23 B. Cells 
were incubated at 37°C and harvested at 15,30 and 60 minutes except cells at time point 0 
which were kept on ice for 5 mins before harvesting. Harvested cells were fixed immediately 
and stained for surface CD21 (, j rc. , 2n) and IgE (rt d). Images were obtained 
by confocal 
microscopy. Images in panel A show three fields of view (i-iii) of cells incubated with LZ- 
CD23 at each time point. Cells incubated in the presence of LZ-CD23 display patching and 
capping of surface marker over the 60 minutes (indicated by arrows) whereas cells incubated 
with no LZ-CD23 retain disperse surface expression of CD21 and IgE. 
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Figure 6.8: Redistribution of CD21 and IgE on primary human B cells by LZ-CD23 A 
Tonsil B cells positive for CD21 and IgE on day 8 of culture with I µg/ml anti-CD40 and 200 
IU/ml 1L4 were incubated in the presence (A) or absence (B) of 500 nM LZ-CD23 A. Cells 
were incubated at 37°C and harvested at 15,30 and 60 minutes except cells at time point 0 
which were kept on ice for 5 mins before harvesting. Harvested cells were fixed immediately 
and stained for surface CD21 and IgE (rcd). Images were obtained by confocal 
microscopy. Cells incubated in the presence of LZ-CD23 display patching and capping of 
surface marker over the 60 minutes (indicated by arrows) whereas cells incubated with no LZ- 
CD23 retain disperse surface expression of CD21 and IgE. 
Table 6.2: B cells displaying patching or co-capping of CD21 and mIgE following 
incubation with LZ CD23 B 
Incubation time (mins) 
0 15 30 60 
B cells + LZ-CD23 B 
2 in 31 
(6%) 
29 in 46 
(63%) 
34 in 45 
(76%) 
25 in 42 
(60%) 
B cells alone 
1 in 28 
(4%) 
1 in 15 
(7%) 
2 in 28 
(7%) 
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Table 6.3: B cells displaying patching or co-capping of CD21 and mIgE following 
incubation with LZ CD23 A 
Incubation time (- 
0 15 30 60 
B cells + LZ-CD23 A 
2 in 27 14 in 20 16 in 23 1-2i n 21 
(7%) (70%) (70%) (57%) 
B cells alone 
2 in 28 1 in 32 2 in 33 1 in A 
(7%) (3%) (6%) (3%) 
Images shown in figure 6.7, panel A display the effect LZ-CD23 B had on the surface 
localization of CD21 and mIgE over 60 minutes. At 0 minutes, the expression of both 
CD21 and mIgE seems to be dispersed evenly around the cell surface, and both the 
green and red for CD21 and mIgE respectively can be distinguished as separate colours 
with minimal overlap (yellow) at this resolution. 
After 15 minutes, cells incubated with 500 nM LZ-CD23 B start to display some 
localised patching of markers aggregating in small clusters on the cell (examples 
indicated by arrows). Both CD21 and mIgE appear to be patching in the same areas 
indicated by yellow overlap. At 30 minutes this patching is more pronounced with 
larger areas of yellow, i. e. overlapped CD21 and mIgE clustering on the cell surface and 
suggesting that the patches have coalesced into caps. At 60 minutes, patching is still 
observed, however in comparison with 30 minutes, CD21 and mIgE are still 
in the same 
area (indicated by yellow overlap) but the distribution is more similar to 
15 minutes 
with localised patches indicated by arrows. Strikingly, cells 
incubated in the absence of 
LZ-CD23 B displayed none of the patching of markers as shown 
in panel B. 
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Figure 6.8 shows cells incubated with LZ-CD23 A applied at the same concentration as 
LZ-CD23 B. Once again, arrows indicate co-localised patching of CD21 and mII-'E from 
15 minutes, through 30 minutes whilst at 60 minutes the distribution of both markers. 
whilst still in the same areas, has become more diffuse. 
6.4.1 Co-capping and patching of CD21 and IgE on B cells occurs in the presence 
of LZ-CD23 
Due to limited availability of the confocal microscope, it was not possible to image a 
very large number of cells to visualise a wide variety of responses to incubation with 
LZ-CD23. In order to be assured that the observations in figures 6.7 and 6.8 were 
representative, cells displaying patching and capping of CD21 and mIgE in the presence 
of LZ-CD23 were counted. Because cells were spread across the entire slide and 
typically there would be only a single cell per field of view, many fields of view were 
observed, scanning across the slide for CD21+IgE+ cells. For each CD21+IgE+ cell 
counted, it was noted whether it displayed the patching and capping phenomena 
indicated by the arrows in figures 6.7 and 6.8, or whether the markers were randomly 
distributed around the cell surface in a ring. Tables 6.2 and 6.3 present the numbers for 
cells incubated with LZ-CD23 B and LZ-CD23 A respectively. These data indicate that 
whilst not all CD21+IgE+ cells were targeted by LZ-CD23, cells incubated 
in the 
presence of LZ-CD23 displayed a greater proportion of co-capping and patching 
(57- 
76%) in comparison with cells with no LZ-CD23 added (0-7%). 
It would thus appear that the presence of LZ-CD23 
influences the localisation of CD-' 1 
and mIgE perhaps by co-crosslinking and aggregating these markers 
in the same area. 
While these observations do not indicate any direct interaction 
between CD21 and mI`gE 
-144- 
Chapter 6 
on human nd CD21 
mediated by LZ-CD23, it suggests that LZ-CD23 has the ability to cause the clustering 
I 
of what appears to be large networks of CD21 and mIgE in proximity. This suggests an 
attractive scenario in which the synergistic signalling through many CD21 and mIgE 
molecules establish a signalling platform from which events leading to sIýgE up- 
regulation may originate. 
6.5 The localisation of CD38 is not influenced by LZ-CD23 
In order to demonstrate the specificity of LZ-CD23-mediated clustering of surface 
CD21 and mIgE, the localisation of an additional molecule not known to bind CD23 
was observed when incubated with 500 nM LZ-CD23 B. CD38 was chosen because B 
cells incubated with anti-CD40 and IL-4 harvested at the time point of the microscopy 
experiment were shown to express CD38 on 76% of the cell compartment as 
demonstrated by flow cytometry (figure 6.9). CD38 is a molecule expressed on 
activated naive B cells found at high levels within the germinal centres of secondary 













Figure 6.9: Expression of CD38 on B cells incubated for 8 days with anti-CD40/IL4 
Tonsil B cells were incubated with 1 µg/ml anti-CD40 and 
200 IU/ml IL4 for 8 days. A sample 
of 1x 105 cells was analysed for surface CD38 expression 
by CD38-FITC and analysed by flow 
cytometry. Cells expressing CD38 (green 
line) represented 76% of the cell sample with the solid 
purple area representing cells stained with a 
FITC isotype control. 
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LZ-CD23 was incubated with cells using the protocol described in chapter 2. section 
2.9.3. Cells were stained for expression of CD38 (chapter 2, section 2.9.3) using a 
FITC-conjugated anti-CD38 antibody, and to standardise the use of fluorochromes. the 
presence of CD38 was detected using the same Alexa 488-cojugated secondary 
antibody as was used for the detection of CD21. Because the co-localisation effect of 
LZ-CD23 on CD21 and mIgE was seen to be most striking at 30 minutes from the 
images shown in figures 6.7 and 6.8, cells were incubated for 30 minutes before 
harvesting and staining. Cells incubated with LZ-CD23 were again observed for 
patching and capping of CD38 compared with cells incubated with no LZ-CD? 3. 
Examples of images viewed for this experiment are shown in figure 6.10. 
The staining of CD38 for all cells for all conditions at both time points was uniform 
around the cell periphery. This suggests that CD38 is evenly distributed around the cell 
surface and the incubation with LZ-CD23 has no effect on this 
distribution. Therefore 
LZ-CD23 is neither binding to, nor indirectly influencing the localisation of 
CD38 on 
the surface of these B cells. 
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Figure 6.10: Localisation of B cell surface CD38 is not affected by incubation with 
LZ-CD23 B 
Tonsil B cells positive for CD38 following incubation for 8 days with 1 µg/ml anti-CD40 and 
200 IU/ml IL4 were observed for surface expression of CD38 following 30 minutes in the 
presence (A) or the absence (B) of 500 nM LZ-CD23. Following 30 minutes incubation at 37°C 
or 5 minutes incubation on ice (0 minutes time point), cells were immediately fixed with 2% 
formaldehyde/0.05% azide and stained for surface CD38. CD38 localisation was detected with 
Alexa 488 and visualised using confocal microscopy. LZ-CD23 is not seen to influence the 
surface localisation of CD38 over the 30 minute time period, observed by the absence of any 
patching of capping of CD38 on the cell surface. Staining is seen instead as a uniform ring 
round the cell. 
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6.6 Summary and discussion 
D23 effect on human I, and CD21 
In this chapter, a series of experiments has been described investigating the effect of 
LZ-CD23 on the localisation of CD21 and mIgE expressed on the surface of primary 
human B lymphocytes. To test whether CD23 was able to co-ligate surface-expressed 
CD21 and mIgE, primary human tonsil B cells were first assayed for surface expression 
of both CD21 and mIgE to assess whether CD21+IgE+ cells indeed existed and if so. at 
what time point they emerge. Expression of CD21 was seen to decrease over 10 day s 
while, as expected, mIgE expression was seen to increase in cells from five B cell 
donors incubated with anti-CD40 and IL-4; this correlated with the detection of sIgE in 
the supernatants, typically a day following the first appearance of mIgE surface 
expression. Cells cultured in media alone retained CD21 levels at around 60-85% and 
did not induce mIgE surface expression. Patient variability accounts for a certain 
heterogeneity in the levels of each marker. Dual-expressing CD21+IgE+ cells accounted 
for 16-29% of the cell population at their highest levels, depending on the donor. and 
were observed from day 6,7 or 8 of culture correlating with the up-regulation of mIgE 
and retention of CD21 on a proportion of these cells. 
B cells isolated from the PBMCs of normal and allergic donors (characterised 
by skin- 
prick tests and RAST) were analysed for CD21, mIgE and sIgE to assess whether 
the 
(unknown) allergic status of tonsil donors could account 
for the phenotypic variability 
between donors. It was postulated that a donor's ability to upregulate 
IgE may be a 
product of their allergic status. From a pool of 
five allergic and four normal donors. 
CD21, mIgE and sIgE expression was assessed at 
0.7,14 and 21 days. There was no 
significant difference observed for the expression of any marker 
between the donor 
groups at each time point studied. Any 
differences observed in expression «erc 
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therefore more likely to be the individual response of a cell population to anti-CD40 and 
IL-4 rather than a predisposition to IgE expression. 
Having observed that CD21+IgE+ cells could be detected from around day 6-8 of culture 
in approximately 20% of cells, the effect of LZ-CD23 on the localisation of these 
markers was assessed. The confocal microscopy staining technique as described in 
chapter 5 was used as a means of visualising the movement of CD2I and mIgE in 
response to LZ-CD23. Before cells were exposed to LZ-CD23, CD21 and mIgE ww ere 
seen to be distributed around the cell surface with minimal overlap, observed by a ring 
of green (CD21) and red (mIgE) with no overlapping yellow. Following 15 minutes of 
incubation with LZ-CD23, both CD21 and mIgE were seen to start patching together as 
small yellow clumps around the surface. After 30 minutes, these patches were seen to 
coalesce as larger yellow caps at one part of the cell. According to Taylor et al. (1971) 
patching is a transient process, whereas the movement of markers into caps requires a 
metabolic contribution from the cell, a process often accompanied by movement of the 
cell's cytoskeleton. It could therefore be possible that LZ-CD23 is inducing a metabolic 
process within the cell to promote the formation of CD21 and mIgE caps. Given that 
these caps were observed on up to 76% of cells incubated with LZ-CD23 B and 
70% of 
cells incubated with LZ-CD23 A in comparison with 6% of cells 
incubated in the 
absence of LZ-CD23, this is striking evidence that LZ-CD23 
is able to gather both 
CD21 and mIgE into large co-capped clusters on the cell surface. 
It would be of interest 
to observe whether the cell cytoskeleton was involved 
in the formation of these caps. 
By staining for CD38, known to not bind 
CD23, in the presence and absence of LZ- 
CD23, the specificity of LZ-CD23 for CD21 and 
IgE was tested. The absence of patches 
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or caps of CD38 indicated that LZ-CD23 does not cause the non-specific movement of 
markers other than those to which it binds on the cell surface. 
Taylor et al. (1971) observed patching and capping of immunoglobulins using anti-Ig 
antibodies, therefore it would appear that LZ-CD23 is in effect acting as a bispecific 
"antibody" for CD21 and mIgE by drawing them together. In order to confirm these 
conclusions concerning CD21 and mIgE capping, a bispecific antibody binding CD21 
and mIgE at the same epitopes as CD23 is currently in development. Although the 
capping of CD21 and mIgE does not prove that they are interacting, it at least suguests 
that by crosslinking them in the same proximity, a signalling platform may be 
established as has been observed for the clustering of IgM and CD21 into lipid rafts by 
antigen coated with complement (Cherukuri et al., 2001). 
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Chapter 7: Biological activity of LZ-CD23 and its effect on IgE synthesis 
7.1 Introduction 
A large body of work implicates CD23 in the regulation of IgE (chapter 1. section 1.8 & 
1.9). It has been established that signalling through membrane CD23 (mCD2 3) results 
in the down-regulation of soluble IgE (sIgE) from committed B cells (Cho et a!.. 1997; 
Luo et al., 1991; Sherr et al., 1989). In contrast, soluble CD23 (sCD23) fragments have 
been observed to have both an enhancing (Pene et al., 1988a; Sarfati et al.. 1984b: 
Saxon et al., 1990) and suppressive (Sarfati et al., 1992) effect on sIgE synthesis from B 
cells. This disparity has been largely attributed to the size and crosslinking capability of 
the different CD23 fragments. 
It has been previously inferred that sIgE up-regulation by CD23 fragments larger than 
25 kDa relies on the interaction of sCD23 with CD21 (Aubry et al., 1992. Bonnefoy el 
al., 1995; Henchoz et al., 1994). Furthermore, sCD23 has been shown to exert its IgE- 
potentiating effect only on B cells pre-committed to IgE synthesis (Sarfati and 
Delespesse, 1988), therefore the presence of membrane IgE (mIgE) also appears to be a 
critical factor for CD23 to exert its effect. In a manner analogous to activation of naive 
B cells through the crosslinking of IgM and CD21 by complement-decorated antigen. as 
observed by Fearon and colleagues (Carter and Fearon, 1992; Dempsey and 
Fearon, 
1996), Gould et al. proposed a model whereby CD23 activates B cells and 
drives I`gI: 
synthesis by the synergistic signalling through CD21 and mIgE (Gould et al.. 
1997). 
The work described in this chapter outlines a series of experiments 
to stud% the 
capability of LZ-CD23 to upregulate sIgE synthesis. 
Previous chapters hav c 
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demonstrated that LZ-CD23 is capable of high affinity binding to IgE and that it also 
binds to CD21. LZ-CD23 also has the potential to specifically co-crosslink both CD-' 1 
and mIgE on the surface of B cells. Work will be described that explores whether the 
co-expression of CD21 and mIgE is important for the up-regulation of IgE in an in vitro 
system. 
7.2 LZ-CD23 does not degrade in culture or interfere with the IgE detection 
ELISA 
The SPR data in chapter 4 demonstrated that LZ-CD23 binds to IgE. The work in this 
chapter describes how LZ-CD23 A and B may stimulate IgE up-regulation using ELISA 
to detect sIgE in the supernatants of cell cultures. It was therefore necessary to assess 
whether LZ-CD23 degraded over the culture period into smaller fragments which are 
known to downregulate sIgE synthesis (McCloskey et al., submitted; Sarfati et al., 
1992) and additionally to see whether LZ-CD23 in the supernatant would effect the 
detection of sIgE by ELISA. To test the first concern, LZ-CD23 was diluted in culture 
medium for 10 days and compared with freshly thawed LZ-CD23 on an anti-CD2 3 
western blot (figure 7.1 A). To test the second concern, the WHO IgE standard was 
diluted to a constant concentration of 80 ng/ml in culture medium and LZ-CD23 titrated 
in double dilutions from 10,000 ng/ml to 10 ng/ml into the diluted IgE. A control 
condition with IgE alone diluted to 80 ng/ml was also prepared. 
After 10 days of 
incubation at 37°C, to mimic cell cultures, each culture supernatant was analysed 
in 
triplicate for sIgE (figure 7.1 B). 
Collectively, the results in figure 7.1 reveal that 
LZ-CD2 3 neither degrades nor 
interferes with IgE detection by ELISA at any concentration. 
Since LZ-CD21 A and 
- 152- 
hapter 7 Biological activi 
LZ-CD23 B were shown to have identical IgE-binding characteristics in chapter 4. this 
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Figure 7.1: LZ-CD23 does not degrade in culture or interfere with IgE detection 
by ELISA 
d A: LZ-CD23 B was diluted to a concentration of 2 ýighnl in culture med u 11 
incubated for 10 days at 370C. This sample was then run on a non-reducing SDS-PAGE 
gel, along with a fresh sample of CD23 for comparison, and probed for CD233 using I 
pg/ml BU38. CD23 was revealed using anti-mouse HRP and chemoluminescence. 
B: LZ-CD23 B was titrated in doubling dilutions from 10,000 ng/ml to 10 ng/ml and 
added to 80 ng/ml IgE WHO standard, diluted in culture medium, using IgE at 80 ng/ml 
alone as a control. After 10 days of incubation at 37C, IgE was analysed 
by ELISA. 
LZ-CD23 B did not interfere with IgE detection and no concentration 
differed 
significantly from IgE alone. 
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7.3 LZ-CD23 stimulation of IgE from human tonsil B cells 
The capacity to upregulate sIgE synthesis from human tonsil B cells was tested for both 
LZ-CD23 A and LZ-CD23 B. In this first set of experiments. B cells were isolated from 
human tonsils, cultured either with anti-CD40 and IL-4, or with culture media alone. 
and incubated in the presence and absence of LZ-CD23 A at concentrations of 1000. 
100 and 10 ng/ml. These three concentrations of LZ-CD23 were chosen to be equal to. 
lower than and in excess of the endogenous protein which, from previous experience in 
this laboratory, has been detected in anti-CD40/IL-4 stimulated B cell culture 
supernatants. LZ-CD23 A was added at day 0 and cells harvested at 3.7 and 10 days of 
culture. Supernatants were analysed for sIgE content by specific ELISA. LZ-ß'D23 A 
was shown to upregulate sIgE only from B cells cultured with anti-CD-PO and IL-4 
(figure 7.2, i and ii). 
In two of three experiments, using three different sets of tonsil B cells, sIgE was 
significantly increased by the addition of LZ-CD23 A in comparison with cells cultured 
with anti-CD40 and IL-4 alone (figure 7.2 i-ii). In the first experiment. this 
enhancement was seen on addition of 1000 ng/ml and 100 ng/ml LZ-CD23 
(figure 7.2. 
i), whereas, in a second experiment, 1000 ng/mI LZ-CD2-') caused an up-regulation 
whilst the lower concentrations had no effect (figure 7.2 
ii). In a third experiment LZ- 
CD23 A did not have any effect on sIgE up-regulation 
(figure 7.2, iii). Cells cultured in 
media alone consistently did not produce sIgE either 
in the presence, or in the absence 
of LZ-CD23 (data not shown). These observations suggest 
that LZ-CD-13 only targets B 
cells that have already class-switched to 
IgE. thus complementing previous observations 
that soluble CD23 fragments enhance ongoing 
IgE synthesis from IgE-committed 
B 
cells (Sarfati and Delespesse, 1988; 





Figure 7.2: IgE enhancing effect of LZ-CD23 A on B cells from three tonsils 
B cells from three tonsils (i-iii) were cultured at a density of 5x 10 /ml vvith I ýIg/m 
anti-CD40 and 200 IU/ml IL4 or in media alone. LZ-CD23 A was added at day 0 at 
1000 (yellow), 100 (green) and 10 ng/ml (blue). Cells were also cultured with anti- 
CD40 and IL4 alone (red). Cells were harvested at day 3,7 and 10 and supernatants 
analysed in triplicate for IgE by ELISA. Cells cultured in media alone consistently 
produced no IgE in the presence or the absence of LZ-CD23 (data not shown). The P 
value was calculated by a Student T-Test where P:! ý 0.05 was considered significant. 
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7.4 LZ-CD23 promotes IgE secretion from B cells in a time-dependent manner 
The above experiment demonstrated that LZ-CD23 enhanced sIgE synthesis from two 
of three B cell preparations. However, it did not give any indication as to when LZ- 
CD23 may have acted on the cells because protein was added on day 0. In a second set 
of experiments, B cells from two tonsil donors were cultured as before with anti-CD40 
and IL-4. Cells were harvested once again on days 3,7 and 10. however, LZ-CD2-')' A or 
LZ-CD23 B was added 24 hours before cells were harvested. 
IgE secretion was once again enhanced at day 10 in the presence of both 1000 ng/ml 
LZ-CD23 A and LZ-CD23 B (figure 7.3). Additionally, LZ-CD23 B enhanced slgE 
synthesis on day 7 when added at a concentration of 10OOng/ml (figure 7.3) ii). There 
was no significant effect observed at the lower concentrations of 100 or 10 ng/ml on any 
day for either LZ-CD23 preparation. As before, LZ-CD23 had no effect on cells not 
already induced to class-switch to IgE (data not shown). 
To observe whether the enhanced sIgE synthesis could be correlated with the expression 
of CD21 and rnIgE on the B cell surface, the above experiment was repeated and 
additionally, the harvested cells analysed for surface CD21, mIgE and 
CD21+IgE+ 
expression by flow cytometry. The results in figure 7.4, panel A demonstrate once again 
that the addition of 1000 ng/ml LZ-CD23 A to cells at 
day 9 of incubation , vith anti- 
CD40 and IL-4 causes the enhanced secretion of slgE when analysed 
in the day 10 
supernatant. The lower concentrations of LZ-CD23 
had no effect on slgE sý rithesis and 
cells cultured with no anti-CD40 or IL-4 produced no sIgE 
in the presence or the 
absence of LZ-CD23 A (data not shown). 
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Figure 7.3: Time-dependent IgE enhancement of LZ-CD23 on human tonsil B cells 
Tonsil B cells were cultured at a density of 5x IW/ml with I pg/ml anti-CD40 and 200 
IU/ml IL-4 or in media alone. LZ-CD23 A (1) and LZ-CD23 B (11) were added on day 2, 
6 or 9 at 1000 (yellow), 100 (green) and 10 ng/mI (blue). As a control, cells were also 
cultured with anti-CD40 and IL-4 alone (red). Cells were harvested at day 3,7 and 10 
and supernatants analysed for IgE by ELISA. Cells cultured in media alone consistently 
produced no sIgE in the presence or the absence of LZ-CD23 (data not shown). The P 
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Figure 7.4: The time-dependent IgE enhancement from human tonsil B cells by 
LZ-CD23 does not affect membrane expression of IgE 
A: Tonsil B cells were cultured at a density of 5x 105/nil with I pp/ml anti-CD40 and 
200 IU/ml IL-4 or in media alone. LZ-CD23 A was added on day 2,6 or 9 at 1000 
(yellow), 100 (green) and 10 ng/ml (blue). As a control, cells were also cultured with 
anti-CD40 and IL4 alone (red). Cells were harvested at day 3,7 and 10 and supernatants 
analysed for IgE by ELISA. Cells cultured in media alone consistently produced no IgE 
in the presence or the absence of LZ-CD23 (data not shown). The P value was 
calculated by a Student T-Test where P:! ý 0.05 was considered significant. 
B-D: Cells harvested for supernatants on day 3,6 and 10 were also stained for surface 
CD21 (B), IgE (C) and CD2 I AgE (D) and analysed by flow cytometry. The addition of 
1000 (yellow), 100 (green) or 10 ng/ml (blue) LZ-CD2-)' A had no effect on surface 
CD21 or IgE levels in comparison with cells cultured, ývith CD40 and IL-4 alone (red). 
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Flow cytometry analysis of the cells harvested at each time point revealed that. while 
levels of each surface marker changed over the course of 10 days as a result of culture 
with anti-CD40 and IL-4, the addition of LZ-CD23 at all concentrations had no effect 
on the surface expression of CD21, mIgE or CD21+IgE+ at any of the time points. The 
increase of slgE synthesis on day 10 would suggest that LZ-CD233 promoted a secreted 
isoform of IgE, such as one that has been previously reported (Batista et al., 1995: 
Kamowski et al., 2006; Saxon et al., 1991). Interestingly, it was noticed that the 
percentage of CD2 1 +IgE+ cells was at its highest at day 10 so LZ-CD-'? 33 A added on dav 
9 could be promoting slgE up-regulation by targeting the proportion of cells expressing 
both CD21 and IgE. 
7.5 Summary and discussion 
The biological activity of LZ-CD23 has been assessed through work described in this 
chapter. Using a series of in vitro assays, the ability of both LZ-CD23 A and LZ-CD2-') 
B to stimulate IgE from human tonsil B cells has been explored. 
Having established that LZ-CD23 would neither interfere with an IgE detection ELISA 
nor degrade over 10 days of culture at 370C, two assays were designed to test 
1, -, F 
synthesis mediated by LZ-CD23. The first involved the incubation of 
B cells \ý Ith LZ- 
CD23 A at 1000,100 and 10 ng/mI for up to 10 days, following addition of 
LZ-C D-23 to 
the cells on day 0 in the presence or absence of anti-CD40 and 
IL-4. On remoN, al of 
supernatant from cells in culture on day 3,7 or 10, a significant up-reUILIlation 
of sh-) 1: 
was observed by day 10 on addition of 1000 and 
100 ng/ml LZ-CD-"', A in cells from 
in a second. -, 
I(-, E levels %ýcrc 
one tonsil and on addition of 1000 ng/ml 
by daY 10 1 
unaffected by LZ-CD23 in a third tonsil. 
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The timing of both LZ-CD23 A and LZ-CD2) B addition to cells appeared to be 
important for sIgE up-regulation. This was demonstrated using the second assay in 
which cells were harvested on day 3,7 and 10 as before, but addition of LZ-CD--"l was 
delayed until 24 hours ahead of the cell harvest day. sIgE synthesis ý\as significantIv 
up-regulated by both 1000 ng/mI LZCD23 A and LZ-CD23 B when added on daY 9 to 
cells cultured with anti-CD40 and IL-4. Additionally, 10OOng/ml and 100 ng ml LZ- 
CD23 B caused a significant up-regulation of IgE when added on dav 6. 
Flow cytometry was used to analyse surface CD21 and IgE expression of cells 
incubated with LZ-CD23 A. Levels of CD2 I +IgE+ cells were at their highest hN daý 10 
and therefore it appeared that LZ-CD23 A was affecting only production of slgE at a 
time where CD21 and m1gE were co-expressed on the surface of 20% of the cells. In 
contrast,, all three concentrations of LZ-CD23 A had no effect on the surface expression 
of mIgE despite the stimulation of sIgE synthesis at day 10. It has previouslý been 
reported that different isoforms of both membrane and soluble IgE exist \\ hose 
expression depends on the use of internal polyadenylation sites situated along the 3' 
untranslated region (UTR) of the s gene (Batista et al., 1995; Saxon et al., 1991). 
It has 
been recently suggested that the transcription of these isoforms 
is dependent on the 
differentiation state of the cell where the binding of cis-acting 
factors affects the 
composition, and thus cleavage, of the polyA site (Kamowski et al.. 
2006). It ýNOLIld be 
interesting to determine whether LZ-CD23 up-regulates sIgE synthesis 
bý promoting 
the binding of cis-acting factors which may favour preferential usage 
of one poly-A 
Experiments described here have shown that both LZ-CD23' 
A and LZ-CD-"i B Nýere 
biologically active in stimulating slgE secretion 
in an in Otro B cell '-, \,, tciii. Theý- 
have 
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also highlighted how the timing of LZ-CD23 addition to cells. along ývith the co- 
expression of CD21 and mIgE seems to be important for slgE stimulation. The results 
obtained here are from a limited number of tonsil B cell preparations and -, e\ cral niore 
replicates would be needed to confirm a consistent trend. Further analysis of the tinie 
between day 7 and 10 would also allow a greater understanding of when LZ-CD2) is 
targeting cells. 
As a result of culture with IL-4, B cells upregulate and secrete sCD-233 (Bonnefo. v et al., 
1988a; Chretien et al., 1990). Preliminary work is underway to preclude the effect of 
endogenous sCD23 on sIgE secretion before LZ-CD23 is added. Early experiments 
involving the removal of supernatant and resuspension with LZ-CD23 Im c been 
performed but the results have not been reproducible and are thus omitted here. 
Work is ongoing in this laboratory to study the mechanisms behind sIgE up-regulation 
including the effect of LZ-CD23 on B cell proliferation and promotion of B cell 
survival. 
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Chapter 8: Summary and General Discussion 
In this thesis I have described the purification, and aspects of biophysical and biological 
characterisation of a soluble recombinant fragment of human CD23 ' 3. \, IanN- studics have 
been published implicating soluble CD23 (sCD23) in the up-regulation of soluble 
(slgE), the major antibody, central to allergic reactions. Whilst early data utillsed CD2'i 
derived from cell lines or serum from allergic donors, it is only relatively recentl\ that 
recombinant forms of CD23 have been expressed and purified to deten-nine the 
structural and functional properties of CD23. Due to its susceptibility to proteases, it has 
been difficult to characterise full length CD23 fragments. Instead, previous woi-k has 
mainly focussed on the structure and function of the smaller fragments implicated in 
IgE down-regulation. 
8.1 Purification and characterisation of LZ-CD23 
The work presented here used a soluble form of human CD23. designed by D. Conrad 
and colleagues (Chen et al., 2002; Kelly et al., 1998), incorporating an 
N-terminal 
leucine zipper - hence the acronym LZ-CD23 - to promote stabilised self-association 
in 
the absence of ligand binding or the constraints of a cell membrane. 
In these original 
studies, it was demonstrated to be able to bind IgE with an affinity 
that even competed 
with the IgE-FcsRI interaction through the enhanced avidity achieved 
by co-operatiN e 
binding of more than one lectin head, presumably as a result of 
its abilitý' to form stable 
oligomers (Kelly et al., 1998). This molecule was 
therefore chosen for its potential for 
studying the effects of CD23 on IgE synthesis 
in biological systems. 
The expression vector for LZ-CD23 was produced 
and kindlN, donated b" D. 
Conrad for 
expression in a prokaryotic system. 
E. coli was unable to correctly refold 
LZ-C'I)'-). and 
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to obtain a purified product, several steps had to be folloýN-ed. Protein had to be isolated 
from inclusion bodies and renatured in a controlled redox environment. Durin, -, the 
purification, several problems were encountered including proteolYsis, alleN-lated bý 
filtering buffers and treating all purification equipment Ný-lth protease inhibitors. and 
aggregation of protein during ultrafiltration or dilution of concentrated material into 
refold buffers, overcome by slow dilution of small amounts of protein. 
Due to the low yields of LZ-CD23, it was necessary to prepare several batches of 
protein for use in the biophysical and biological assays. Two preparations have been 
described here,, differing only by the buffers in which they were stored. Throughout the 
thesis they have been referred to as LZ-CD23 A (stored in 22 50 mM Tris, I '- 5 mM NaC 
1) 
and LZ-CD23 B (stored in TBS). Both been characterised as fully as possible to allow 
the substitution of LZ-CD23 A by LZ-CD23 B when LZ-CD'-"3 A was depleted. As part 
of the characterisation, it was desirable to ascertain whether the addition of the leucinc 
zipper had led to oligomerisation of the molecule in the absence of ligand binding or the 
constraints of a cell membrane, as has been previously shown for other leucine zipper 
proteins (Harbury et al., 1994; Harbury et al., 1993). For LZ-CD2-"I. this was assessed 
by two methods. Firstly, the molecular mass was estimated using (-)el 
filtration 
chromatography to determine if the molecule eluted 
from a column as a trimer. 
However, due to the elongated shape of the stalk, the Mr of 
LZ-CD" could not be 
compared to the globular molecular weight markers used 
to calibrate a gel filtration 
column, and it appeared to elute as a much 
larger molecule than its sequence. c% en as a 
trimer, suggested. 
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The oligomerisation state was therefore examined using analytical ultracentrifugation. 
Using sedimentation equilibrium to analyse the composition of the protein preparation. 
the sample of LZ-CD23 B was shown to contain two non-interactino comporients. The 
best fits described a mixed population of monomers and higher molecular N\eilght 
oligomers (hexamers). Despite this sample heterogeneity, IgE bindino assessed by SPR 
demonstrated a high affinity interaction to IgE Fc for both LZ-CD23 A and B. 
characterised by a biphasic kinetic interaction with KDvalues of 2.0 x 10-6 \1 and 1.0 x 
10-8 M. These values were consistent with a detailed SPR anah-sis of the binding 
kinetics of exCD23 (a full length monomeric CD23 fragment as determined by AUC) 
with IgE Fc (Hibbert et al., 2005). The reason for the similar kinetics between these t\\ o 
molecules can be attributed to ligand-induced oligmerisation of exCD2 -3 
binding to loll 3 
Fc. It appeared that oligornerisation in the absence of ligand binding \ý as not necessary 
to cause high affinity binding. However, despite these matching KDvalues for LZ-CD2') 
and exCD23, an important difference between the two interactions was observed in the 
markedly slower dissociation of LZ-CD23, the higher affinity component appeared to 
be accounting for the majority of the observed kinetics. This was probably due to the 
leucine zipper driving self association of LZ-CD23 on binding to ligand and stabilising 
the LZ-CD23 - IgE Fc complex, allowing an 
increased avidity due to co-operativelý 
bound lectin heads. 
The LZ-CD23 - CD21 interaction was observed using 
a direct sandývich ELISA. 
However, in a competition ELISA, LZ-CD23 could only partiallý- 
inhibit the binding of 
sCD21 to immobilised LZ-CD23. These results suggested 
that the proportion of actl\*c 
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The heterogeneous composition of LZ-CD23 along with the potentiallý- overestimated 
levels of active material suggests that the bacterial expression sVstem is inappropriate 
for LZ-CD23. Work is currently being undertaken to develop a mammalian expression 
system to express LZ-CD23. This would allow the cell to fold LZ-CD2') and avold the 
loss of protein through in vitro folding. 
8.2 Co-localisation of CD21 and IgE by LZ-CD23 
The hypothesised mechanism by which sCD23 fragments upregulate sIgE is based oil 
the analogy with the activation of mature, naYve B cells by the crosslinking of 1(-, \l and 
CD21 by antigen coated in complement (Carter and Fearon, 1992: Dempsey el ýJ, 
1996). Whereas this event is antigen specific, the up-regulation of slgE by CD2_') is 
antibody isotype specific, since CD23 targets a population of IgE-expressing CD21+ 
cells not yet terminally differentiated to plasma cells, by co-ligating ml, (! E and CD21. t, 
While the interaction of sCD23 with CD21 was shown to be important for sIgF' 
stimulation (Aubry et al., 1992; Bonnefoy et al., 1995) along with the presence of rnIgE 
on cells (Sherr et aL, 1989), the above crosslinking of CD21 and mIgE by CD23 has not 
yet been proven. A protocol was devised to visualise co-ligation of CD21 and IgE on 
the surface of human B cells, using confocal microscopy. The existence of transitional 
CD21+IgE+ B cells was demonstrated by incubating tonsil B cells with anti-CD40 and 
IL-4 for 10 days to induce IgE class switching. In five tonsil B cell preparations. nilgi', 
was up-regulated from day 6, with CD21 levels persisting for a 
few additional days thus 
giving a window period between day 7 and 10 in which 
B cells co-expi-essed both 
molecules on between 15-25% cells. Observed variability 
between patients' IeN, els of 
mIgE was not found to be a product of allergic status as 
demonstrated bý, phenotý-picallý 
analysing CD21 and IgE on the surface of allergic and normal 
PBMC B cells. 
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Using confocal microscopy it was shown that mIgE and CD21 co-localised into patchý:, 
or caps as early as 15 minutes following incubation ýý-ith both LZ-CD2-') A and LZ- 
CD23 B. Cells incubated for up to 60 minutes in the absence of LZ-CD2-') retained a 
random distribution of CD21 and mIgE around the cell circumference with no co- 
localisation observed. Patching and capping was observed in over 60% of cases wheTl 
either LZ-CD23 A or LZ-CD23 B was added to cells. The interaction of CD21 and 
migE in the patches or caps could not be determined at the resolution afforded by 
confocal microscopy. However, it is appealing to conjecture that the specific induction 
of CD21-IgE patch/cap formation by LZ-CD23 may establish the scaffold for a 
signalling platform for B cell activation and IgE secretion. 
Monomeric derCD23 was unavailable for use in the confocal cross-linking experinients. 
It has been shown experimentally that, despite its inability to oligomerise due to the 
absence of the stalk, derCD23 contains distinct and non-overlapping binding sites for 
both CD21 and IgE (Hibbert et al., 2005). Whilst this would suggest that a lectin head 
alone may bind CD21 and IgE in solution, the steric positioning of mIgE and CD'- I 
molecules on a cell surface may hinder in vivo crosslinking by a derCD23 lectin hcýid 
due to the relative sizes (IgE, 170kDa; CD21,145kDa; derCD23 16kDa) and binding 
site accessibilities of each molecule. Small sCD23 fragments containing the monovalent 
lectin head alone have been shown to downregulate IgE (Sarfati et al.. 
1992). This may 
be due to the binding of lectin heads to single CD21 or IgE molecules. xN-I-iich ývould 
sequester them and render them unavailable for crosslinking. 
In the context of cellular 
t-- - is activation, valency would appear to be important. 
The complement fragment C"d i 
itself monovalent but when crosslinked by sepharose allows 
the entrý- of activated 13 
3 
cells into S-phase, in contrast to monomeric 





(Melchers et al., 1985). In addition, the direct attachment of tiA-o or more C'3d molecules 
to antigen was observed to enhance antigen immunogenicitý, up to 10-000-fold in 
contrast to monomeric Od (Dempsey et al., 1996). Similarlýý, free calcium 
concentrations were shown to be enhanced by anti-Ig antibodies in combination xvith 
poly-valent Od, yet suppressed by monomeric Od (Tsokos et al., 1990). 1 licsc 
observations would suggest that the valence of a stimulus is crucial in gox, eming 
whether a positive or negative signal is transmitted through the BCR and/or CD2 1. Any 
signal resulting from the LZ-CD23 interaction with CD21 and mIgE is therefore likek 
to rely on its ability to crosslink these two molecules. 
8.3 LZ-CD23 as a potentiator of IgE synthesis 
To complete the characterisation of LZ-CD23, its ability to upregulate IgE xNas 
explored. It was observed that the timing LZ-CD23 addition to cultures appeared to be 
critical for the biological activity. When added after up-regulation of 1(,, E had occurred 
from day 6, LZ-CD23 was seen to stimulate IgE when added at concentrations of 1000 
ng/ml. Importantly, this up-regulation correlated with the persistence of CD21-1(, I-. * 
cells and was consistently not observed in cells that were not already committed to IgE 
synthesis. The synthesis of sIgE must be tightly controlled to prevent the systemic 
activation of effector cells in response to cross-linking of disregulated levels of allergen- 
specific IgE. Both CD23 and IgE are up-regulated in an IL-4-rich milieu, therefore if 
CD23 were to only target a subpopulation of CD2 I+ cells expressing mIgE as a result 
of 
the local IL-4 environment, its effect on cells would 
be limited, thus avoiding the 
inappropriate up-regulation of slgE. 
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8.4 CD23 in allergy 
How might conditions favour the production of sCD23 fragments and co-lio-ation of' 
mIgE and CD21 in allergic individuals? In the target organs of allergic disease. e. o. the 
nasal mucosa in allergic rhinitis and the bronchial mucosa of asthmatics, both allerg7en- I 
activated Th2 cells and mast cells secrete IL-4 and express CD40-11gand. resultin-g) in 
local class switching to IgE (Coker et al., 2003; Coker et al., 2005; Durham. 1997: 
Snow et al., 1999; Takhar et al., 2005). In this environment one might expect to find B 
cells expressing CD21, mIgE and CD23. Additionally, tight junctions between cells in 
these tissues may restrict the diffusion of sCD23 and result in high local concentrations 
that would favour oligornerization and co-ligation of mIgE and CD21. This paracrine 
activity would favour the action of trimeric CD23 molecules on local B cells near the 
point of CD23 cleavage, leading to clonal expansion and Ig secretion. This signal \wuld 
be lost as a result of the diffusion and proteolysis of CD23 fragments. Therefore, IgE 
regulation by CD23 could be occurring at local sites of inflammation. Indeed, in sim 
studies reveal a vastly expanded population of IgE+ B cells and plasma cells in the nasal 
mucosa of hay fever patients (Gould et al., 2006; KleinJan et al., 2000). 
8.5 Future work 
Having demonstrated high affinity and high avidity binding, as well as successful co- 
localisation of mIgE and CD21 by LZ-CD23, it will be instructive to continue usim-, this 
molecule for the dissection of the mechanism of IgE regulation 
from human B celk. 
However, due to the difficulties experienced in producing sufficlent quantities of 
L/- 
CD23 from the prokaryotic system, a mammalian expression systeiii Is 
beIng developed. 
-ith higher vields and Future experiments would benefit from a more efficient systeni ýN 
protein homogeneity. 
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The mechanism by which sCD23 fragments upregulate L-YE still remains elusiNe. 
Although work presented here suggests that LZ-CD23 can upregulate lgoE from some B 
cells while derCD23 can downregulate IgE (McCloskey et al.. submitted). it i" still 
unclear whether sCD23 targets individual cells, whether it affects IgE transcription or 
translation, or whether it targets a certain B cell subpopulation. Work is currently in 
progress within our laboratory to address all these issues. The effects of LZ-CD23 on 
IgE mRNA, circle transcripts and germline gene transcripts are being inN-estigated using Z-- 
realtime PCR, and the nature of the cell type targeted by sCD233. eg. memory or naYve B 
cell,, is being investigated using FACS-sorted B cell subsets. 
The potential for LZ-CD23 to cause IgE and/or CD21 translocation into rafts would be 
interesting to study, following observations implicating a role for lipid rafts in B cell 
signalling (Cheng et aL, 1999). An elegant series of experiments from the laboratory of 
Pierce and colleagues has demonstrated the translocation of IgM and CD21 into rafts, 
mediated by complement-tagged antigens (Cherukuri et al., 2001). In this \\ork. 
crosslinking of both CD21/CD19 with IgM was demonstrated to cause the prolonged 
residency of IgM in lipid rafts stabilised by CD2 I /CD 19, which was accompanied by an 
enhanced phosphorylation of Lyn. CD23 crosslinking of CD21 and IgE may also result 
in the translocation of m1gE and CD21 into rafts. Lipid rafts are traditionally Isolated in 
detergent insoluble fractions of cell lysates, followed by western blot probing of sPecific 
proteins, though some controversy remains as to the validity of results obtained 
in this 
manner (reviewed by Munro, 2003). Recent advances in 
high resolution fluorescence 
microscopy offer a way of visualising the localisation of molecules. and potentially 
their 
association with lipid rafts, intracellular kinases and the intracellular 
architecture 
- 169 - 
lapter 8 Discussion 
K-enworthy et al., 2000; Pierce, 2004), which could be applied to 
msslinking of mIgE and CD21. 
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Appendix 
Amino Acid Sequence data for LZ-CD23 
I MASMTGGQQM GRGSEFENRM KQIEDKIEEI LSKIYHIENE 
41 IARIKKLIGE RNCWHWDTTQ SLKQLEERAA RNVSQVSKNL 
81 ESHHGDQMAQ KSQSTQISQE LEELRAEQQR LKSQDLELSW 
121 NLNGLQADLS SFKSQELNER NEASDLLERL REEVTKLRME 
161 LQVSSGFVCN TCPEKWINFQ RKCYYFGKGT KQWVHARYAC 
201 DDMEGQLVSI HSPEEQDFLT KHASHTGSWI GLRNLDLKGE 
141 FIWVDGSHVD YSNWAPGEPT SRSQGEDCVM MRGSGRWNDA 
181 FCDRKLGAWV CDRLATCTPP ASEGSAESMG PDSRPDPDGR 
221 LPTPSAPLHS 
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